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ABSTRACT 
 
Daniel Oliver Kechele:  Novel Functions of Adrenomedullin, Receptor Activity-Modifying 
Protein 2, and Gpr182 in Cardiovascular Disease and Cancer 
 (Under the direction of Kathleen Caron) 
 
The multifunctional circulating peptide, adrenomedullin (AM) signaling through its G 
protein-coupled receptor (GPCR) complex, comprised of the calcitonin receptor-like receptor 
(CLR) and receptor activity-modifying protein 2 (Ramp2), is required for lymphatic 
development and embryonic survival, as well as numerous functions in adult cardiovascular 
physiology.  However these functions, especially during adulthood, have not been fully 
elucidated.  Using both gain- and loss-of-function mouse models these studies aimed to 
further elucidate the roles of AM signaling during cardiovascular homeostasis and tumor 
progression.  Endothelial restoration of Ramp2 is sufficient to rescue the embryonic lethality-
associated with global loss of Ramp2.  However, the developmental loss of Ramp2 in non-
endothelial cells led to spontaneous hypotension, dilated cardiomyopathy, and multi-organ 
inflammation in adult survivors.  Smooth muscle cell- or global-deletion of CLR did not 
recapitulate these phenotypes, indicating that Ramp2 is likely interacting with other GPCRs, 
including parathyroid hormone and glucagon receptors, to maintain cardiovascular 
homeostasis.   
While AM signaling is essential for lymphatic development and maintenance, it is 
unclear how AM influences tumor lymphatics.  Tumor cells engineered to overexpress or 
knockdown AM did not alter tumor growth or angiogenesis.  High tumor-derived AM caused 
tumor and lymph node lymphangiogenesis and increased metastasis.  While AM is typically 
considered protective, these data suggest that AM signaling could enhance tumor 
progression.    
iv 
 
While CLR/Ramp2 is the canonical AM receptor, it was previously thought that the 
AM receptor was the orphan GPCR, Gpr182, of which almost nothing is known.  Using a 
knock-in reporter mouse model to map Gpr182 expression in vivo, Gpr182 was enriched in 
the active stem cells in the small intestine.  Gpr182 was dispensable during development 
and homeostasis, but when challenged with irradiation injury or adenoma model, reduced 
Gpr182 led to intestinal hyperproliferation during regeneration and enhanced adenoma 
formation, respectively.   
Together, these studies demonstrated the importance of endothelial AM signaling 
during development, the complexity of GPCR/RAMP interactions in vivo, the 
underappreciated functions of AM signaling in tumor lymphatic metastasis, and the role of 
Gpr182 as a negative regulator of intestinal proliferation; all of which could represent 
pharmacological-tractable targets to treat a number of cardiovascular and neoplastic 
diseases.   
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Chapter I. Introduction: Adrenomedullin Function in Vascular Endothelial 
Cells: Insights from Genetic Mouse Models1  
 
Overview 
Adrenomedullin is a highly conserved peptide implicated in a variety of physiological 
processes ranging from pregnancy and embryonic development to tumor progression.  This 
chapter highlights past and current studies that have contributed to our current appreciation 
of the important roles adrenomedullin plays in both normal and disease conditions.  There is 
a particular emphasis on the functions of adrenomedullin in vascular endothelial cells and 
how experimental approaches in genetic mouse models have helped to drive the field 
forward. 
 
Introduction 
The Multifunctional Adrenomedullin Peptide 
Adrenomedullin (gene=Adm; protein=AM) is a highly conserved multifunctional 
peptide that is implicated in a wide variety of physiological processes including angiogenesis 
and cardiovascular homeostasis.1   For over a decade, the association of ~2-fold elevations 
in plasma levels of AM peptide with a wide variety of cardiovascular disease conditions has 
prompted intense inquiry into understanding the functions and roles of AM in human disease 
                                                          
1 Reprinted with permission from:  Natalie O. Karpinich, Samantha L. Hoopes, Daniel O. 
Kechele, Patrica M. Lenhart, Kathleen M. Caron.  Adrenomedullin function in vascular 
endothelial cells: insights form genetic mouse models.  Current Hypertension Reviews. 
2011;7:228-239. 
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(Figure 1-1).  Moreover, the recent development of highly precise methods for the 
quantitation of proadrenomedullin (proADM) as a reliable surrogate of mature AM plasma 
levels,2 has paved the way for the introduction of AM as a clinically useful biomarker for the 
staging of adverse cardiovascular events, including myocardial infarction, sepsis and 
community acquired pneumonia.3-6  While it is clear that AM can elicit powerful effects on 
vascular smooth muscle cells and thus acutely modulate vascular tone, numerous studies in 
the past 5 years have elucidated essential functions of AM on vascular endothelial cells.  In 
the following sections information is summarized pertaining to the multi-faceted role of AM in 
endothelial cells during development, how perturbations in AM signaling may lead to 
vascular pathologies, and recent discoveries regarding AM that have contributed in 
substantial ways to the broader field of vascular biology.  Much of these discoveries have 
been unraveled through the use of sophisticated genetic animal models (Tables 1-1 and 1-
2), and so special emphasis has been placed on describing the merits and shortcomings of 
these approaches and also highlighting current questions that are of predominant interest to 
the field today. 
 
Adrenomedullin GPCR-Mediated Signaling in Endothelial Cells 
G-protein coupled receptors (GPCRs) are widely expressed proteins that span the 
cell membrane 7 times and respond to a variety of stimuli including peptides, proteins, small 
organic compounds, lipids, amino acids, and cations.  AM binds and signals through the 
GPCR calcitonin receptor-like receptor (gene=Calcrl; protein=CLR).  The discovery of a 
novel class of GPCR-associated proteins called receptor activity-modifying proteins 
(gene=Ramp; protein=RAMP)7 provided insight into how GPCRs signal.  The RAMPs are 
single-pass transmembrane accessory proteins that regulate the translocation of GPCRs to 
the plasma membrane as well as provide ligand specificity to these receptors.  The tissue 
specific and temporal expression pattern of RAMPs determines the responsiveness of 
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GPCRs to particular ligands.  For example, AM binds to the CLR receptor when CLR is 
associated with either RAMP2 or RAMP3.  However, co-expression of CLR with RAMP1 
changes the ligand specificity to another potent vasodilator called calcitonin gene-related 
peptide (CGRP), a related family member of the AM peptide.  The ability of CLR to bind 
multiple ligands provides a unique mechanism by which the receptor can initiate a variety of 
signaling pathways.  Since the AM receptor CLR and the 3 mammalian RAMPs are highly 
expressed in the vasculature, this cell signaling paradigm is being intensely investigated to 
determine how it can be exploited for the potential treatment of conditions such as 
pulmonary hypertension8, cardiovascular disorders,9 and the inhibition of cancer 
metastasis.10 
The binding of AM to its receptor CLR results in a myriad of downstream effects 
including modulation of endothelial cell survival, proliferation, and vessel permeability.   For 
example, AM-induced proliferation and migration of lymphatic endothelial cells is mediated 
in part by cAMP and downstream MEK/ERK pathways.11  Similar results were shown using 
cultured HUVECs.  AM-mediated induction of HUVEC proliferation and migration through 
activation of PKA, PI3K, and focal adhesion kinase were observed and then further 
substantiated in whole animal studies.12, 13  AM induced the proliferation and migration of 
cultured human umbilical vein endothelial cells (HUVECs)12 and numerous studies have 
shown a direct role for AM in endothelial growth and survival.14-16 
Using in vitro experiments, AM was found to regulate the permeability and migration 
of HUVECs.17   Previous studies indicated that adult Ramp2+/- mice had increased vascular 
permeability and overexpression of Ramp2 in BECs resulted in reduced permeability.18  AM 
also reduces the permeability of HUVECs and pulmonary artery endothelial cells treated 
with permeabilizing agents including hydrogen peroxide and thrombin.19  AM has been 
shown to regulate the transport of molecules across the blood brain barrier in cerebral 
endothelial cells by modulating permeability.20  In cerebral endothelial cells, AM regulated 
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various functions of the blood brain barrier including increasing transendothelial electrical 
resistance, reducing fluid-phase endocytosis, and reducing permeability for sodium 
fluorescein which indicate that the cerebral endothelial cell junctions are tightened by AM.20  
Also in an in vivo model, AM treatment reduced lung vascular permeability resulting from 
ventilator use in a mouse model where prolonged mechanical ventilation was 
administered.21  Overall, these data provide evidence for the role of AM as a junctional 
tightening factor to help regulate endothelial cell permeability.  
Although AM functions to promote endothelial cell growth and proliferation in both the 
blood and lymphatic vasculatures, Fritz-Six et al. have shown that there is an enhanced 
effect of AM on lymphatic endothelial cells (LECs) as compared to blood endothelial cells 
(BECs).22  This biological distinction in AM function is based upon the finding that LECs are 
enriched in the expression of AM and its receptor components, Calcrl and Ramp2.22-24  This 
increase in Calcrl expression is mediated in part by induction of the transcriptional regulator 
of lymphatic specification, Prox1.22  It is therefore not surprising that loss of any component 
of the AM signaling axis (Adm, Calcrl, or Ramp2) results in embryonic lethality associated 
with profound lymphatic vascular defects.22 Furthermore, several in vitro and in vivo 
experiments reveal that AM controls lymphatic permeability and flow through reorganization 
of junctional proteins ZO-1 and an adherens protein VE-Cadherin, independent of changes 
in junctional protein gene expression.25  Administration of AM to a monolayer of LECs 
resulted in tightening of the lymphatic endothelial barrier by reorganization of a tight junction 
protein at the plasma membrane to form continuous cell-cell contacts. Through the use of in 
vivo tail microlymphography, local administration of AM in a SvEv129/6 mouse tail resulted 
in decreased velocity of lymph uptake from the interstitial space and movement through the 
lymphatic dermal capillaries in the tail.25  Thus, it becomes critically important to consider the 
pleiotropic effects of AM not just on blood endothelial cells, but also on neighboring 
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lymphatic vessels—a dynamic that may ultimately help resolve the complex functions of AM 
peptide in cardiovascular disease, tumor progression and inflammation.  
While activation of GPCRs typically leads to induction of classical second messenger 
signaling systems, it is now appreciated that more complex levels of regulation exist.26, 27  
Therefore, it is not surprising that pathway cross-talk is one mechanism through which AM 
modulates certain endothelial cell functions.  For example, Yurugi-Kobayashi et al. describe 
a novel embryonic stem cell differentiation system to study mechanisms of arterial-venous 
specification.  They demonstrated that coordinated signaling of AM/cAMP, VEGF, and Notch 
induces arterial endothelial cell differentiation from vascular progenitors.28  Furthermore, 
GPCR-induced transactivation of receptor tyrosine kinases is another mechanism that 
allows interaction between signaling molecules.  Evidence exists that AM and VEGF 
pathways are likely to interact in endothelial cells.  Although an earlier study claimed that 
AM-induced capillary tube formation in HUVECs was independent of VEGF activation,14 a 
more recent study by Guidolin et al. demonstrated that VEGFR2 inactivation inhibited AM-
mediated angiogenesis in HUVECs.29  This latter finding suggests that the pro-angiogenic 
effects of AM require transactivation of the receptor tyrosine kinase VEGFR2.  Although 
controversy still exists regarding the degree of cooperation between pathways, it is certainly 
intriguing to consider that regulation of endothelial cell biology may very likely involve 
coordination of multiple signaling molecules.  We now must begin to unravel these 
complexities and elucidate whether these interactions occur differentially in blood and 
lymphatic endothelial cells and identify the intermediate molecular players involved in 
pathway cross-talk in the vasculature. 
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Development 
Endothelial Adrenomedullin Signaling is Essential for Embryonic Development 
Work by multiple independent groups has established the importance of AM 
signaling during development.  The use of gene targeted mouse models clearly indicates 
that functional AM signaling is essential for embryonic survival.  The genetic ablation of 
Adm,30-32 Calcrl,33 Ramp218, 22, 34 or the enzyme responsible for functional AM amidation, 
peptidylglycine alpha-amidating monooxygenase (PAM)35 all result in midgestational lethality 
associated with severe interstitial edema and cardiovascular defects.  The conserved 
phenotypes between these knockout (KO) mice is compelling genetic evidence that the 
CLR/RAMP2 complex is the main receptor of AM during development, and also is the first in 
vivo confirmation that RAMP2 functionally interacts with CLR.22 
Although the overt phenotypes of these KO mice are conserved, the physiological 
cause of edema and lethality is still debated.  One possible hypothesis is that loss of AM 
signaling causes developmental cardiac abnormalities that lead to heart failure, thus 
resulting in edema and death that is similar to previously characterized KO mice with 
developmental heart failure.36-38  Supporting this line of thought, our lab showed that Adm-/-, 
Calcrl-/-, and Ramp2-/- mice have smaller hearts due to decreased myocyte proliferation and 
increased apoptosis.  Additionally, they have increased left ventricle trabecularization, which 
leads to decreased ventricular volume.22, 30, 33  However, an alternative hypothesis is that 
vascular defects are responsible for the phenotypes, since Adm,30  Calcrl,33 and Ramp218 
are abundantly expressed in the developing endothelium and vascular smooth muscle cells 
(vSMC).  To help resolve between the two hypotheses, we generated an endothelial-specific 
Calcrl-/- mouse using a Tie2 promoter to drive Cre recombinase expression which 
recapitulated the phenotype observed in global KO mice,22 indicating that AM signaling in 
endothelial cells is essential for embryonic development, further supported by Ramp2 
rescue in Chapter II.  A remaining caveat to this conclusion is the fact that Tie2-Cre 
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mediated excision also occurs in developing endocardial cells.  Therefore, to definitively 
determine if cardiac abnormalities contribute to this phenotype the reverse experiment using 
Cre lines specific to cardiac myocytes would be beneficial.  
Although vascular defects are responsible for the edema in these KO mice, it 
remained unclear whether defects in the blood or lymphatic endothelium were the principle 
cause of the phenotypes.  Given the role of AM in regulating vascular permeability, it seems 
reasonable that loss of AM signaling could lead to increased vascular permeability and a 
resulting buildup of interstitial fluid.  In support of this idea, the KO mice have thinner aorta 
and carotid artery walls due to a decrease in vSMC proliferation,18, 30, 33 although the 
endothelium lining the aorta appeared to be normal.33  There are reported abnormalities in 
endothelial basement membranes and a down-regulation of junctional proteins in Adm-/- and 
Ramp2-/- embryos that may lead to increased vascular permeability and hemorrhage,18, 31 
but these phenotypes were observed in a small proportion of animals and not conserved in 
all studies.  In addition, the severity of the edema and their survival beyond e10.5 does not 
resonate with other knockout mouse models with established vascular permeability 
defects.39-41  In contrast, the onset (Calcrl=e12.5, Adm=e13.5, Ramp2=e14.5) and severity 
of the phenotype closely resembles other genetic mouse models that delete genes essential 
for lymphatic development, including Prox1,42  Sox18,43 and Vegfc.44  To determine whether 
lymphatic vasculature defects may contribute to the edema observed in AM signaling KO 
animals, we performed a comprehensive study of AM signaling expression and function 
during lymphatic vascular development.22  It is most likely that a combination of both blood 
and lymphatic defects leads to the edema and lethality in the KO mice given the integrated 
physiology between the two vasculatures.   However, more specialized genetic assays are 
required to resolve the relative contributions of each vasculature within these KO mice.45   
An alternative approach to assess the role of AM signaling in development would be 
to use transgenic mouse models that overexpress Adm, Calcrl, or Ramp2.  Interestingly, no 
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developmental phenotypes have been reported in gain-of-function mouse models of AM 
signaling, either by vascular Adm overexpression46 or vSMC-specific Ramp2 
overexpression,47 though these models displayed adult cardiovascular phenotypes.  Given 
the essential nature of AM signaling within the endothelium, it would be interesting to over-
express Calcrl or Ramp2 specifically in the endothelium, which to our knowledge, has not 
yet been reported (See Chapter II). 
 
Adrenomedullin vs. Proadrenomedullin 
One potential caveat with the majority of Adm-/- studies is that the gene targeting 
strategies delete the entire Adm coding sequence,30, 31 which results in the genetic KO of 
two functionally active peptides, AM and proadrenomedullin N-terminal 20 amino acid 
peptide (PAMP).48  PAMP is small peptide that is produced during post-transcriptional 
splicing of preproadrenomedullin and has numerous actions to complement or antagonize 
AM signaling.48-51  For two of the reported Adm deficient mouse lines, the design of the 
targeted allele could not rule out whether the observed phenotypes in the KO animals were 
due to loss of AM, PAMP, or both.30, 31  This controversy was partially resolved using a third 
independent Adm-/- mouse, which left PAMP intact, and illustrated that loss of AM alone was 
enough to recapitulate embryonic lethality.32  However, these mice lacking only AM had a 
milder phenotype (less edema and no cardiovascular abnormalities) when compared to KO 
mice lacking both peptides.  This inconsistency in phenotypes could be attributed to 
differences in mouse strain and/or gene targeting approach.32  However, a more intriguing 
hypothesis, which remains to be vigorously experimentally addressed, is that AM and PAMP 
may have non-redundant functions during cardiovascular development.52 
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Developmental Role of RAMP2 vs. RAMP3 
While Ramp2-/- mice recapitulated the Adm-/- and Calcrl-/- phenotypes, it appears that 
RAMP3, another RAMP that associates with CLR and binds AM, is not essential for 
embryonic survival since Ramp3-/- mice develop normally to adulthood.  There also appears 
to be no functional redundancy between RAMP2 and RAMP3 in development, since there is 
no transcriptional compensatory mechanism of either RAMP in response to loss of the 
other.18, 34  Although RAMP3 has been implicated in receptor trafficking,7, 53, 54 the functional 
role of the AM/CLR/RAMP3 signaling complex is not well understood in vivo.  
 
New Developmental Insights of Adrenomedullin Pathway 
A recent study by Nicoli et al. expanded our knowledge regarding the role of CLR 
during embryonic vascular development using a zebrafish model.  By knocking down crlr 
they showed drastic vascular defects due to decreased expression of vegf.  While vegf 
appears to be the critical mediator in the vascular development since overexpression of vegf 
is able to rescue the crlr knockdown phenotype, it still appears that crlr is essential for 
appropriate levels of vegf.    This study provides in vivo evidence that crlr is downstream of 
sonic hedgehog, but upstream of vegf and notch signaling in arterial differentiation and 
development.55  Modulation of vegf levels by AM signaling were previously reported in 
mice56 but a complete characterization of AM and VEGF interactions is not well understood.  
It is novel that sonic hedgehog appears to regulate crlr expression and further dissection of 
this pathway in animal models would improve our understanding of how CLR is regulated 
during development.   The zebrafish model system has recently been used to study 
lymphatic development57-59 and it would be interesting if phenotypes seen in Adm-/-, Calcrl-/-, 
and Ramp2-/- mice could be recapitulated in zebrafish. 
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Physiology and Pathophysiology 
Adrenomedullin Signaling in Pregnancy 
AM signaling is known to be a critical component for initiation and progression of 
normal pregnancy.  By the third trimester of a normal pregnancy, plasma levels of AM 
increase 4- to 5-fold.60-65  AM is highly expressed in all vascular tissues which include the 
placenta and uterus.66, 67  Our previous studies in Adm+/- female mice expressing 50% less 
AM revealed that there is disrupted fertility, placentation, uterine receptivity, and fetal growth 
resulting from reduced AM expression.68   AM signaling components are also expressed in 
the trophoblast cells,69-74 which take on an endothelial-like function during the process of 
decidual maternal spiral artery remodeling during pregnancy.  The trophoblast giant cells 
deriving from the trophectoderm invade and replace the vascular wall by inducing a loss of 
endothelial cells and smooth muscle cell coverage to allow for higher blood flow to the fetus 
through the spiral arteries.  Failure of this remodeling process to occur is a hallmark feature 
of preeclampsia.  Further research needs to be performed to determine the extent to which 
AM signaling affects trophoblast cells in the process of maternal spiral artery remodeling 
during pregnancy.  
  
Adrenomedullin Signaling and Cardiovascular Biology 
AM has been reported to be upregulated in various cardiovascular conditions1, 75, 76 
and is a potent angiogenic factor as well as a cardioprotective factor.1  Plasma AM 
increases 2-fold in conditions such as essential hypertension, renal failure and congestive 
heart failure (Figure 1-1).77, 78  Previous studies with gene-targeted KO mice for Adm and 
Calcrl indicated that AM signaling is important for cardiovascular development.22, 30, 33  
Genetic reduction of Adm results in enhanced cardiovascular damage including increased 
cardiac hypertrophy in male Adm+/- mice79 and marked perivascular fibrosis, coronary artery 
intimal hyperplasia and oxidative stress with AngII/high-salt treatment.32  AM protects the 
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heart from hypertrophy and fibrosis during cardiovascular stress such as hypertension and 
cardiac hypertrophy, myocardial infarction, heart failure and atherosclerosis,80, 81 but the 
exact mechanisms of AM-mediated cardioprotection have not been fully elucidated.  A 
comprehensive review of the cardioprotective function of AM during hypertension and heart 
failure has recently been provided by several groups.9, 82 
Endothelial dysfunction is characterized by reduced endothelium-dependent vascular 
relaxation which is associated with most forms of cardiovascular disease.  It is partially 
impacted by reduced nitric oxide and upregulation of adhesion molecules to result in a 
proinflammatory and prothrombotic state.83  Research also suggests that endothelial 
dysfunction may act as an early marker of atherosclerosis.84 One study indicated that Adm 
and its receptor components, Calcrl and Ramps were upregulated in the aorta of 
apolipoprotein E-deficient (ApoE-/-) mice.85  Loss of apoE ultimately results in a mouse model 
of spontaneous atherosclerosis because apoE is important in the removal of circulating 
lipoproteins.86  When these mice were fed an atherogenic diet and treated with AM, the 
appearance of atherosclerotic lesions was reduced.85  This study further indicates that AM 
may help to protect against the progression of atherosclerosis, but the exact mechanism for 
this action remains to be understood.  Expression of adhesion molecules in LECs87 and liver 
sinusoidal endothelial cells88 were reduced in response to AM treatment.  Similar results 
were seen with VEGF-treated HUVECs.89  Thus, AM may impact endothelial dysfunction 
partially by modulating adhesion molecule expression.  With respect to endothelium-
dependent vascular relaxation, AM is known to induce vasodilation which is mediated 
partially by endothelium-derived nitric oxide.90-94  Also, in a rat model of sepsis induced by 
cecal ligation and puncture, administration of AM and AM-binding protein (AMBP-1 also 
known as complement factor H) were shown to prevent against endothelial cell dysfunction 
and decreased endothelium-dependent vascular relaxation in thoracic aorta.95  These 
studies implicate AM as having a protective role in cardiovascular disease and endothelial 
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dysfunction, but further research needs to be performed to investigate how AM directly 
impacts on the cardiac endothelial cells to regulate their function.   
 
The Role of Adrenomedullin Signaling in Response to Injury, Vascular Dysfunction and 
Wound Healing 
Endothelial proliferation and angiogenesis are known to be impacted by AM 
signaling.  In a hind-limb ischemia model, AM promotes endothelial cell proliferation and 
capillary formation and conversely, Adm+/- mice showed reduced blood flow and capillary 
development.56  Other whole animal studies using matrigel plugs to assess vascular growth 
demonstrated the role of AM in vascular regeneration because AM increased blood flow and 
capillary densities through PKA- and PI3K-dependent pathways.12, 13  AM also induced tube-
formation of HUVECs cultured on matrigel.14  Another study pertaining to RAMP2 
expression also revealed similar findings.  An aortic ring assay and matrigel plug assay with 
adult Ramp2+/- mice revealed that with decreased RAMP2 expression there was reduced 
neovascularization in response to growth factor stimulation.18  Collectively, these studies 
indicate the importance of AM in endothelial cell proliferation and angiogenesis in adult 
mice.   
AM signaling is known to impact the blood and lymphatic vasculature in other 
physiological processes and pathological conditions. In a pathological mouse model of 
subcortical vascular dementia (chronic cerebral hypoperfusion), AM was shown to promote 
arteriogenesis and angiogenesis as well as inhibit oxidative stress and preserve white 
matter in the brain.96  AM signaling can also induce anti-apoptotic and anti-inflammatory 
effects in response to injury.  In the sinusoidal endothelial cells of the liver, AM helps to 
protects these cells from cold injury during the process of cold preservation for a liver 
transplant by decreasing endothelial cell apoptosis and inflammation.88  Conversely, in 
Adm+/- and Ramp2+/- mice there is increased apoptosis of the sinusoidal endothelial cells in 
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the liver after cold injury88 further indicating that AM signaling helps to regulate apoptosis.  
Wound healing is an essential physiological process that requires angiogenesis and 
lymphangiogenesis for proper healing.  Since AM is a known angiogenic factor and 
lymphangiogenic factor,22 it is not surprising that AM signaling is necessary in the wound 
healing process.  In an ischemia/reperfusion mouse model of a pressure ulcer, AM 
administration reduced the wound area and accelerated angiogenesis as well as 
lymphangiogenesis.97  Also in a wounded HUVEC monolayer, AM promoted vascular 
regeneration via activation of endothelial Akt in a PKA- PI3K- dependent manner.12  
Lymphedema is a hallmark condition of lymphatic dysfunction resulting in the swelling of one 
or more limbs due to accumulation of interstitial fluid.  In Balb/C mice with tail lymphedema, 
AM treatment improved lymphedema and increased the number of lymphatic and blood 
vessels near the injury site.11  Taken together, these data indicate that AM is an essential 
component for proper endothelial cell function in both physiological and pathological states 
to regulate apoptosis, inflammation, and lymphangiogenesis as well as angiogenesis.   
An important issue to still address is to determine the exact role of AM signaling 
during adulthood by using temporal and spatial KO mice for components of the AM signaling 
system to evaluate physiology and function of the vascular beds in these mice.  Previous 
studies with genetic KO mice for the AM signaling system reveal an enhanced impact of AM 
on lymphatic vascular development relative to blood vascular development.22  It has also 
been shown that the gene expression of AM receptor components, Calcrl and Ramp2, are 
enhanced in LECs compared to BECs.23, 24  Due to these known differences of AM signaling 
between BECs and LECs, it would be interesting to determine whether there is also an 
enhanced effect of AM on the lymphatic vasculature in adult physiology and pathology.   The 
underlying mechanisms through which AM impacts the lymphatic vasculature, blood 
vasculature as well as the more specialized cardiac tissue during adulthood also needs to 
be identified.   
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Adrenomedullin Expression in Tumor Progression 
The AM peptide was initially isolated from a human adrenal tumor 
(pheochromocytoma) due to its platelet cAMP elevating activity.76  Since this discovery 
almost 20 years ago, investigation into the role of AM in tumors has greatly expanded.  Early 
studies noticed elevated levels of AM in lung and brain tumors98, 99 and a comprehensive 
survey of human tumor cell lines from lung, breast, brain, ovary, colon, and prostate 
substantiated those reports.100  AM has been implicated in a variety of pro-tumor functions 
including acting as an autocrine growth factor,100-102 apoptosis survival factor,15 promoter of 
tumor cell motility and invasion,102-104 and molecular intermediate to enhance communication 
between tumor cells and immune cell infiltrates105.  Furthermore, it has been suggested that 
the presence of AM in tumors may signify a more aggressive tumor phenotype due to 
correlation between Adm gene expression and histological tumor grade.102, 106  
The mechanism(s) by which Adm gene expression is transcriptionally regulated in 
tumors remains unclear.  It is likely that AM can be both an autocrine and paracrine factor107 
by providing tumor cells a growth advantage in addition to acting on surrounding endothelial 
cells to promote proliferation and changes in vessel permeability to perhaps facilitate 
metastasis.  Moreover, it has been suggested that hypoxia may play a role in AM 
production.8, 108  Tumors often develop hypoxic zones in areas where blood flow is 
inadequate to supply the necessary oxygen required for the growing tumor cells.  As a result 
of this unfavorable state, hypoxia inducible factor-1 (HIF-1) is activated which in turn 
upregulates a number of genes to compensate for the reduced oxygen microenvironment.  
Interestingly, a HIF-1 dependent mechanism was found to increase the expression of Adm 
in hypoxic human tumor cell lines.109  Furthermore, Adm and Calcrl were found to be 
upregulated in microvascular endothelial cells cultured under low oxygen conditions.110  
Together, these results show that both tumor cells and surrounding endothelial cells are 
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responsive to hypoxic conditions and may provide a mechanism for elevated AM levels in a 
tumor setting.    
 Although the precise role of AM in tumor development and progression is still 
unresolved, significant progress has been made to better understand how AM affects not 
only a tumor cell, but also the endothelial cells in the surrounding microenvironment.  
Analysis of immunohistochemical staining of human ovarian cancer found that in addition to 
tumor cells, AM was also localized to the endothelial cells of the surrounding stroma.106  
Furthermore, an in vitro co-culture system found that HUVECs became activated upon 
exposure to tumor cells and consequently increased transcriptional activity of Adm, among 
other factors.111  Since AM directly impacts endothelial cell proliferation and permeability, 
AM induced modulation of vessels may affect the spread of cancer cells to distant sites via 
blood or lymphatic vasculature, as shown in Chapter III.  Research groups have been 
performing the in vivo studies necessary to confirm that AM promotes tumor progression 
through its known angiogenic properties.  Several reports have shown that inhibition of AM 
action by neutralizing antibodies or AM antagonist AM22-52 have reduced the growth of tumor 
xenografts in vivo by suppressing vascular development.56, 112, 113 
While much of the focus in understanding the process of tumor lymphangiogenesis 
and angiogenesis has been upon the VEGF protein family, the contribution of AM to this 
process should not be underappreciated.  Clearly, the studies described above point to AM 
as a valid target for potential cancer therapies although more research is necessary.  
Generation and validation of preclinical mouse models that are able to rigorously test AM as 
a target are greatly needed.  Since the embryonic lethal phenotype of Adm-/- mice makes 
studying this signaling pathway more complicated, novel genetic mouse models (Table 1-1) 
using conditional alleles18, 22, 114 and vascular endothelium specific Cre animals are a starting 
point for such tumor studies.    Furthermore, these mouse models will be needed to refine 
our understanding of the metastatic process.  Given the knowledge that AM can act on both 
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the blood and lymphatic endothelium, a key question that remains to be answered is by 
what mechanisms do tumor cells disseminate into the blood and/or lymphatic vessels.   
 
Summary and Future Directions 
The use of genetic animal models in the field of AM research has produced 
significant contributions toward understanding the biology of this pleiotropic molecule, with a 
renewed appreciation for is critical regulation of endothelial cells function during 
development and vascular diseases.  To date, AM has been implicated in lymphatic 
vascular development, in proper functioning of blood and lymphatic endothelial cells and in a 
variety of conditions such as pregnancy, cardiovascular disease, and tumor progression 
(Figure 1-2).  Despite the strides that have been made, there is much more to learn 
regarding the mechanisms mediating AM function and regulation.  With the generation of 
additional sophisticated molecular biology tools such as genetic mouse models, we are 
poised to refine our current knowledge as well as discover other novel roles for this peptide 
and signaling partners in normal and disease physiology. 
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Tables 
 
 
 
Table 1-1: Gene Targeted Mouse Models for Studying Adrenomedullin 
Signaling  
Mouse Model Development 
or Adulthood 
Result Reference 
Adm-/-  Development  
-Embryonic lethal (e14.5), edema, 
smaller hearts, reduced myocyte 
proliferation and increased 
apoptosis, increased left ventricle 
trabecularization, thinner aorta and 
carotid artery walls, increased 
vascular permeability, hypoplastic 
jugular lymph sac  22, 30-32 
Adm+/-  Adulthood 
-Pregnancy: Disrupted fertility, 
placentation, and fetal growth                                                 
-Cardiovascular:  Increased damage 
including hypertrophy, reactive 
oxygen species (ROS), and fibrosis                                                                                                                                   
-Liver cold injury: increased 
apoptosis of the sinusoidal 
endothelial cells      32, 68, 79, 88 
Admfl/fl/Tubulin 
Tα-1-Cre+  Adulthood  
-High anxiety, hyperactive, impaired 
motor coordination  114 
Calcrl-/-  Development  
-Embryonic lethal (e13.5), similar 
phenotype as Adm-/- mice  22, 33 
CalcrlLoxP/-
/Tie2Cre+  Development  
-Embryonic lethal (e16.5) and 
recapitulation of Adm-/-, Calcrl-/-, and 
Ramp2-/-  phenotype  22 
Ramp2-/- and  
Ramp2fl/fl/ 
CAG-Cre+ Development  
-Embryonic lethal (e15.5), similar 
phenotype as Adm-/- mice  
18, 22, 34 
Ramp2+/-  Adulthood 
-Increased vascular permeability 
and decreased neovascularization                            
-Liver cold injury: increased 
apoptosis of the sinusoidal 
endothelial cells  18, 88 
PAM-/-  Development  
-Embryonic lethal (e14.5) and 
phenocopy of Adm-/-, Calcrl-/-, and 
Ramp2-/- mice due to loss of 
amidation of AM peptide 35 
Adrenomedullin  (Adm);  Calcitonin receptor-like receptor (Calcrl); Receptor activity 
modifying protein (RAMP);  Peptidylglycine alpha-amidating monooxygenase (PAM) 
18 
 
 
 
 
 
 
 
 
Table 1-2: Vascular Assays for Studying Adrenomedullin Function  
Assay Result Reference 
Atherogenic Model  
-Atherogenic diet and AM treatment in ApoE-/- 
mice resulted in reduced formation of 
atherosclerotic lesions 85 
Tail 
microlymphography  
-AM injected mice showed reduced 
permeability of the dermal lymphatic 
capillaries 25 
Matrigel plug 
-AM increased vascular regeneration                                                                                                       
-Ramp2+/- mice exhibited reduced 
neovascularization 12, 13, 18 
Aortic ring 
-Ramp2+/- mice exhibited reduced 
neovascularization in response to growth 
factor stimulation 18 
AngII/high-salt  
-AM+/- mice exhibited increased reactive 
oxygen species (ROS), vascular fibrosis, and 
intimal thickening 39 
Prolonged 
mechanical 
ventilation 
-AM treatment reduced lung vascular 
permeability resulting from ventilator use 
21 
Chronic cerebral 
hypoperfusion  
-AM promoted arteriogenesis and 
angiogenesis 96 
Hind-limb ischemia 
-AM promotes endothelial cell proliferation and 
capillary formation                                                           
-Adm+/- mice showed reduced blood flow and 
capillary development 56 
Wound healing                   
(Pressure Ulcer -
Ischemia reperfusion 
model) 
-AM reduced wound area and increased 
angiogenesis and lymphangiogenesis 
97 
Tail lymphedema  
-AM improved lymphedema and increased 
number of lymph and blood vessels 11 
Tumor xenografts  
-Blocking AM signaling results in reduced 
vascular development 56, 112, 113 
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Figures 
 
Figure 1-1. Fold Change in Plasma Adrenomedullin Levels in a Variety of Human 
Conditions.  Bars indicate average fold change in circulating AM levels in various disease 
categories or conditions based on published human clinical data.  The dashed horizontal 
line at 2.33 represents the average fold increase in plasma AM levels across all conditions 
depicted. Number above each bar indicates the number of published observations 
assessing plasma AM levels in each category. The clinical papers that were used for our 
analysis are listed according to the following broad categories: cancer,115-120 
cardiovascular,4, 115, 117, 121-148 hepatic and renal,128, 129, 131, 132, 149-160 pulmonary, 6, 129, 161-166 
infectious & autoimmune,167-173 normal pregnancy,61, 62, 64, 65, 174-178 and pregnancy 
complications.61, 65, 178-190 
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Figure 1-2.  Adrenomedullin Signaling in Development and Vascular Biology.   
(A) Loss of AM signaling causes embryonic lethality due to severe edema associated with 
impaired lymphatic vascular development.  (B) In the adult, AM is an angiogenic, 
lymphangiogenic, and a cardioprotective factor that also regulates vascular permeability and 
inflammation.  Expression of AM is also implicated in pregnancy and tumor progression. 
(LEC = lymphatic endothelial cell) 
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Chapter II: Endothelial restoration of receptor activity-modifying protein 2 is sufficient 
to rescue lethality, but survivors develop dilated cardiomyopathy2 
 
Overview   
Receptor activity-modifying proteins (RAMPs) serve as oligomeric modulators for 
numerous G protein-coupled receptors (GPCRs), yet elucidating the physiological relevance 
of these interactions remains complex.  Receptor activity-modifying protein 2 (Ramp2) null 
mice are embryonic lethal, with cardiovascular developmental defects similar to those 
observed in mice null for canonical adrenomedullin/calcitonin receptor-like receptor (CLR) 
signaling.  We aimed to genetically rescue the Ramp2-/- lethality in order to further delineate 
the spatiotemporal requirements for RAMP2 function during development and thereby 
enable the elucidation of an expanded repertoire of RAMP2 functions with Family B GPCRs 
in adult homeostasis.  Endothelial-specific expression of Ramp2 under the VE-cadherin 
promoter resulted in the partial rescue of Ramp2-/- mice, demonstrating that endothelial 
expression of Ramp2 is necessary and sufficient for survival.  The surviving Ramp2-/- Tg 
animals lived to adulthood and developed spontaneous hypotension and dilated 
cardiomyopathy, which was not observed in adult mice lacking CLR.  Yet, the hearts of 
Ramp2-/- Tg animals displayed dysregulation of Family B GPCRs, including parathyroid 
hormone and glucagon receptors as well as their downstream signaling pathways.  These 
data suggest a functional requirement for RAMP2 in the modulation of additional GPCR 
                                                          
2 Reprinted with permission from:  Daniel O. Kechele, William P. Dunworth, Claire E. Trincot, 
Sarah E. Wetzel-Strong, Manyu Li, Hong Ma, Jiandong Liu, Kathleen M. Caron.  Endothelial 
restoration of receptor activity-modifying protein 2 is sufficient to rescue lethality, but 
survivors develop dilated cardiomyopathy. Hypertension. In Press, 2016. 
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pathways in vivo, which is critical for sustained cardiovascular homeostasis. The 
cardiovascular importance of RAMP2 extends beyond the endothelium and canonical 
adrenomedullin/CLR signaling, in which future studies could elucidate novel and 
pharmacologically-tractable pathways for treating cardiovascular diseases.    
 
Introduction 
Receptor activity-modifying proteins (RAMPs) are single-pass transmembrane 
proteins that physically interact with numerous G protein-coupled receptors (GPCRs) to 
regulate receptor trafficking, ligand binding specificity and downstream G protein coupling 
and signaling. Biochemical and pharmacological studies have revealed functional RAMP 
interactions with many GPCRs including, calcitonin receptor-like receptor (CLR = protein, 
Calcrl = gene), calcitonin receptor (CTR), parathyroid hormone receptor 1 and 2 (PTHR1 
and PTHR2), glucagon receptor (GCGR), secretin receptor (SCTR), vasointestinal peptide 
receptor 1 and 2 (VIPR1 and VIPR2), calcium sensing receptor (CaSR), an estrogen 
receptor (GPR30), and likely additional RAMP-interacting GPCRs will be identified in the 
future.7, 191-193  Thus, in their capacity as endogenous oligomeric GPCR partners, RAMPs 
can exert powerful modulation on nearly every aspect of GPCR function and on a wide 
range of physiological processes.   However, our understanding regarding the complexity 
and consequences of RAMP-GPCR interactions in vivo lags behind our current structural, 
biochemical and pharmacological knowledge and thus presents a limitation toward 
harnessing the potential pharmacological utility of this family of proteins.   
There exist three mammalian RAMPs, each encoded by single genes, which have 
been systematically knocked out by our laboratory and others.18, 34, 194  As expected, based 
on their broad tissue distribution, the phenotypes of Ramp null mice are extensive and 
largely reflect their interactions with multiple GPCRs.195  Ramp1 and Ramp3 null mice 
survive to adulthood, while Ramp2-/- mice exhibit embryonic lethality at mid-gestation due to 
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cardiovascular defects in the heart, blood, and lymphatic vasculatures.18, 22, 34, 194, 196, 197 
These phenotypes are essentially identical to those observed in mice lacking the genes that 
encode for CLR and its Ramp2-associated ligand, adrenomedullin (AM), indicating that 
RAMP2 is essential for canonical CLR/AM signaling during embryonic development.  Yet, 
mice that are haploinsufficient for Ramp2 also exhibit an expanded constellation of 
endocrine-related phenotypes that are not observed in CLR and AM haploinsufficient mouse 
models.198  Therefore, these data imply that RAMP2 must exert functional modulation of 
other GPCRs, which is supported by its in vitro biochemical interaction with CTR, PTHR1/2, 
GCGR, and VIPR1/2.191  To date, ascribing a functional relevance for these other putative 
RAMP2-interacting GPCR pathways in adult physiological systems has been precluded by 
the embryonic lethality of Ramp2-/- mice.         
Here, we have developed a novel Ramp2 transgenic mouse model which 
overexpresses Ramp2 specifically in the endothelium, with the hypothesis that restoration of 
RAMP2 in the endothelium will rescue the lethality-causing vascular defects associated with 
loss of CLR/AM signaling during embryogenesis.  Indeed, endothelial RAMP2 is sufficient to 
rescue the embryonic lethality of many Ramp2-/- mice.  Thus, the surviving mice, which 
express Ramp2 in the endothelium but lack Ramp2 in every other cell type, provided us with 
the opportunity to further elucidate the functional implications of the loss of Ramp2 on adult 
cardiovascular physiology and respective changes in other Ramp2-associated GPCRs. 
 
Methods 
Mouse Studies 
Previously published SvEv-Ramp2+/- and Calcrlflox/flox mice were both fully 
backcrossed (>10 generations) onto a C57BL/6J genetic background for these studies.22, 34  
A novel endothelial-specific Ramp2 transgenic mouse was generated and crossed to the 
Ramp2+/- mice.  All Ramp2 mice used in this study were maintained on an isogenic 
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C57BL/6J genetic background.   The Calcrlflox/flox mice were crossed with either the SJL-
Tg(Tagln-cre)1Her (SM22-Cre) or the inducible CAGG-CreERTM mouse to conditionally 
delete Calcrl specifically within developmental vascular smooth muscle cells (vSMC) or 
ubiquitously in adult mice, respectively.   Adult CAGG-CreERTM females were administered 
with tamoxifen (TAM) as previously published.199  Genotyping and RT-PCR primers and 
probes are listed in Supplemental Table 2-S1.  Females between 4-8 months of age were 
used in all Ramp2-associated studies, males 3-4 months of age for vSMC-specific Calcrl 
studies, and females 16 month old for ubiquitous Calcrl studies.  Mice were acclimated and 
conscious for both non-invasive tail cuff blood pressure and echocardiography analysis and 
anesthetized with isoflurane for intra-arterial blood pressure measurements. Organs weights 
and heart chamber dissections were normalized to either body weight or tibia length as 
previously described.200  Biological N of 3-10 mice per genotype was used for each 
experiment.  Endothelial cells from adult mice were isolated with magnetic-associated cell 
sorting using CD31-specific antibodies as previously described.201  Cardiomyocytes from 
adult mice were isolated using collagenase digestion as previously described.202    All animal 
experiments were approved by the Institutional Animal Care and Use Committee of The 
University of North Carolina at Chapel Hill. 
Statistical Analysis 
Statistical analysis was determined with GraphPad 5.0 and data is represented as 
mean ± SEM.  The unpaired student T-test was used to compare two groups, while one way 
ANOVA with Tukey’s Multiple Comparison test was used to compare ≥ 3 groups.  Survival 
data were compared by Mantel-Cox and Gehan-Breslow-Wilcoxon tests.  Significant 
differences are represented as * p <0.05, ** p <0.01, ***p <0.001. 
Additional detailed methods are provided in the Online Supplemental Data. 
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Results 
Generation and Characterization of Endothelial-Specific Ramp2 Transgenic Animals 
  A diagram of the Cdh5-Ramp2 transgene (Tg) depicts the murine vascular cadherin 
5 (Cdh5) promoter driving the expression of a flagged-tagged murine Ramp2 cDNA 
(Supplemental Figure 2-S1A), which was successfully integrated into the genome of two 
independent founder lines on the C57BL/6J genetic background.  Expression of FLAG-
Ramp2 protein was confirmed using both transgenic founder lines in a variety of adult 
tissues including the heart, kidney, lung and intestine (Supplemental Figure 2-S1B).  Semi-
quantitative RT-PCR revealed the presence of FLAG transcript within whole adult lung 
tissue and CD31+ endothelial-enriched cells in the Tg animals, but not wild-type 
endothelium (Supplemental Figure 2-S1C), which resulted in a modest increase in overall 
Ramp2 gene expression levels within lung CD31+ endothelial cells of Tg animals compared 
to wild-type animals (Supplemental Figure 2-S1D).  Ramp2 expression was significantly 
higher in the left ventricles of Tg animals compared to wild-type—a finding which we 
attribute to the endothelial-driven transgene expression, as compared to the low levels of 
endogenous Ramp2 expression in isolated cardiomyocytes (Supplemental Figure 2-S1E) 
and previously reported expression in vSMCs.92, 203  Tg(Cdh5-Ramp2) mice bred normally, 
with expected Mendelian and sex ratios at birth, and no obvious phenotypic defects. 
 
Transgenic Endothelial Ramp2 Partially Rescues Embryonic Lethality of Ramp2-/- Mice 
We sought to determine whether endothelial Ramp2 expression could rescue the 
previously reported Ramp2-/- embryonic lethality by interbreeding the hemizygous Tg(Cdh5-
Ramp2) animals with Ramp2+/- non-transgenic (ntg) animals, on an isogenic C57BL/6J 
genetic background.18, 22  Ramp2+/- Tg(Cdh5-Ramp2) mice (hereafter referred to as Ramp2+/- 
Tg) were crossed to Ramp2+/- ntg animals to generate Ramp2-/- embryos with or without 
expression of the transgene.  At e14.5, all six possible genotypes were observed 
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(Supplemental Figure 2-S2A).  As expected, embryos lacking Ramp2 display non-
hemorrhagic edema associated with arrested lymphangiogenesis22, yet the Ramp2-/- Tg 
embryos showed significantly less edema than Ramp2-/- ntg littermates (Figure 2-1A-B).  
Unlike the small, hypoplastic jugular lymph sacs of Ramp2-/- ntg embryos, the jugular lymph 
sacs of the Ramp2-/- Tg were comparable in size to those of Ramp2+/+ littermates (Figure 2-
1C-D), demonstrating that transgenic restoration of functional Ramp2 in the endothelium 
leads to improvement of the edematous phenotype.      
In addition to defects in lymphatic development, loss of Ramp2 or AM/CLR signaling 
leads to small, disorganized hearts and thin vSMC walls.22, 30, 33  The aortic endothelium of 
viable embryos appeared intact with no signs of hemorrhagic leakage or endothelial 
dysfunction as previously reported in some Ramp2-/- embryos.18  However, the aortic vSMC 
layer was significantly thinner in Ramp2-/- ntg and Ramp2-/- Tg embryos (Figure 2-1E-F).  
Likewise, the hearts of e14.5 Ramp2-/- Tg animals were comparable in size to Ramp2-/- ntg 
littermates, which were both significantly smaller than controls, despite detectable 
expression of Ramp2 in Ramp2-/- Tg hearts (Figure 2-1G-I).  Consistent with previous 
reports, these data reflect that Ramp2 expression is required for normal vSMC and cardiac 
development and that endothelial Ramp2 restoration is not sufficient to rescue these 
defects, thus confirming non-endothelial roles of Ramp2 during cardiovascular development.   
Unlike the Ramp2-/- ntg embryos, which uniformly die by e15.5, Ramp2-/- Tg embryos 
survive to term at near-Mendelian ratios, but a large number of these animals were found 
stillborn at postnatal day 1 (Supplemental Figure 2-S2B).  Nevertheless, by postnatal day 7, 
40% of the expected Mendelian ratio of Ramp2-/- Tg pups were viable, which represents a 
significant survival rescue when compared to the completely penetrant lethality of Ramp2-/- 
ntg mice (Table 2-1).  These surviving Ramp2-/- Tg mice were indistinguishable from 
Ramp2+/+ littermates (Supplemental Figure 2-S2C).  Interestingly, there was a significant 
skewing in the sex ratio of the surviving Ramp2-/- Tg mice, such that 78% were female.  
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These data demonstrate that transgenic endothelial restoration of Ramp2 is able to blunt the 
endothelial and edematous phenotypes observed with global Ramp2 genetic deletion, 
leading to significantly improved survival.   
 
Surviving Ramp2-/- Tg Adult Mice are Hypotensive 
The surviving Ramp2-/- Tg mice, which express Ramp2 in the endothelium but lack 
Ramp2 in all other cells, provided an opportunity to evaluate how Ramp2 loss-of-function 
during development affects adult cardiovascular homeostasis.  Diastolic, systolic, and mean 
arterial blood pressures were significantly reduced in Ramp2-/- Tg compared to Ramp2+/+ ntg 
and Tg female controls (Figure 2-2A).  Importantly, there were no significant differences in 
basal blood pressure between Ramp2+/+ ntg and Ramp2+/+ Tg mice, indicating that the 
decreased blood pressure was not caused solely by the transgene.  Moreover, the reduced 
basal blood pressure of Ramp2-/- Tg mice was observed without the exogenous 
administration of the canonical, hypotensive ligand AM, which was previously required to 
lower blood pressures in a vSMC-specific overexpression model of Ramp2.47, 204   
Similar to the developmental defects in vSMC wall thickness of the Ramp2-/- Tg 
embryos and other models lacking AM/CLR/Ramp2 function22, 30, 33, the vSMC walls were 
significantly thinner in Ramp2-/- Tg adult descending aortas compared to wild-type controls 
(Figure 2-2B).  Intra-arterial blood pressure measurements further confirmed the 
hypotensive phenotype of adult Ramp2-/- Tg females (Figure 2-2C).  To test vSMC 
responsiveness, Ramp2-/- Tg and controls were challenged with intravenous injections of the 
-adrenergic receptor agonist, phenylephrine, and the vasodilator, AM.  The Ramp2-/- Tg 
adults were capable of normal vasoconstriction and vasodilation as compared to controls 
(Figure 2-2C).  So, although the thinner vSMC walls likely play a role in the hypotensive 
phenotype of Ramp2-/- Tg mice, additional systemic changes likely contribute to the 
hypotension.    
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Ramp2-/- Tg Mice Develop Spontaneous Dilated Cardiomyopathy Phenotype 
Considering the hypotension and the developmental defects observed in Ramp2-/- Tg 
embryonic hearts, we next assessed how cardiac function and morphology were altered in 
adult Ramp2-/- Tg mice.  Echocardiography on conscious mice revealed significantly dilated 
left ventricles during both diastole and systole, with significantly larger left ventricle volumes 
and left ventricle internal diameter dimensions in the Ramp2-/- Tg mice compared to 
Ramp2+/+ and Ramp2+/-, with and without the transgene (Table 2-2).  Representative M-
mode echocardiograms from Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2-/- Tg illustrate the 
ventricular dilation in Ramp2-/- Tg mice (Figure 2-3A), which resulted in a trending increase 
in calculated cardiac output in these animals (Table 2-2).  Septum and left ventricle posterior 
wall dimensions of Ramp2-/- Tg mice were unchanged from controls, although there was a 
non-significant trend towards a thinner posterior wall.  There was also a modest, but 
significant reduction in both ejection fraction and fractional shortening in the Ramp2-/- Tg 
dilated hearts.  These data indicate that loss of Ramp2 in non-endothelial cells leads to a 
spontaneous dilated cardiomyopathy (DCM)–like phenotype in adult mice, which at 6 
months of age had not yet progressed to heart failure, as indicated by the elevated cardiac 
output and sufficient heart function.  
Upon dissection, we observed that the hearts of Ramp2-/- Tg mice were grossly 
enlarged compared to wild-type and Ramp2-/- ntg mice (Figure 2-3B-C).  The adult Tg mice 
had no differences in body weight (Ramp2+/+ ntg: 28.4 ± 1.4 g, Ramp2+/+ Tg: 28.4 ± 1.2 g, 
Ramp2-/- Tg: 28.3 ± 1.2 g) or tibia length (Ramp2+/+ ntg: 17.6 ± 0.2 mm, Ramp2+/+ Tg: 17.9 ± 
0.1 mm, Ramp2-/- Tg: 17.8 ± 0.2 mm) regardless of their Ramp2 genotype.  Yet, total heart 
weights were significantly larger in the Ramp2-/- Tg mice when normalized to both body 
weight (Figure 2-3D) or tibia length (Ramp2+/+ ntg: 7.3 ± 0.4 mg/mm, Ramp2+/+ Tg: 6.5 ± 0.2 
mg/mm, Ramp2-/- Tg: 9.0 ± 0.3** mg/mm; **p<0.01).  Moreover, when normalized to body 
weight the left ventricle (Figure 2-3E), right ventricle (Figure 3F), and right atria (Ramp2+/+ 
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ntg: 0.15 ± 0.01 mg/g, Ramp2+/+ Tg: 0.15 ± 0.01 mg/g, Ramp2-/- Tg: 0.21 ± 0.02* mg/g; 
*p<0.05) all exhibited significant enlargement in the Ramp2-/- Tg animals compared to all 
other genotypes.  Similar significant trends were observed when the individual chamber 
weights were normalized to tibia length (LV:TL; Ramp2+/+ ntg: 5.4 ± 0.3 mg/mm, Ramp2+/+ 
Tg: 4.8 ± 0.2 mg/mm, Ramp2-/- Tg: 6.5 ± 0.2** mg/mm; **p<0.01).   
Cross-sectional area of myocytes within the left ventricle revealed slight, but 
significant cardiomyocyte hypertrophy, with no changes in left ventricular capillary density, in 
the Ramp2-/- Tg mice compared to controls (Figure 2-4A-D).  Picrosirius red staining showed 
no differences in perivascular fibrosis, but there was significantly increased interstitial 
fibrosis in the Ramp2-/- Tg hearts compared to hearts of Ramp2+/+ and Ramp2+/+ Tg mice 
(Figure 2-4E-H).  There were elevated levels of the oxidative stress indicator, lipid 
peroxidase evidenced by 4-hydroxynonenal (4-HNE) staining in Ramp2-/- Tg hearts (Figure 
2-4I-J).205  Together, the modest increases in hypertrophy, fibrosis, and oxidative stress, as 
well as modest decline in heart function, further support that 6 month old Ramp2-/- Tg mice 
exhibit a compensated, DCM-like phenotype. 
 
Adult Ramp2-/- Tg Mice Develop Multi-Organ Inflammation 
 DCM and hypotension can lead to vascular congestion and organ dysfunction 
throughout the body.206-208  Consistently, we observed that the spleen to body weight ratio 
was significantly increased in the Ramp2-/- Tg mice compared to all other genotypes (Figure 
2-5A).  Ramp2-/- Tg mice also exhibited macroscopic vascular congestion within their livers 
compared to control animals (Figure 2-5B).  Furthermore, multi-organ histology revealed a 
marked increase in the number of inflammatory foci, particularly surrounding the 
vasculature, within the liver (Figure 2-5C-D), kidney (Figure 5E-F) and lungs (Figure 2-5G-
H).  A diagnostic profile of adult serum from wild-type and Ramp2-/- Tg mice revealed few 
significant changes in circulating ions or enzyme levels that are typically indicative of 
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hepatocellular or renal damage (Supplemental Table 2-S2).  This supports that the end-
organ inflammation in Ramp2-/- Tg mice is likely downstream of altered hemodynamics due 
to DCM and hypotension, rather than primarily due to loss-of-function of Ramp2 in end-
organs.  
 
Conditional Calcrl Deletion Does Not Lead to a Dilated Cardiomyopathy Phenotype 
Since CLR and AM represent the most well-characterized, canonical pathway for 
RAMP2 modulation and the knockout mice for these genes recapitulate the Ramp2-/- 
developmental phenotypes, it is reasonable to consider that disruption of this pathway, 
which has been demonstrated to be cardioprotective in both animal studies and in humans32, 
77, 81, 209, may underlie the DCM and hypotensive phenotypes in Ramp2-/- Tg mice.  To test 
the functions of CLR in non-endothelial cells, we generated cardiac- and vSMC-specific 
Calcrl null mice using the SM22-Cre mediated excision.  The CalcrlloxP/loxP; SM22Cre+ mice 
were born at expected Mendelian ratios and survived to adulthood (Supplemental Figure 2-
S3A).  Relative Calcrl expression was significantly reduced in aortic vSMCs and hearts of 
CalcrlloxP/loxP; SM22-Cre+ compared to CalcrlloxP/+; SM22-Cre+ littermates (Supplemental 
Figure 2-S3B).  Importantly, CalcrlloxP/loxP; SM22-Cre+ adult males were normotensive and 
had no basal changes in heart function, size, or morphology (Supplemental Table 2-S3 or 
Figure 2-S3C).  Similarly, cardiac-specific Calcrl deletion using the αMHC-Cre+ transgenic 
line also failed to recapitulate the DCM phenotype, with animals surviving to adulthood with 
no basal cardiac dysfunction (Dackor R & Caron K.M., unpublished data, [2016]).   These 
data demonstrate that cardiac- and vSMC-specific Calcrl expression is not required for 
embryonic development or adult cardiovascular maintenance. 
We have previously shown that temporal, global deletion of Calcrl in adult 
CalcrlloxP/loxP; CAGG-CreERTM mice results in dilated lymphangiectasia in many lymphatic 
vascular beds throughout the body.199  However, these mice did not display any obvious 
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cardiac phenotypes and they had similar heart to body weight ratio as TAM-injected control 
mice (CalcrlloxP/loxP; CAGG-CreERTM:  4.43 ± 0.19 mg/g versus Calcrlflox/flox:  4.13 ± 0.14 mg/g, 
respectively).  Furthermore, conscious echocardiography of CalcrlloxP/loxP; CAGG-CreERTM 
female mice, even at 14 months of age, failed to reveal any significant changes in left 
ventricle internal diameter, function, or heart size compared to control mice (Supplemental 
Table 2-S4).  Collectively, these data, generated from three independent series of 
conditional deletion approaches, indicate that the global-, cardiac- or vSMC-specific loss of 
Calcrl does not recapitulate the DCM phenotype observed in the Ramp2-/- Tg animals.  
Therefore, this strongly suggests that the Ramp2-/- Tg phenotype is imparted by other 
RAMP2-associated GPCR pathways. 
 
Ramp2-/- Tg hearts exhibit reduced signaling pathways and expression of numerous RAMP-
associated GPCRs 
The genetic reduction or down-regulation of the transcriptional regulator CREB207, 210 
and the crucial PPAR pathway transcription factor, Pgc-1α211-213, have both been shown to 
be involved in DCM pathogenesis.  Thus as expected, the relative expression of Pgc-1α was 
significantly down-regulated in left ventricles and in an enriched cardiomyocytes fraction of 
Ramp2-/- Tg hearts compared to controls (Figure 2-6A-B).  There was also a significant 
reduction in phosphorylated CREB compared to total CREB and Gapdh in the Ramp2-/- Tg 
hearts compared to Ramp2+/+ ntg and Ramp2+/+ Tg hearts (Figure 2-6C).    Numerous 
Family B GPCRs signal through these pathways, including the Gcgr which has been shown 
to signal through cAMP to activate both CREB and PPAR transcription214-217, and both the 
Pthr1 and CaSR signal through cAMP and CREB.218-220  Interestingly, the gene expression 
levels of these RAMP-associated GPCRs were significantly down-regulated in the left 
ventricles of Ramp2-/- Tg mice compared to those of control animals, whereas genes 
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encoding for other RAMP-associated GPCRs, like Calcr, Vipr1, and Gpr30, were unchanged 
(Figure 2-6D). 
Similar gene expression changes in these Family B GPCR expression profiles were 
confirmed in isolated cardiomyocyte fractions (Figure 2-6E), further supporting the myocyte-
specific genetic dysregulation.  Calcrl expression was significantly increased in left ventricle, 
but not in the cardiomyocyte-enriched fraction, demonstrating that Calcrl upregulation is 
from a non-cardiomyocyte cell type.  The expression of both Pthr1 and Gcgr were 
significantly decreased during development in the hearts of Ramp2-/- ntg and Ramp2-/- Tg 
embryos (Figure 2-6F), supporting that these changes are specific to Ramp2 loss rather 
than secondary to the Cdh5-driven Ramp2 Tg or the DCM phenotype, as might be the case 
for CaSR.  Serum analysis revealed no significant dysregulation of circulating calcium or 
glucose, thereby eliminating uncompensated Pthr1 or Gcgr systemic signaling as a cause 
for the cardiovascular phenotypes (Supplemental Table 2-S2).  Collectively, these data 
demonstrate that genetic loss of Ramp2 in non-endothelial cells of the heart leads to down-
regulation of RAMP2-associated GPCRs, Gcgr and Pthr1, as an underlying mechanistic 
basis for the decreased pCREB and Pgc-1α responsible for the pathogenesis of the DCM-
like phenotype in Ramp2-/- Tg mice (Figure 2-6G).   
 
Discussion 
In this study, we generated an endothelial-specific Ramp2 Tg mouse model to 
attempt to rescue the embryonic lethality due to global loss of Ramp2.  While no Ramp2 null 
mice survive to birth, we observed a significant number of Ramp2-/- Tg born and able to 
survive into adulthood.  This result further confirms that endothelial Ramp2 is essential for 
embryonic survival and represents, to our knowledge, the first genetic rescue of the global 
Ramp2 null lethality. 
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It remains unclear why a significant number of Ramp2-/- Tg pups survive to late-
gestation, but are stillborn.  Interestingly, it was recently shown that mice with endothelial 
excision of Ramp2 during development using a Cdh5-Cre died during late-gestation.206  
Additionally, they report that approximately 5% of the endothelial Ramp2 knockouts live into 
adulthood and develop large hearts, hypotension, and multi-organ vasculitis.  In this current 
study we found that 40% of Ramp2-/- Tg survived to adulthood, and also developed similar 
cardiovascular and inflammatory phenotypes.  These two mouse models, as well as a 
previously published endothelial-specific deletion of Calcrl, demonstrate that adequate 
levels and timing of endothelial Ramp2/CLR/AM signaling are critical for embryonic 
survival.22 
In addition, these studies identify potential sex-dependent mechanisms of Ramp2, or 
Cdh5, regulation and function, as evidenced by the substantially reduced numbers of male 
Ramp2-/- Tg survivors.  We have previously shown that adult Ramp2+/- females have 
endocrine phenotypes not present in Ramp2+/- males.198  In addition, Ramp3-/- males, but not 
females, displayed exacerbated cardiovascular phenotypes when challenged with 
hypertension.193, 196   Thus, while RAMP2 and RAMP3 interact with both similar and different 
GPCRs, our observations of sex-dependent phenotypes in these genetic animals will 
provide an area for interesting future investigations.  
The complex compensatory mechanisms through which RAMP-mediated AM/CLR 
signaling regulate blood pressure have not been fully elucidated. It is well documented that 
AM infusion acts to lower blood pressure through both vSMC and endothelium, but it 
remains disputed if altered AM expression using genetic models alters basal blood 
pressure.31, 79, 91, 92, 221  Moreover, while developmental loss of Ramp2 leads to spontaneous 
hypotension and adult Ramp1-/- mice develop hypertension.197, 206  Calcrl deletion in vSMC 
and cardiomyocytes appears dispensable for regulation of basal vascular tone in adult 
males. It is evident that Ramp2 and AM signaling plays a role in vSMC and myocardium 
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development and function, which likely contributes to the pathogenesis of hypotension and 
DCM in Ramp2-/- Tg survivors.  Yet, the hypotension and DCM phenotypes occur despite 
maintenance of normal cardiac output.  It is further possible that the developmentally-
induced thin vSMC walls contribute to reduced vascular tone; however we demonstrated 
their ability to effectively respond to acute phenylephrine vasoconstriction. Therefore, 
additional studies that explore the entire repertoire of RAMP-mediated GPCRs will be 
required for full elucidation of the mechanistic basis for the hypotension in Ramp2-/- Tg 
survivors.        
Loss of Ramp2 in multiple non-endothelial cardiac cells, along with altered humoral 
signaling could lead to cardiac dysfunction and DCM pathogenesis.  The genetic 
dysregulation in isolated cardiomyocytes suggests roles of Ramp2/GPCRs specifically in 
cardiomyocytes. Interestingly, a recently published study demonstrated that a 
cardiomyocyte-specific Ramp2 deletion led to a DCM-like phenotype due to mitochondrial 
dysfunction and irregular calcium handling, which the authors attribute to loss of CLR/AM 
signaling.222  Similarly, this study suggests that cardiomyocyte loss of Ramp2 in the Ramp2-/- 
Tg mice is likely responsible for the DCM.  Moreover, our data demonstrates that neither 
cardiomyocyte- or vSMC-specific loss of Calcrl during development or conditional Calcrl 
deletion in adults recapitulate the DCM phenotype observed in the Ramp2-/- Tg and the 
aforementioned Ramp2flox/flox; MHC-MerCreMer mice.222  Therefore, collectively, these 
studies imply the involvement of other RAMP-associated GPCRs.  
It is apparent that RAMPs interact with numerous GPCRs biochemically, although in 
vivo physiologic evidence of these interactions is limited.  We found that lack of Ramp2 in 
non-endothelial cells leads to decreased expression of cardiac Pthr1 and Gcgr.  
Interestingly, human PTHR1 and GCGR interact specifically with RAMP2 and not RAMP1 or 
RAMP3 in which RAMP2 is important in chaperoning both GPCRs to the plasma 
membrane.191 Furthermore, it was recently demonstrated that RAMP2 was important in 
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GCGR ligand selectivity between glucagon and glucagon-like peptide 1, which have 
opposing physiologic effects on glucose homeostasis and cardiovascular function.223  While 
GCGR has not been directly connected to DCM pathogenesis, glucagon can alter calcium 
signaling in myocytes and glucagon-like peptide 1 improves glucose uptake and survival of 
canines with DCM.214, 224  Likewise PTHR1 signaling is important in vitamin D and calcium 
homeostasis, which have both been associated with DCM.225, 226  Together, Ramp2 loss-of-
function can not only alter both Pthr1 and Gcgr expression simultaneously, but may also 
alter their ability to reach plasma membrane, bind ligands, and signal.  Additionally, we 
observed decreased signaling through CREB and downregulation of Pgc-1α, which both 
have been shown to lead to DCM.207, 210, 211  Both Pthr1 and Gcgr signal through CREB and 
murine deletion of Gcgr led to decreased phosphorylated CREB and Pgc-1a expression 
levels.215, 217  Thus, loss of Ramp2 likely has numerous mechanisms for the development 
and maintenance of cardiac functions both dependent and independent of canonical 
AM/CLR/Ramp2 signaling. 
 
Perspectives 
The in vivo interplay between GPCR/RAMP/Ligand is highly complex and is only 
starting to be understood.  However, a better understanding of these interactions in a spatial 
and temporal manner in a pathophysiologic context will help us better target the unique 
GPCR/RAMP interfaces to potentially treat disease like DCM and hypertension.   
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Novelty and Significance 
What Is New? 
 Using a novel genetic mouse model, we find that endothelial expression of receptor 
activity-modifying protein 2 (Ramp2) is able to rescue the embryonic lethality of 
Ramp2-/- mice. 
 Ramp2 loss-of-function leads to spontaneous hypotension, dilated cardiomyopathy, 
and multi-organ inflammation, which we show are not recapitulated in genetic models 
with loss of calcitonin-receptor-like receptor (CLR) signaling. 
 In vivo loss of Ramp2 causes dysregulation of numerous RAMP-associated GPCRs, 
including the glucagon and parathyroid hormone receptors. 
What is Relevant? 
 The physiological consequences of RAMP interactions with Family B GPCRs have 
been challenging to address due to the embryonic lethality of RAMP2 mice.  Here, 
we elucidate the importance of RAMP2 interactions with several GPCR pathways, 
which can ultimately provide novel targets, or predict off-target consequences, for 
pharmacological therapies against cardiovascular disease.   
Summary 
This study provides genetic in vivo evidence that endothelial Ramp2 expression is 
necessary and sufficient to rescue the lethality of global loss of Ramp2.  Ramp2 expression 
in non-endothelial cells during development is required to maintain adult blood pressure and 
cardiac homeostasis—a process that involves numerous GPCR signaling pathways, 
including glucagon and parathyroid hormone receptor signaling.  Collectively, these studies 
extend the functional repertoire of RAMP-associated receptors in cardiovascular physiology. 
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Tables 
Mendelian 
Ratio 
ntg Tg(Cdh5-Ramp2) 
Ramp2+/+ Ramp2+/- Ramp2-/- Ramp2+/+ Ramp2+/- Ramp2-/- 
Expected N 35  70  35  35  70  35  
Actual N P7 47  88  0  48  83  14* 
Actual/ 
Expected  
134% 126% 0% 137% 119% 40% 
 
Table 2-1:  Endothelial restoration of Ramp2 can rescue the global Ramp2-/- 
embryonic lethality.  Breeding results, both expected Mendelian and actual results from 
Ramp2+/- Tg(Cdh5-Ramp2) crossed with Ramp2+/- ntg.  N = 280 pups.  Significance in 
survival between Ramp2-/- ntg and Ramp2-/- Tg pups determined by the Mantel-Cox test:  
*p<0.001. 
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Echo 
Parameters 
ntg Tg (Cdh5-Ramp2) 
Ramp2+/+ Ramp2+/- Ramp2+/+ Ramp2+/- Ramp2-/- 
Mouse 
Number 
10 4 7 4 7 
Mouse Age 
(wks) 
26.7±1.3 26.8±2.0 29.3±2.3 26.3±2.2 29.7±1.6 
Heart Rate 
(BPM) 
624±15 578±38 574±50 614±55 552±21 
LV Vol, d (µL) 35.6±4.7 32.0±3.9 34.1±6.7 27.9± 5.9 73.4±9.5*,†,‡,§ 
LV Vol, s (µL) 7.6±1.6 5.0±1.4 7.0±2.7 5.4±2.4 23.1±3.5*,†,‡,§ 
CO (mL/min) 16.5±2.1 15.4±1.2 16.1±3.2 13.2±0.9 27.0±4.8* 
EF (%) 81.2±3.0 85.1±2.0 82.4±3.6 83.3±5.1 68.3±2.3*,†,‡,§ 
FS (%) 51.6±2.7 52.9±2.2 51.1±4.0 52.4±6.5 37.9±1.8*,‡ 
IVS, s (mm) 1.13±0.05 1.16±0.06 1.12±0.07 1.07±0.07 1.08±0.07 
IVS, s (mm) 1.72±0.06 1.74±0.06 1.73±0.07 1.68±0.13 1.60±0.07 
LVID, d (mm) 2.94±0.20 2.88±0.14 2.90±0.22 2.70±0.23 4.03±0.22*,†,‡,§ 
LVID, s (mm) 1.52±0.17 1.36±0.13 1.45±0.21 1.32±0.27 2.50±0.14*,†,‡,§ 
LVPW, d 
(mm) 
1.54±0.10 0.96±0.07 1.22±0.13 1.08±0.30 0.87±0.06 
LVPW, s 
(mm) 
1.74±0.13 1.72±0.04 1.76±0.08 1.60±0.20 1.40±0.08 
 
Table 2-2:  Ramp2-/- Tg adults develop left ventricle dilatation and declining heart 
function.  Echocardiography analysis from Ramp2+/+, Ramp2+/-, and Ramp2-/- mice with and 
without the transgene.  BPM, beats per minute; LV, left ventricle; d, diastole; s, systole; CO, 
cardiac output; EF, ejection fraction; FS, fractional shortening; IVS, interventricular septal; 
LVID, left ventricle internal diameter; LVPW, left ventricle posterior wall.  Data represented 
as averages ± SEM with significance of p<0.05 determined by one-way ANOVA with 
Tukey’s Multiple Comparison.  Significant compared to: *Ramp2+/+ ntg, †Ramp2+/- ntg, 
‡Ramp2+/+ Tg, §Ramp2+/- Tg. 
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Figures 
 
 
Figure 2-1:  Endothelial restoration of Ramp2 partially rescues embryonic edema 
leading to prolonged survival of Ramp2-/- mice.  (A) Representative images and (B) 
quantification of edema severity from e14.5 Ramp2+/+, Ramp2-/- ntg, and Ramp2-/- Tg 
embryos.  Edema scoring system: (1) no edema, (2) mild edema, and (3) severe edema.  
(C) Immunohistochemistry and (D) quantification of jugular lymph sac size using Lyve1 
(green) and DAPI (magenta).  CA, carotid artery; JV, jugular vein; JLS, jugular lymph sac.  
(E)   Histology of descending aortas and (F) quantification of aortic vSMC wall thickness.  
(G) Heart histology, (H) quantification of ventricle area, and (I) whole heart relative Ramp2 
expression from viable Ramp2+/+ ntg, Ramp2-/- ntg, and Ramp-/- Tg e14.5 embryos.  
Samples were normalized to Ramp2+/+ ntg and Gapdh expression.  Scale bars: 100 µm.  
Data represented as average ± SEM from N = 3-8 mice per genotype.  Significance 
determined by one-way ANOVA with Tukey’s Multiple Comparison with *p<0.05, **p<0.01, 
and ***p<0.001. 
 
 
 
 
 
 
41 
 
 
 
Figure 2-2:  Ramp2-/- Tg adults are hypotensive.  (A)  Tail-cuff telemetry blood pressure 
analysis from conscious Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2-/- Tg adult female mice.  
(B) Representative images and vSMC wall thickness quantifications of Ramp2+/+ ntg and 
Ramp2-/- Tg descending aortas. Scale Bars:  100 m.  (C) Intra-arterial blood pressure 
measurements from anesthetized Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2-/- Tg mice during 
baseline and after challenged with intravenous bolus of 30 g/kg phenylephrine (PE) or 12 
nmol/kg adrenomedullin (AM).  Drug response represented as a % change from baseline 
(dotted line).   Data represented as average ± SEM from N = 3-5 mice per genotype.  
Significance determined by one-way ANOVA with Tukey’s Multiple Comparison (A, C) or 
unpaired student T-test (B) with *p<0.05 and **p<0.01. 
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Figure 2-3:  Ramp2-/- Tg adults develop spontaneous dilated cardiomyopathy.  (A)  
Representative M-mode echocardiograms from left ventricles of Ramp2+/+ ntg, Ramp2+/+ Tg, 
and Ramp2-/- Tg mice.  Macroscopic (B) and H&E (C) images of whole hearts and left 
ventricles from of Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2-/- Tg mice.  Scale Bars:  2 mm.  
Quantification of heart (D), left ventricle (E), and right ventricle (F) weight normalized to body 
weight.  Data represented as average ± SEM from N = 4-10 mice per genotype.  
Significance determined by one-way ANOVA with Tukey’s Multiple Comparison with 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 2-4:  Ramp2-/- Tg left ventricles hypertrophied with early fibrotic and oxidative 
stress changes.  (A) Histology and (B) wheat germ agglutinin (WGA, white) 
immunohistochemistry showing cardiomyocytes from Ramp2+/+ ntg, Ramp2+/+ Tg, and 
Ramp2-/- Tg left ventricles.  Quantification of (C) cardiomyocyte cross-sectional area and (D) 
capillary density from mouse left ventricles.  Representative images and quantification of left 
ventricles stained with Picrosirius Red showing (E-F) perivascular and (G-H) interstitial 
fibrosis/collagen deposition.  (I) Immunohistochemistry and (J) quantification of 4-HNE 
(white) staining showing relative levels oxidative stress in left ventricles.  Scale Bars:  100 
µm.  Data represented as averages ± SEM from N = 3-4 mice per genotype. Significance 
determined by one-way ANOVA with Tukey’s Multiple Comparison with *p<0.05 and 
**p<0.01. 
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Figure 2-5:  Ramp2-/- Tg have vascular congestion and multi-organ inflammation 
downstream of hypotension and dilated cardiomyopathy.  (A) Spleen to body weight 
ratio from Ramp2+/+, Ramp2+/-, and Ramp2-/- females with and without the transgene.  (B) 
Macroscopic images of liver vasculature abnormalities in Ramp2-/- Tg compared to that of 
Ramp2+/+ ntg and Ramp2+/+ Tg controls.  Histology and quantification of inflammatory foci 
(blue arrows) in (C-D) livers, (E-F) kidneys, and (G-H) lungs from Ramp2+/+ ntg, Ramp2+/+ 
Tg, and Ramp2-/- Tg mice.  Scale Bars:  1 mm (B) and 100 µm (C, E, G).  Data represented 
as averages ± SEM from N = 3-4 mice per genotype.  Significance determined by one-way 
ANOVA with Tukey’s Multiple Comparison with *p<0.05, **p<0.01, ***p<0.001.  
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Figure 2-6:  Decreased signaling and expression of RAMP-associated GPCRs in 
embryonic and adult Ramp2-/- Tg hearts.  RT-PCR showing relative Pgc-1α expression 
from Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2-/- Tg adult left ventricle (A) or cardiomyocytes 
(B).  (C) Quantification and representative western blot of phosphorylated CREB to total 
CREB in Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2-/- Tg left ventricles.  Samples were 
normalized to Ramp2+/+ ntg and CREB with Gapdh used as a loading control.  Relative 
expression of the Family B GPCRs; Calcrl, Calcr, Pthr1, Gcgr, Vipr1, CaSR and Gpr30 in 
(D) whole left ventricles and (E) isolated cardiomyocytes from adult Ramp2-/- Tg mice and 
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Ramp2+/+ controls.  (F) Relative GPCR expression from e14.5 Ramp2+/+ ntg, Ramp2-/- ntg, 
and Ramp2-/- Tg whole hearts.  Samples were normalized to Ramp2+/+ ntg and Gapdh and 
Rpl19 expression.  (E)  Data represented as averages ± SEM from N = 3-5 mice per 
genotype.  Significance determined by one-way ANOVA with Tukey’s Multiple Comparison 
(A, C, D, F) or unpaired student T-test (B, E) with *p<0.05.  (F) Model summarizing 
cardiovascular phenotypes in Cdh5+ endothelium and Cdh5- cells in Ramp2+/+ ntg, 
Ramp2+/+ Tg, and Ramp2-/- Tg adults.    
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Supplemental Methods 
Ramp2 Transgene Construct Generation 
The mouse Ramp2 cDNA with human CD33 signal sequence, FLAG-tag epitope, 
bovine growth hormone polyadenylation tail in pcDNA3.1 backbone was gift from Dr. Walter 
Born.  The mouse vascular endothelial cadherin (Cdh5) promoter with rabbit β-globin intron 
II was extracted from a plasmid which was gift from the Parise Lab.  The pieces of the 
transgene were inserted into pBluescript II KS+/- backbone and confirmed by sequencing. 
The University of North Carolina Animals Models Core microinjected the isolated transgene 
into pronuclei of C57BL/6 embryos and implanted into pseudo-pregnant females using 
standard published procedure.227  
 
Mouse Studies 
SJL-Tg(Tagln-cre)1Her (SM22-Cre) mice were obtained from the Jackson 
Laboratory228.  Vascular smooth muscle- specific Calcrl-null animals were generated by 
crossing CalcrlFlox/Flox with CalcrlloxP/+; SM22-Cre+ mice (Calcrl+/+ x SM22Cre+) generating the 
experimental (CalcrlLoxP/LoxP;SM22Cre+) and control (Calcrl+/LoxP;SM22Cre+) littermate mice 
used for this study.  The SM22Cre+ transgene was expressed in both control and 
experimental mice to ensure Cre recombinase toxicity could not contribute to differential 
phenotypes 229.   All mice used for this study were 3-4 month old male mice on a mixed 
genetic background.  Three to four month old female Calcrlflox/flox; CAGG CreERTM mice were 
injected intraperitoneal with tamoxifen (5 mg/40 g body weight, Sigma) for 5 days to excised 
Calcrl ubiquitously as previously reported.199  Aged matched female Calcrlflox/flox mice injected 
with tamoxifen were used as controls.  Mice were aged between 50-60 weeks post 
tamoxifen administration then conscious echocardiography was used to assess heart 
function.  
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Blood Pressure  
Non-invasive blood pressures were measured using the CODA 8 (Kent Scientific 
Corporation) tail-cuff telemeter as previously described.230  Conscious 5-8 month old Ramp2 
female and 3-4 month CalcrlloxP/loxP;SM22Cre mice were acclimated to tail-cuff apparatus 
measurements for 4 days prior to 3 days of collected blood pressure measurements.  
Systolic, diastolic, and mean arterial pressure was measured 25 times per day per mouse 
and averaged together with measurements from 3 days after acclimation.  Measurements 
were excluded by software if mouse moved during measurement or if mouse heart rate was 
below 450 bpm or above 750 bpm.  For drug studies, mice were anesthetized with 1.5-2% 
isoflurane inhalation and an intra-arterial catheter was inserted into the right carotid artery.  
Measurements were recorded using SciSense Model ADV500 PV control unit with 
Labscribe 2 software (iWorx Systems).  Baseline blood pressure was established before 
drugs were injected into the left jugular vein.  Phenylephrine (Sigma) was delivered at 30 
µg/kg and adrenomedullin (Phoenix Pharmaceuticals) at 12 nmol/kg both diluted in separate 
50 µL saline as previously reported.47, 231  The percent changes were calculated from 
average of measurements 20 s taken 5 s post-injection and normalized to 20 s prior to 
injection.   
 
Echocardiography  
Conscious echocardiography was done using a VSI 2100 high frequency ultrasound 
(VisualSonics) on 5-8 month old female Ramp2 mice and aged female CalcrlloxP/loxP;CAGG-
CreER mice.  M-mode echocardiographs of left ventricle were analyzed using three 
measurements of both diastolic and systolic dimensions and averaged using Vevo 2100 
software (VisualSonics), which calculated heart rate, ejection fraction, fractional shortening, 
and left ventricular volumes.  Approximate cardiac output was determined by stroke volume 
(LV Vol; diastolic – LV Vol; systolic) multiplied by heart rate and divided to 1000.  A 30-MHz 
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probe and Vevo 660 Ultrasonography (VisualSonics) was used for 3-4 month old male 
CalcrlloxP/loxP;SM22Cre mice and controls.  These mice were anesthetized with 1-1.5% 
isoflurane and body temperature was maintained at 37°C by placing mice under a heating 
lamp and heart rate was closely monitored.  
 
Tissue Collection 
Whole mouse necropsy including heart, aorta, lung, kidney, and liver were weighed, 
imaged, and collected in 4% paraformaldehyde, flash frozen in liquid nitrogen, or stored in 
RNALater (Ambion).  Organ weights were normalized to either body weight or tibia length.  
Heart chamber dissections were done to identify chamber-specific changes and collect 
tissue for histology, RNA, and protein from the left ventricle.200  Pregnant females were 
dissected during midgestation and all viable embryos were imaged and collected.  For 
embryonic hearts, e14.5 whole hearts were removed and separated from lungs prior to 
fixation.  Endothelial cells were isolated with magnetic-associated cell sorting using CD31-
specific antibodies as previously described.201  Briefly, all lobes of lungs were collected 
pooled from either transgenic or wild-type adult mice and dissociated using manual mincing 
followed by collagenase type II (Worthington), neutral protease (Worthington), and 
deoxyribonuclease (Worthington).  Single cell suspensions are labeled with PE-rat anti-
mouse CD31 antibody (BD Pharmingen) and subsequently with anti-PE conjugated 
magnetic beads (Miltenyi) and ran through magnetic column to isolate both CD31- and 
CD31+ cell fractions.  Cells pellets were flash frozen and stored at -80C until RNA 
extraction.  Adult cardiomyocytes were isolated with collagenase II digestion using 
previously published protocol202.  Briefly, mice were injected with 100 IU of heparin (Sigma) 
and anaesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 
mg/kg).  Hearts were dissected from thoracic cavity and cannulated to perfusion system 
(Radnoti).  Hearts were perfused with Wittenberg Isolation Buffer with a constant flow of 4 
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mL/min at 37°C for 5 min, followed by Digestion Solution for another 10 min and stopped by 
perfusion with Stop Solution.  The hearts were further teased into small pieces with forceps, 
pipetted into single cells, and filtered through 100m cell strainer. Cardiomyocytes were 
enriched by spinning down at low speed (50 g for 5 min) and pellets were collected in TRIzol 
reagent (Invitrogen) and stored at -80°C.  Descending aorta was collected and the adventitia 
and endothelial layers were removed by enzymatic digestion with collagenase type II 
(Worthington) to obtain purified VSMC as previously described.232 
 
Gene Expression Analysis 
Tissues were either snap frozen in liquid nitrogen and stored at -80°C or stored at -
20°C in RNALater (Ambion).  RNA was extracted using TRIzol reagent and a bead 
homogenizer (Percellys) according to standard procedures, and then DNase treated 
(Promega RQ1) and reverse transcribed with M-MLV (Invitrogen) or iScript cDNA Synthesis 
Kit (BioRad).  Semi-quantitative gene expression analysis was carried out using an in-house 
purified PFu polymerase and products were run out on a 3% agarose gel.  Quantitative gene 
expression was assayed with Taqman master mix with ROX (Applied Biosystems or 
Biobasic) and run on a StepOne Plus (Applied Biosystems).  RT-PCR primers and probes 
are listed in Supplemental Table S1. Biological N was 3-5 mice per genotype and the 
relative expression levels were determined by the ΔΔCt and normalized to Gapdh or Rpl19 
expression.   
 
Whole Mount, Histology, and Immunohistochemistry 
Fixed whole mount tissue was washed and imaged using a Leica MZ16FA dissecting 
stereoscope outfitted with a QImaging Micropublisher 5.0 RTV color CCD camera using 
QCapture imaging software (QImaging).  Paraffin embedded tissues were sectioned and 
stained for hematoxylin & eosin and Picrosirius Red using standard procedures.  H&E and 
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Picrosirius Red slides were imaged using a Leitz Dialux 20 microscope outfitted with a 
QImaging Micropublisher 5.0 RTV color CCD camera.  For immunohistochemistry, paraffin 
sections were deparaffinized, hydrated, permeabilized and blocked with 5% normal donkey 
serum.  Slides were then stained with primary antibodies including, rabbit anti-LYVE1 
(1:300, Fitzgerald), mouse anti-4-HNE (1:40, ABCAM) overnight at room temperature.  
Sections were rinsed, blocked, and incubated with secondary antibodies including, Dylight 
594 isolectin B4 (1:200, Vector Laboratories), rhodamine wheat germ agglutinin (WGA) 
(1:1000, Vector Laboratories), donkey anti-rabbit Cy5 (1:200, Jackson ImmunoResearch), 
donkey anti-mouse Cy3 (1:100, Jackson ImmunoResearch), and Hoechst 33258 (1:1000, 
Sigma-Aldrich) in the dark for 90 minutes at room temperature.  Images were acquired on a 
Nikon E800 fluorescence microscope with a Hammamatsu Orca CCD camera and DAPI, 
Cy2, Cy3, Cy5, Texas Red filter cubes with Metamorph software (Molecular Devices Corp.).  
Image brightness and contrast changes were made equally across all comparable images 
using Photoshop CS4 and color images were pseudo-colored using ImageJ 
(imageJ.nih.gov). 
 
Western Blot 
Tissues were either snap frozen in liquid nitrogen and stored at -80°C.  Protein was 
extracted using Lens Homogenization Buffer with DTT and cOmplete protease inhibitor 
cocktail tablets (Roche) and a bead homogenizer (Percellys) according to standard 
procedures.  Protein concentrations were determined using Pierce bicinchoninic acid (BCA) 
protein assay kit (Thermo Scientific) read on a Mithras LB 940 (Berthold Technologies) plate 
reader.  Protein ran on Mini-Protean TGX SDS-PAGE gel (BioRad) and transferred onto 
nitrocellulose (GE Healthcare) membrane.  Blots were blocked and stained in 5% BSA or 
5% nonfat milk diluted in tris-buffered saline with 0.1% Tween 20.  Blots were incubated in 
primary antibodies including, rabbit anti-DYKDDDDK FLAG M2 (1:750, Cell Signaling), 
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rabbit anti-phosphorylated CREB Ser133 87G3 (1:1000, Cell Signaling), rabbit anti-CREB 
48H2 (1:1000, Cell Signaling), and mouse anti-GAPDH (1:4000, Novus Biologicals) 
overnight at 4°C.  Blots were rinsed, blocked, and incubated with secondary antibodies 
including, goat anti-rabbit Dylight 680 (1:15,000, Thermo Scientific) and goat anti-mouse 
Dylight 800 (1:15,000, Thermo Scientific) in the dark for 60 minutes at room temperature.  
An Odyssey CLx (Li-COR) was used for imaging.  Image brightness and contrast changes 
were made equally across all comparable images using Photoshop CS4 and quantification 
by densitometry was done using thresholds by ImageJ. 
 
Serum Analysis 
Adult females were anesthetized using isoflurane and whole blood was collected by 
retro-orbital bleeds and separated using Microtainer SST tubes (BD Scientific) and serum 
was stored at -20°C. Whole serum (100 L) was loaded onto VetScan Comprehensive 
Diagnostic Profile rotors (Abaxis) and analyzed using VetScan V2 Chemistry Analyzer 
(Abaxis) according to manufacturer’s protocol. 
 
Morphometric Quantification 
Embryonic e13.5 jugular lymph sacs were measured from both sides of embryos 
taken from relatively the same sectional plane.  Embryonic e14.5 cardiac ventricles area 
was measured using images from whole hearts extracted during dissection and qualitatively 
confirmed using histological sections.  Adult and e14.5 descending aorta wall thickness was 
determined by measuring the distance from lumen to edge of vascular smooth muscle cell 
excluding the adventitia with 10-15 measurements made around the circumference of the 
vessel in cross section.  Hypertrophy was assessed by two blinding researchers measuring 
the area of 15 individual cardiomyocytes in cross section from three fields per H&E and 
WGA stained left ventricles. Capillary density quantification has been previously 
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described.200  Briefly, left ventricles were stained with isolectin and WGA and 30 to 50 
cardiomyocytes and bordering capillaries were count using ImageJ and averaged from 3 
fields per left ventricle. Perivascular fibrosis was quantified by measuring the area of 
Picrosirius Red staining surrounding 3-4 equivalent coronary vessels per left ventricle and 
normalizing it to the area of the vessel lumen.  The amount of left ventricle interstitial fibrosis 
and 4-HNE oxidative stress were determined by threshold analysis of the signal normalized 
to the total section area in a 3-4 20x fields per mouse from equivalent regions of the left 
ventricle.  Generalized inflammation was assessed by averaging the number of hematoxylin 
dense foci larger than 0.02 mm2 per section.   
  
 
 
 
 
 
 
 
 
 
 
 
54 
 
Supplemental Tables 
Gene 
Forward Primer  
(5’ – 3’) 
Reverse Primer 
(5’ – 3’) 
Taqman Probe 
(5’-[6~FAM] – 
[TAMRA~6~FAM]-3’) 
Ramp2 (Wild-
type Allele) 
GAAGTCAGGCAG
TCAGGGTTG 
TCTGTCTGGAT
GCTGCCTTGC 
 
Ramp2 (Null 
Allele) 
GACGAGTTCTTC
TGAGGGGA 
TCTGTCTGGAT
GCTGCCTTGC 
 
Ramp2 
CAGAATCAATCTC
ATCCCACTGAG 
GTCCATGCAAC
TCTTGTACTCAT
ACC 
ATGGAAGACTACGAAAC
ACATGTCCTACCTTG 
FLAG-Ramp2 
(Transgene) 
GACTACAAAGAC
GATGACGACAAG
C 
GTCCATGCAAC
TCTTGTACTCAT
ACC 
 
Calcrl (Wild-
type Allele) 
GCGGAGCATATT
CAATCACAAG 
GAAATGTGCTG
TATGTTCAAGC 
 
Calcrl (Flox 
Allele) 
GCGGAGCATATT
CAATCACAAG 
GACGAGTTCTT
CTGAGGGGA 
 
Calcrl (Excised 
Allele) 
GCGGAGCATATT
CAATCACAAG 
GAATAAGTTGA
GCTGGGCAG 
 
SM22-Cre 
GCTGCCACGACC
AAGTGACAGCAA
TG 
GTAGTTATTCG
GATCATCAGCT
ACAC 
 
Pthr1   
Mm00441046_m1 (Life 
Tech) 
Gcgr   Mm00433536_m1 (ABI) 
CaSR   Mm00443375_m1 (ABI) 
Calcrl   Mm00516986_m1 (ABI) 
Ctr (Calcr)   Mm00432271_m1 (ABI) 
Vip1r   Mm00449214_m1 (ABI) 
Gpr30   Mm02620446_s1 (ABI) 
Pgc-1α 
(Ppargc1α) 
  
Mm01208835_m1 (Life 
Tech) 
Gapdh   Mm99999915_g1 (ABI) 
Rpl19   
Mm02601633_g1 
(Thermo/Fisher) 
 
Table 2-S1: Genotype and RT-PCR Gene Expression Primers and Probes 
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Serum Analyte Ramp2+/+ ntg Ramp2-/- Tg P value 
Albumin (g/dL) 3.8 ± 0.1 3.6 ± 0.2 0.33 
Alkaline phosphatase (U/L) 53 ± 7 50 ± 6 0.72 
Alanine aminotransferase (U/L) 53 ± 3 45.8 ± 2 0.15 
Amylase (U/L) 631 ± 8 713 ± 23* 0.02 
Total bilirubin (mg/dL) 0.3 ± 0.0 0.3 ± 0.0 1 
Blood Urea Nitrogen (mg/dL) 22 ± 1 18 ± 2 0.06 
Calcium (mg/dL) 8.6 ± 0.1 8.7 ± 0.2 0.82 
Phosphorus (mg/dL) 6.9 ± 0.3 8.2 ± 0.4 0.06 
Creatinine (mg/dL) 0.2 ± 0.0 0.3 ± 0.0 0.09 
Glucose (mg/dL) 252 ± 11 260 ± 18 0.70 
Sodium (mmol/L) 147 ± 1 148 ± 0 0.82 
Potassium (mmol/L) 5.6 ± 0.5 5.8 ± 0.7 0.85 
Total protein (g/dL) 5.1 ± 0.2 4.8 ± 0.2 0.34 
Globulin (g/dL) 1.2 ± 0.1 1.2 ± 0.1 0.72 
 
Table 2-S2:  Relatively similar systemic circulating factors in Ramp2+/+ ntg and 
Ramp2-/- Tg serum.  Comprehensive diagnostic profile of 100 L of serum from adult 
female Ramp2+/+ ntg and Ramp2-/- Tg mice.  N = 4-5 mice per genotype.  Data represented 
as averages ± SEM with significance determined by the unpaired student T-test: *p < 0.05. 
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Cardiovascular Parameters 
CalcrlloxP/+; SM22-
Cre+ 
CalcrlloxP/loxP; SM22-
Cre+ 
Mouse Number 5 6 
Mouse Age (wks) 12-16 12-16 
Gender Male Male 
Body Weight (g) 33.3 ± 1.6 32.6 ± 0.7 
Mean Arterial Pressure (mmHg) 128.6 ± 4.0 121.6 ± 4.2 
Anesthesia 1.5% Isoflurane 1.5% Isoflurane 
Heart Rate (BPM) 510 ± 12 478 ± 8 
LVID, d (mm) 3.75 ± 0.16 4.00 ± 0.11 
LVID, s (mm) 2.86 ± 0.15 3.06 ± 0.13 
LVPW, d (mm) 1.07 ± 0.08 0.92 ± 0.04 
LVPW, s (mm) 1.28 ± 0.08 1.13 ± 0.07 
Ejection Fraction (%) 25.8 ± 3.1 23.6 ± 1.7 
Fractional Shortening (%) 48.8 ± 6.2 47.4 ± 2.9 
Cardiac Output (mL/min) 16.0 ± 2.0 15.3 ± 0.7 
HW:BW (mg/g) 5.48 ± 0.34 5.31 ± 0.21 
LV:BW (mg/g) 4.04 ± 0.27 3.78 ± 0.16 
 
Table 2-S3:  Vascular smooth muscle cell conditional Calcrl deletion does not lead to 
hypotension or dilated cardiomyopathy phenotype in adult males mice.  Tail-cuff 
telemetry, echocardiography, and dissection measurements from 12-16 week old male 
CalcrlloxP/+; SM22-Cre and CalcrlloxP/loxP; SM22-Cre.  Mice were conscious for blood pressure 
measurements, but under isoflurane anesthesia for echocardiography.  BPM, beats per 
minute; LV, left ventricle; LVID, left ventricle internal diameter; LVPW, left ventricle posterior 
wall, HW, heart weight; BW, body weight.  Data represented as averages ± SEM with 
significance determined by the unpaired student T-test. 
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Heart Parameters Calcrlflox/flox 
CalcrlloxP/loxP;  
CAGG-CreERTM+ 
Mouse Number 7 6 
Mouse Age (wks) 70.4 ± 1.8 (+TAM 12-16) 68.2 ± 2.5 (+TAM 12-16) 
Gender Female Female 
Anesthesia Conscious Conscious 
Heart Rate (BPM) 577 ± 29 614 ± 29 
LV Volume, d (µL) 51.7 ± 6.0 47.9 ± 3.5 
LV Volume, s (µL) 12.5 ± 2.3 12.2 ± 1.8 
Cardiac Output (mL/min) 23.0 ± 2.0 22.3 ± 1.0 
Ejection Fraction (%) 73.1 ± 4.3 74.9 ± 2.6 
Fractional Shortening (%) 42.3 ± 3.6 43.0 ± 2.4 
IVS, d (mm) 1.13 ± 0.08 1.13 ± 0.04 
IVS, s (mm) 1.72 ± 0.09 1.63 ± 0.08 
LVID, d (mm) 3.63 ± 0.20 3.40 ± 0.10 
LVID, s (mm) 2.13 ± 0.24 1.94 ± 0.11 
LVPW, d (mm) 0.93 ± 0.14 0.98 ± 0.10 
LVPW, s (mm) 1.50 ± 0.11 1.55 ± 0.13 
HW:BW (mg/g) 3.89 ± 0.31 4.13 ± 0.20 
LV:BW (mg/g) 2.84 ± 0.19 2.97 ± 0.14 
 
Table 2-S4:  Global conditional Calcrl deletion does not lead to dilated 
cardiomyopathy phenotype in aged females.  Echocardiography and dissection 
measurements from conscious aged female Calcrlflox/flox and CalcrlloxP/loxP; CAGG-CreERTM 
mice injected with TAM when 12-16 weeks old.  BPM, beats per minute; LV, left ventricle; d, 
diastole; s, systole; IVS, interventricular septal; LVID, left ventricle internal diameter; LVPW, 
left ventricle posterior wall, HW, heart weight; BW, body weight.  Data represented as 
averages ± SEM with significance determined by the unpaired student T-test. 
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Supplemental Figures 
 
Figure 2-S1:  Endothelial-specific overexpression of murine Ramp2.  (A) Transgene 
construct utilizing the vascular-specific Cdh5 promoter to drive FLAG-tagged murine Ramp2 
cDNA.  (B)  Ramp2-FLAG transgene protein was detected in both transgenic founders 1 
and 2 in the heart (H), intestine (I), kidney (K), and lung (L).  FLAG protein was not detected 
in wild-type tissue.  (C)  Semi-quantitative RT-PCR of FLAG transgene transcript in isolated 
lung CD31+ endothelium from transgenic and wild-type mice.  RT-PCR for Ramp2 
expression from (D) isolated CD31+ endothelium and whole lungs and (E) isolated 
cardiomyocyte and whole left ventricles from adult Ramp2 Tg and wild-type controls.  
Samples normalized to wild-type whole tissue expression and Gapdh. 
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Figure 2-S2:  Generation of gene-targeted Ramp2 deficient mice with and without 
Ramp2 Tg.  (A)  Ramp2+/+ Tg(Cdh5-Ramp2)1 mice were bred to Ramp2+/- ntg animals to 
generated Ramp2+/- Tg.  PCR representing the six genotypes possible at e14.5 generated 
from the parent cross of Ramp2+/- Tg mice with Ramp2+/- ntg. (B) Kaplan-Meier survival plot 
of Ramp2-/- embryos with and without the Tg.  (C) Representative images surviving 
Ramp2+/+ Tg and Ramp2-/- Tg pups.  Significance were determined by Mantel-Cox and 
Gehan-Breslow-Wilcoxon tests with ***p<0.001. 
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Figure 2-S3:  Generation and characterization of vascular smooth muscle cell-specific 
Calcrl deficient mice.  (A) PCR representing the four genotypes generated from the parent 
cross of CalcrlFlox/Flox x Caclrl+/LoxP; SM22Cre+.  The recombined “loxP” allele is only detected 
in SM22Cre+ mice and all mice were born at the expected Mendelian ratios.  (B) Relative 
Calcrl gene expression in aortic (Ao.) VSMCs, bladder, heart, skeletal muscle (Sk. Ms.), 
liver, and lung from adult CalcrlLoxP/LoxP; SM22Cre+ and CalcrlLoxP/+; SM22Cre+ controls.  (C) 
Representative images of H&E stained left ventricles from adult males of both genotypes.  
Scale bar:  1 mm.  Data represented as averages ± SEM with *p < 0.05 determined by the 
unpaired student T-test and was normalized to individual tissues CalcrlLoxP/+;SM22Cre+ 
expression. 
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Chapter III: Dosage of adrenomedullin correlates with tumor and lymph node 
lymphangiogenesis3 
 
Overview   
Adrenomedullin (AM) is a potent lymphangiogenic factor that promotes lymphatic 
endothelial cell (LEC) proliferation through a pharmacologically-tractable G protein-coupled 
receptor.  Numerous types of human cancers have increased levels of AM, however, the 
functional consequences of this have not been characterized.  Therefore, we evaluated 
whether modulating adrenomedullin gene (Adm) dosage within tumor cells affects 
lymphangiogenesis.  Murine Lewis Lung Carcinoma (LLC) cells that overexpress or under-
express Adm were injected subcutaneously into C57BL/6 mice and tumors were evaluated 
for growth and vascularization.  A dosage range from ~10% to 200% of wild-type Adm 
expression did not affect LLC proliferation in vitro or in vivo, nor did it affect angiogenesis.  
Importantly, the dosage of Adm markedly and significantly influenced tumor 
lymphangiogenesis.  Reduced Adm expression in tumors decreased the proliferation of 
LECs and the number of lymphatic vessels, while elevated tumor Adm expression led to 
enlarged lymphatic vessels.  Moreover, overexpression of Adm in tumors induced sentinel 
lymph node lymphangiogenesis and led to an increased incidence of Ki67 positive foci 
within the lung.  These data show that tumor-secreted AM is a critical factor for driving both 
                                                          
3 Reprinted with permission from: Natalie O. Karpinich, Daniel O. Kechele, Scott T. 
Espenschied, Helen H. Willcockson, Yuri Fedoriw, Kathleen M. Caron.  Adrenomedullin 
gene dosage correlates with tumor and lymph node lymphangiogenesis.  FASEB Journal.  
2013;27(2):590-600. 
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tumor and lymph node lymphangiogenesis.  Thus, pharmacological targeting of AM 
signaling may provide a new avenue for inhibition of tumor lymphangiogenesis.  
Introduction 
The spread of tumor cells to distant sites in the body can occur through the blood or 
the lymphatic vascular system.  Although the importance of the lymphatic system has been 
recognized for over 100 years, studies in understanding the molecular mechanisms of the 
metastatic process in lymphatics have lagged behind the more aggressively studied blood 
vasculature.  This has been due, in part, to incomplete knowledge about the function of 
lymphatic vessel networks and related lymphoid tissues, as well as a lack of lymphatic-
specific markers.  The discovery of lymphatic endothelium specific markers (such as 
LYVE1,233 podoplanin,234 and Prox142) has greatly enhanced our ability to investigate the 
lymphatic vasculature as a conduit for tumor cell dissemination.   
The expansion of lymphatic vessels in and around tumors can facilitate the spread of 
tumor cells through the lymphatics.235, 236 Clinical studies show that increased peritumoral 
lymphatic vessels are associated with a higher number of metastatic lymph nodes (LNs) and 
subsequently, poor breast cancer patient outcome.237 The structural nature of lymphatic 
vessels, including their thin endothelium and lack of a basement membrane, is likely to 
make them more accessible to tumor cell escape.238 Recent studies have begun to elucidate 
that tumor secreted signals are necessary to first prime the sentinel LNs to form a metastatic 
niche.  Thus, the presence of tumor and LN lymphangiogenesis serves as an early indicator 
of the metastatic process. Numerous animal model studies have focused on the VEGF 
protein family and identified VEGF-A,239 VEGF-C,240-243 and VEGF-D244 as drivers of tumor 
and LN lymphangiogenesis and subsequent lymphatic metastasis. However, a more 
comprehensive understanding of factors involved in promoting vascular changes within a 
tumor would enhance our understanding of the molecular components necessary for 
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metastasis and thus, better guide design of drugs for effective management of metastatic 
disease. 
Adrenomedullin (Adm: gene; AM: protein) is a 52 amino acid peptide vasodilator that 
binds to and signals through the G-protein coupled receptor (GPCR), calcitonin receptor-like 
receptor (Calcrl: gene; CLR: protein) when the receptor is associated with receptor activity 
modifying protein 2 (RAMP2).  We and others have consistently shown that the expression 
of Calcrl and Ramp2 is increased in lymphatic endothelium compared to blood 
endothelium.22, 23, 245, 246  We have also recently demonstrated that AM signaling is required 
for normal development of the murine lymphatic vascular system, since genetic loss of either 
Adm or its associated signaling partners, Calcrl or Ramp2, results in embryonic lethality with 
profound interstitial edema as a consequence of arrested lymphatic vascular development.22  
Since AM and its receptor partners are among the first GPCRs implicated in 
lymphangiogenesis,247 there is an opportunity to expand beyond the current repertoire of 
RTK inhibitors and include a new arsenal of GPCR-based therapeutics for the inhibition of 
tumor (lymph)angiogenesis.  
AM peptide was initially isolated from a human adrenal tumor76 and abundant 
evidence continues to emerge implicating this peptide in tumor biology (reviewed in 248).  For 
example, in human tumors and numerous tumor cell lines, elevated AM levels have been 
reported to promote tumor cell survival, stimulate endothelial cell proliferation and help 
tumor cells evade immune surveillance.100, 103, 249  Genomic profiling analysis of human 
breast tumors found Adm as part of a 13 gene signature that correlated with distant 
metastases and poor outcome.250  Based on these clinical data and on the robust lymphatic 
phenotypes in AM signaling mouse models (Adm, Calcrl, Ramp2), we sought to determine 
how the lymphangiogenic properties of AM influence tumor progression.  Using Lewis Lung 
Carcinoma (LLC) cells, we generated stable cell lines with a gene titration for Adm 
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expression, allowing us to query the contribution of Adm to lymphangiogenesis and 
angiogenesis in an in vivo mouse model. 
 
Materials and Methods 
Cell Culture   
Lewis Lung Carcinoma cells (ATCC, Manassas, VA, USA) were cultured in DMEM 
supplemented with 1X penicillin/streptomycin and 10% fetal bovine serum.   
 
Adm overexpression   
The complete coding sequence of murine Adm cDNA was cloned into the pcDNA3.1 
expression vector (Life Technologies, Grand Island, NY, USA) that contains a CMV 
promoter and neomycin selection cassette.  LLC cells were transfected with either AM-
pcDNA3.1 or empty vector using Lipofectamine 2000 (Life Technologies, Grand Island, NY, 
USA).  Individual clones were selected and maintained in growth media containing 400 
µg/mL G418.   
 
Adm RNAi   
Three shRNA sequences (Dharmacon, Thermo Fisher Scientific, Lafayette, CO, 
USA) spanning the length of Adm were subcloned into the pSUPER vector (OligoEngine, 
Seattle, WA, USA) and co-transfected with a zeocin resistance plasmid (kindly provided by 
Dr. James M. Anderson, NIH) into LLC cells using Lipfectamine 2000.  Individual clones 
were selected and maintained in growth media containing 1mg/mL zeocin (InvivoGen, San 
Diego, CA, USA). 
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In Vitro Growth Assays   
Stably transfected LLCs were seeded (7.5x104 cells/well) into 6-well plates and 
grown in complete DMEM. Cell number and viability were determined using the Countess 
automated cell counter (Life Technologies, Grand Island, NY, USA).   
 
Mice and tissue processing   
Female (6-8 wk old) C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME, USA) 
were injected subcutaneously in the flank with LLC cells (1x106 in 100µl PBS) that 
overexpress or knockdown Adm. Control mice were injected with LLC cells expressing a 
scrambled shRNA or empty vector. Tumors were measured with calipers [volume = 
(length)(width)2 /2], and 14 d after injection, mice were euthanized and tissues were 
harvested.  Routine histological processing and sectioning was performed.  All experiments 
involving mice were approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill.  
 
Immunohistochemistry   
Antibodies: monoclonal rat anti-mouse Ki67(1:60, Dako, Denmark); polyclonal goat 
anti-mouse PECAM-1 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA); polyclonal 
rabbit anti-mouse LYVE-1 (1:200, Fitzgerald Industries International, Acton, MA, USA), 
monoclonal Syrian hamster anti-mouse Podoplanin (1:50, Developmental Studies 
Hybridoma Bank, Iowa City, IA, USA); and monoclonal rat anti-mouse F4/80 (1:75, 
eBioscience, San Diego, CA, USA). Tumor and LN sections were permeabilized, blocked 
with 5% normal donkey serum, and incubated overnight at room temperature with primary 
antibodies. Sections were then rinsed, blocked, and incubated for 2 hours at room 
temperature with Dylight 488 (1:200, Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA), Alexa568 (1:200, Life Technologies, Grand Island, NY, USA), and DAPI (1:2000).  
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For Ki67 light level staining, sections were treated for antigen retrieval with citrate buffer in a 
microwave (15 min). The sections were rinsed, pretreated with 50% alcohol followed by  3% 
peroxide to block endogenous peroxidase activity.  After blocking in 10% NDS (30 min), the 
sections were incubated in primary antibody to Ki67 in 2% NDS overnight. After rinses and 
blocking in 2% NDS, the sections were incubated in a biotinylated secondary antibody (1 hr, 
1:200, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) followed by 
ExtrAvidin peroxidase (1hr, 1:5000, Sigma). Antibody binding sites were visualized using 
nickel-intensified diaminobenzidine (DAB, Sigma). Sections were counterstained with 
toluidine blue and coverslipped. 
 
Image analysis   
Images were acquired on a Nikon E800 microscope with a Hammamatsu camera 
with Metamorph software (Molecular Devices, Inc., Sunnyvale, CA, USA).  To quantify 
colocalization of PECAM-1 or LYVE-1 with Ki67, a total of 3 step-sections were analyzed 
per tumor.  For blood vessel number analysis, two vascular hotspot regions per section were 
analyzed for a total of 6 measurements per tumor.  For lymphatic vessel number analysis, all 
vessels located within the tumor but at the tumor margin were counted from each of the 3 
step sections per tumor.  Vessel area was measured using ImageJ software.  For LNs, 
lymphatic density was quantified by determining the threshold of LYVE-1+ fluorescence 
using ImageJ.  The entire cross-sectional area of the LN was included in density analysis.  A 
total of four step-sections per LN were averaged for each mouse (4-6 mice per genotype).  
Data represents the mean ± SEM and statistical significance was determined by unpaired 
two-tailed Student’s t-test. 
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Gene expression analysis   
Total RNA was isolated from stably transfected LLC cells or tumors using Trizol 
reagent (Sigma, St. Louis, MO, USA) followed by RQ1 DNase treatment (Promega, 
Madison, WI, USA).  qRT-PCR for murine Adm,30 Calcrl, Mac-1, Vegf-a, Vegf-c and Vegf-d 
were performed with Assay on Demand (Applied Biosystems, Carlsbad, CA, USA).  Graphs 
(GraphPad Software Prism 5, La Jolla, CA, USA) represent an average of 3 independent 
runs run in duplicate normalized to Gapdh.   
 
Optical Projection Tomography   
After fixation, lung lobes were rinsed in PBST overnight and then boiled for 10 
minutes in citrate buffer.  Tissue was washed in PBST, ice cold acetone, and ddH2O, 
blocked overnight followed by a one wk incubation with primary antibodies at 4°C with Ki67 
and rabbit anti-mouse Caveolin1 (Abcam, Cambridge, MA, USA).  Lung lobes were then 
incubated for 3 d in secondary antibody at 4°C using donkey anti rabbit 488 (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) and goat anti rat Texas Red (Life 
Technologies, Grand Island, NY, USA), followed by an overnight wash in PBST.  To prepare 
samples for OPT scanning, individual lung lobes were embedded in 1% low-melt agarose, 
dehydrated overnight in methanol and rendered optically transparent by incubating them in 
BABB for 48 hours before being scanned in a BiOPTonics 3001M Optical Projection 
Tomography Scanner (MRC Technology, Scotland, UK) equipped with Cy2 and Texas Red 
excitation filters.  For image acquisition and analysis, 900 images were captured per 
channel per sample.  Images were aligned and reconstructed into 3D renderings using 
nRecon software (SkyScan, Belgium) and color overlay 3D renderings were generated 
using the BiOPTonics Viewer application.  These 3D renderings of Ki67 stained lungs were 
used to quantify proliferative foci using DataViewer (SkyScan, Belgium) and ImageJ (v1.45, 
NIH) by three independent, blinded investigators.  
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Results 
Adm gene dosage in LLC  
Initially isolated in 1951 as a spontaneous lung carcinoma of a C57BL/6 mouse,251 
LLC cells have been widely used to study metastasis and angiogenesis in a variety of 
murine implantation models.    Quantitative RT-PCR analysis showed that LLC cells express 
abundant Adm (Figure 3-1A), but interestingly, there is negligible expression of its receptor 
Calcrl (Figure 3-1B).  The discovery that LLC cells lack the AM receptor CLR is a 
serendipitous advantage to our studies, since it removes the confounding possibility that 
changes in AM dosage directly affect tumor growth through CLR signaling.  Therefore, any 
resultant phenotypes due to differences in tumor-secreted AM levels can be attributed to 
AM-mediated signaling in the surrounding microenvironment. 
To evaluate the effects of varied levels of tumor-secreted AM on tumor 
lymphangiogenesis, we generated stable LLC lines that either had reduced or 
overexpression of Adm.  Using three shRNA sequences that span the length of the Adm 
gene, sequence #266 showed a drastic (92%) reduction in Adm expression while sequence 
#555 and #709 showed a 50% and 68% decrease in expression, respectively as compared 
to the scrambled shRNA control (Figure 3-1C).  Thus, sequence #266 was used for all 
subsequent in vitro and in vivo experiments.  An expression plasmid containing the murine 
Adm cDNA was used to generate stable AM overexpressing LLC cells.  qRT-PCR analysis 
showed an almost 2-fold increase in Adm expression in these cells as compared to their 
empty vector controls (Figure 3-1C).  Importantly, modulation of Adm dosage did not affect 
Calcrl expression levels in the LLC cells (Figure 3-1B). 
 Since AM can act as a growth factor for tumor cells, we wanted to determine 
whether altering the dosage of Adm affected LLC growth rates.  Because these cells 
expressed little to no Calcrl, (Figure 3-1B) we did not anticipate that changes in Adm 
expression would affect their growth.  To confirm this and ensure that AM would not 
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influence proliferation though a non-canonical pathway, we counted cells over a 6 d time 
course.  As expected, cell numbers were comparable among the high and low Adm 
expressing LLC cells and their respective controls (Figure 3-1D).  Moreover, there were no 
changes in cell viability by trypan blue exclusion over the same time course (Figure 3-1E). 
Throughout our study, we used the empty vector and scrambled controls separately 
for both the Adm overexpressor and RNAi conditions, respectively.  However, we found no 
statistically significant differences between them and so, for the remainder of our study they 
are represented as a single control group. 
 
Adm gene dosage is maintained in tumors in vivo 
To determine whether dosage of Adm expression influences tumor growth in vivo, 1 
x 106 cells were injected subcutaneously into C57BL/6 mice.  Palpable tumors were 
measured with calipers and consistent with a lack of Calcrl expression in LLC cells, we 
found no significant effect of Adm dosage on tumor volume (Figure 3-2A).  To ensure that 
the in vitro dosage of Adm was maintained in vivo, we analyzed expression of Adm and 
Calcrl in tumors and found that dosage of Adm was maintained (Figure 3-2B).  Although not 
statistically significant, it appears that Calcrl expression is modulated in an Adm dose 
dependent manner (Figure 3-2C).  We attribute this to the heterogeneous nature of tumors 
including the presence of blood and lymphatic endothelial cells and macrophages which are 
rich sources of both AM and CLR. 
 
Adm dosage does not promote tumor angiogenesis 
A significant body of research supports AM as an angiogenic factor.8, 108  To assess 
whether levels of tumor-derived AM influence angiogenesis, tumor sections were stained 
with a blood endothelial marker (PECAM1) and the proliferation marker Ki67.  Surprisingly, 
we found that varying the dosage of tumor AM expression did not influence the number of 
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blood vessels within the tumor but at the tumor margin (Figure 3-3A).  Furthermore, the 
dosage of Adm in the tumors had no effect on the number (Figure 3-3B) or proliferation of 
PECAM1+ cells (Figure 3-3C).    Taken together, we conclude that AM is not modulating 
angiogenesis in this model. 
 
Expression of Adm is necessary for tumor lymphangiogenesis 
To investigate whether dosage of Adm influenced lymphangiogenesis we excised the 
tumors and performed routine H&E staining on the tumor sections (Figure 3-4A).  We first 
wanted to determine whether expression of AM affected the number of tumor associated 
lymphatic vessels.  The lymphatic-specific marker LYVE1 revealed a dose-dependent effect 
of AM on the total number of lymphatic vessels (Figure 3-4B, graph).  Double 
immunofluorescence analysis of LYVE1 and podoplanin expression confirmed the lymphatic 
identity of these vessels (Figure 3-4B).  We then quantified the number of LYVE1+ cells at 
the tumor margin and found a dose-dependent effect of Adm expression on the number 
(Figure 3-4C) and proliferation (Figure 3-4D) of LYVE1+ cells, with approximately three times 
more LYVE1+ cells in tumors overexpressing Adm compared to tumors with reduced Adm.   
Collectively, these results reveal that AM is a necessary and critical component for 
promoting tumor-associated lymphangiogenesis since reduction of Adm expression 
significantly reduced the proliferation and accumulation of lymphatic endothelial cells as well 
as the number of lymphatic vessels.  
 
Adm dosage does not alter tumor macrophage or Vegf levels 
The recruitment of macrophages to tumors serves to enhance endothelial cell 
survival and proliferation and thus promote tumor progression and metastasis.252  In addition 
to secreting lymphatic growth factors, like VEGF-C and VEGF-D,253 a subset of tumor-
associated macrophages can be positive for LYVE-1 and can also transdifferentiate into 
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lymphatic endothelial cells.254  As expected, we found that some individual LYVE1+ cells in 
the AM-dosed tumors were also positive for the macrophage marker F4/80 (Figure 3-5A).  
Importantly though, none of the LYVE1+ vessels expressed the macrophage marker (Figure 
3-5B).  F4/80 immunohistochemistry on tumor sections coupled with quantitative RT-PCR 
analysis for an additional macrophage marker, Mac-1 (Figure 3-5C, graph) revealed no 
statistical difference in either Mac-1 or F4/80 expression in either high or low Adm-
expressing tumors or their respective controls (Figure 3-5C).   
Alternatively, it is possible that enhanced lymphangiogenesis associated with Adm 
overexpression could be due in part to up-regulation of other known lymphangiogenic 
factors, such as VEGF-A, -C, or -D.  However, qRT-PCR analysis for these genes in the 
tumors revealed no statistical difference compared to controls (Figure 3-5D).  This negative 
result is important because it eliminates the possibility that elevated (or decreased) levels of 
tumor AM augment VEGF expression.     
 
Overexpression of Adm increases vessel area 
AM acts as a potent vasodilator of blood vessels through relaxation of vascular 
smooth muscle cells.255  Consistent with this function, we found that high levels of tumor AM 
markedly increased the diameter of tumor blood vessels (Figure 3-6A)—a change that 
occurred in the absence of enhanced angiogenesis, as documented by a lack of difference 
in PECAM1+ cells and vessels with varying dosage of Adm (Figure 3-3).  Moreover, the 
diameter of blood vessels in tumors with low levels of Adm was comparable to that in control 
tumors, suggesting that reduction of Adm does not affect the ability of existent blood vessels 
to maintain their morphology and that a certain threshold of Adm expression is necessary to 
achieve an increase in vessel diameter. 
Similarly, the lymphatic vessels in tumors with high levels of Adm expression were 
approximately three times larger than those in control tumors and in tumors with reduced 
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Adm expression (Figure 3-6B).  We attribute the enlarged lymphatic vessels in Adm 
overexpression tumors to either the enhanced LEC proliferation (Figure 3-4D) or a 
secondary physiological response to increased blood vasodilation and tissue perfusion. 
 
Overexpression of Adm induces LN lymphangiogenesis 
 Preclinical studies have supported the concept that tumor secreted factors can 
induce LN lymphangiogenesis and thus facilitate distant metastasis.256-258  Therefore, we 
analyzed sentinel, sub-iliac LNs to evaluate whether Adm dosage affected LN lymphatic 
vessel growth.  Interestingly, the proportion of LYVE1+ staining was significantly elevated in 
the sentinel LNs of mice bearing Adm overexpressing tumors (Figure 3-7).  Changes in the 
extent of LN lymphangiogenesis correlate with the lymphatic vascular changes observed in 
the tumors.  Specifically, Adm RNAi tumors had fewer lymphatic vessels whereas the Adm 
overexpression tumors had more lymphatic vessels, in addition to increased lymphatic 
vessel diameter.  Collectively, these findings demonstrate that elevated AM levels in tumors 
contribute to the sentinel LN lymphangiogenesis.  
 
Overexpression of AM promotes distant metastasis  
Tumors overexpressing Adm showed enlarged lymphatic vessel diameter 
accompanied with increased LN lymphangiogenesis.  To determine whether the AM-induced 
changes in the tumor lymphatic vessels and draining LN potentiate metastasis to a distant 
organ we used high resolution 3D optical projection tomography (OPT).259  This method, 
shown in Figure 3-8A and seen more dramatically in Supplemental Movies 1-3, allowed us 
to visualize in 3-dimensions the extent of tumor metastasis throughout an entire lung lobe.  
Using Ki67 as a surrogate marker for proliferating tumor cells we were not able to detect 
Ki67 staining in the lungs of wild-type (non-tumor injected) mice (data not shown).  Scans 
from lung lobes of mice bearing Adm RNAi tumors showed very little Ki67+ staining, which 
73 
 
was comparable to those levels observed in mice with control tumors (Figure 3-8A).  This 
data correlates well with these groups having similarly small lymphatic vessels in the tumor 
(Figure 3-6B).  In contrast, lungs from mice with Adm overexpressing tumors had a marked 
and statistically significant increase in Ki67+ foci compared to those of mice with control 
tumors (Figure 8A), which also consistently correlated to the effects of Adm overexpression 
on tumor lymphatic vessel size (Figure 3-6B) and LN lymphangiogenesis (Figure 7).  Using 
adjacent tissue sections, H&E (Figure 3-8B) and Ki67 (Figure 3-8C) staining confirmed Ki67+ 
tumor foci within the lungs of mice bearing Adm OExp tumors, while only individual Ki67+ 
cells were present within the lungs of mice bearing control and Adm RNAi tumors (Figure 3-
8C).   
 
Discussion 
High levels of AM have been reported in a variety of human solid tumors248 and gene 
profiling studies in mice have shown a 4-fold increase in Adm expression in tumor 
lymphatics as compared to normal tissue.260  Until now, the functional consequences of 
elevated Adm expression in tumors and the surrounding microenvironment have been 
largely unknown.  We have developed an in vivo tumor model in which the dosage of the 
lymphangiogenic peptide AM is directly correlated to changes in lymphatic vessels at the 
tumor margin as well as distal changes in sentinel LN lymphangiogenesis and increased 
Ki67 staining in the lung (Figure 8C).   
Most research into how expansion of the lymphatic vascular system contributes to 
tumor cell dissemination has focused upon the VEGF protein family, but evidence is 
emerging that other factors, such as the angiopoietins,261, 262 prostaglandins,263 and the 
chemokine CCL21 also participate in tumor lymphangiogenesis and metastasis.264, 265 
Although the autocrine effects of AM on tumor cells has been studied,102, 266 this study is the 
first to implicate AM as a contributing factor to tumor lymphangiogenesis by systematically 
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assessing how AM dosage affects both blood and lymphatic vasculature in the developing 
tumor.  Adm RNAi approaches show that AM is an essential factor for driving the process of 
tumor and LN lymphangiogenesis.  In contrast, overexpression of Adm in tumors is sufficient 
to exacerbate these processes. 
Despite the presence of both intra- and peritumoral lymphatics in many tumors, it has 
been suggested that only the lymphatic vessels at the tumor margin are functional,235 since 
high interstitial fluid pressure within tumors can collapse or block intratumoral vessels, thus 
impeding the metastatic process.  Padera and colleagues found that in VEGF-C 
overexpressing tumors, increased lymphatic vessel surface area in the tumor margin was 
sufficient to promote lymphatic metastasis despite the absence of functional intratumoral 
lymphatics.267  They propose that increased lymphatic surface area allows more opportunity 
for cancer cells to leave the primary tumor and disseminate to LNs and distant tissues.  We 
show similarly robust results, since Adm overexpressing tumors have increased lymphatic 
surface area and LNs with enhanced lymphangiogenesis, as compared to tumors with low 
levels of AM.  
Our findings show that AM preferentially induced lymphangiogenesis in this tumor 
model, since effects upon the blood vasculature were limited to an increase in vessel 
diameter.  The selective function of vascular growth factors on different types of endothelial 
cells has previously been described.  For example, when VEGF-C was overexpressed in 
MCF-7 or MDA-MB-435 breast cancer cells, mainly lymphangiogenic effects were 
observed.240, 241  By contrast, the overexpression of VEGF-C in a melanoma xenograft study 
showed that VEGF-C was able to affect both angiogenesis and lymphangiogenesis.268  The 
disparity in angiogenesis induction between the two models has been attributed to 
differences in the in vivo proteolytic processing of VEGF-C and thus the selective induction 
of lymphangiogensis due to VEFGR-3 activation rather than VEGFR-2.240  In the case of 
AM, the selective and preferentially robust effects we observed on lymphatic vessels 
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compared to blood vessels may largely be attributed to the enhanced expression of the AM 
receptor, Calcrl and its cognate receptor activity modifying protein 2 (Ramp2) in lymphatic 
endothelial cells.  Our group, and several others,22, 23, 245, 246 have consistently shown that 
expression of the Calcrl and Ramp2 genes are intrinsically enriched in lymphatic endothelial 
cells, partly under the control of the lymphatic transcriptional regulator, Prox1.22  In addition, 
Jin et al. showed enhanced lymphangiogenesis in response to AM administration using an 
in vivo wound healing model.11  Therefore, in the setting of this particular tumor 
microenvironment, the sensitivity of blood or lymphatic vasculature to a dosage range of AM 
ligand is likely controlled by the relative level of AM receptor expressed on these different 
endothelial cells. 
Although tumor mRNA expression analysis showed no changes in expression of 
Mac-1 or Vegf ligands, it remains possible that other factors may also contribute to the 
lymphatic phenotypes observed in the AM dosage LLC model.  For example, a recent study 
showed that macrophage-derived AM promotes angiogenesis and melanoma growth.269   
Furthermore, a B16 melanoma model showed that B lymphocytes are necessary for LN 
lymphangiogenesis since B-cell deficient mice were unable to induce LN 
lymphangiogenesis.257  In that study, the extensive lymphangiogenesis in the draining LN 
was associated with a 20- to 30- fold increase in lymph flow,257 and so, consideration of how 
other factors, such as lymph flow, could facilitate tumor cell entry into the lymphatics is 
warranted.  
Our study highlights the need to explore AM and its receptors as potential 
therapeutic targets for selective modulation of tumor lymphatics.  Additionally, how AM-
induced tumor and LN lymphangiogenesis contribute to distant metastasis remain to be 
more rigorously assessed.  Our previously published in vitro study showed that AM 
stabilizes the LEC barrier through a structural reorganization of junctional proteins.25  
Whether these effects will be consistently maintained in an in vivo tumor setting, where 
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vessels are notoriously leaky, will be a very interesting question to address.  In this regard, a 
recent study by Alitalo and colleagues found that  an angiopoietin-2 blocking antibody 
promoted endothelial stabilization and thereby inhibited metastasis.270  Thus the effects of 
tumor-derived factors on lymphatic permeability may play a predominant role in promoting 
the metastatic process. 
Indeed, the Calcrl receptor and its associated receptor activity modifying proteins 
(RAMPs) have already been exploited by the pharmaceutical industry for the treatment of 
migraine pain.271  So, there is strong precedent to support the feasibility of the Calcrl/Ramp2 
interface as a pharmacological target to inhibit AM signaling.  Our in vivo studies provide the 
framework and rationale for inhibiting AM function in order to attenuate tumor 
lymphangiogenesis and would add a new and complementary facet to our current arsenal of 
anti-(lymph)angiogenesis cancer therapies for the future. 
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Figures 
 
 
 
Figure 3-1.  In vitro characterization of the LLC cell line.  A-C) qRT-PCR analysis 
amplifying murine Adm and Calcrl mRNA. Mouse embryo normalized to 1 was used as a 
calibrator in panels A and B.  Scrambled RNAi and empty vector conditions were normalized 
to 100 in panel C.  Graphs in panels A and C depict 1 representative experiment while the 
data in panel B are an average of 3 independent experiments.  D) Growth curve for the Adm 
RNAi, Adm OExp, and control LLC cells showed no differences in cell growth over 6 d.  E) 
No change in AM-dosed LLC cell viability was detected by trypan blue exclusion over 6 d. 
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Figure 3-2.  In vivo tumor analysis.  A) Measurements of tumor volume showed no 
differences in growth of Adm RNAi (n=8), Adm OExp (n=7), and control (n=13) tumors 
during a 14 d time course.  B, C) qRT-PCR analysis revealed that Adm dosage is 
maintained in the tumors (B); no statistical change in Calcrl expression among the tumor 
groups (C).  
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Figure 3-3.  Adm expression does not affect angiogenesis.  Adm expression does not 
affect angiogenesis.  PECAM-1 (green)-, Ki67 (red)-, and DAPI (blue)-stained tumor 
sections revealed that dosage of Adm did not affect the average number of blood vessels 
(A), and the total number (B) or proliferation (C) of PECAM-1+ cells.  Dashed line delineates 
tumor margin.  Data are expressed as the average ± SEM of 2 fields/step section/tumor (6 
total fields), with no statistical differences among the tumor groups; 3 step sections/tumor 
were analyzed.  Scale bars = 50 µm. 
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Figure 3-4.  Adm expression is necessary for lymphangiogenesis.  Adm expression is 
necessary for tumor lymphangiogenesis.    A) Representative H&E stained tumor sections.  
B) LYVE-1 (green) and podoplanin (red) costain confirmed lymphatic identity of the vessels 
and showed that the average number of lymphatic vessels per tumor section increased with 
Adm dosage.  Dashed line delineates tumor margin.  Data represent the average number of 
lymphatic vessels within the tumor but at the tumor margin per tumor section; 3 step 
sections/tumor were analyzed. C, D) Dosage of Adm affected the total number of LYVE-1+ 
cells (C), and proliferation (Ki67, red) of LYVE-1+ (green) cells correlated with increased 
Adm tumor expression (D).  Data are expressed as the average of 2 fields/step-
section/tumor (6 fields total) ± SEM (from 3 sections).  Scale bars = 50 µm. 
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Figure 3-5.  Adm dosage does not affect macrophage or Vegf levels.  A) LYVE-1 
(green)-, F4/80 (red)-, and DAPI (blue)-stained tumor sections revealed the presence of 
LYVE-1+ and F4/80+ cells.  B) No colocalization of LYVE-1 and F4/80 was found in 
lymphatic vessels.  C) Dosage of Adm did not affect F4/80 expression or Mac-1 levels 
(graph).  D) Dosage of Adm did not affect Vegf-a (left panel), Vegf-c (center panel), or Vegf-
d (right panel) levels.  Scale bars = 50 µm.  
 
 
 
 
 
 
 
 
82 
 
 
 
Figure 3-6.  Elevated Adm expression increases the diameter of blood and lymphatic 
vessels.  Immunofluorescence analyses revealed that overexpression of Adm in LLC 
tumors caused a statistically significant increase in the area of PECAM-1+ blood vessels (A) 
and LYVE-1+ lymphatic vessels (B).  Dashed line delineates tumor margin.  Data are 
expressed as mean ± SEM, with an average of 40 vessels/genotype analyzed.  Scale bars = 
50 µm. 
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Figure 3-7.  Tumor Adm expression influences sentinel LN lymphangiogenesis.  
Statistically significant increase in the density of lymphatic (LYVE-1) staining in the LNs was 
observed when mice harbored an Adm OExp tumor.  Data are expressed as mean ± SEM 
for 4-6 mice/group.  Scale bars = 200 µm. 
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Figure 3-8.  Overexpression of AM promotes distant metastasis.  A) Scans showed and 
quantitative evaluation confirmed that lung lobes from mice that harbored an Adm OExp 
(n=6) tumor had more Ki67+ foci as compared to lobes from Adm RNAi (n=7) and control 
mice (n=12).  B, C) H&E (B) and Ki67 (C) staining verified OPT scans and showed scattered 
Ki67 staining in lung sections from mice bearing Adm RNAi or control tumors.  By contrast, 
proliferative (Ki67+) foci were detected in lungs harboring an Adm OExp tumor.  Arrows 
indicate individual proliferating cells; arrowhead points to proliferative foci.  D) Model 
illustrates how tumor levels of AM affect local vascular changes which then may impact 
distant metastasis.  Tumors with low AM levels have fewer lymphatic vessels (green), no 
blood (red) or lymphatic vessel area enlargement, reduced LN lymphangiogenesis, and 
fewer Ki67+ spots in the lungs as compared to a tumor with high levels of AM.  Notably, 
while expression of tumor AM is necessary for lymphangiogenesis, levels of angiogenesis 
remain unaffected with changes in AM dosage.  Scale bars = 800 µm (A); 20 µm (B, C). 
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Chapter IV:  Conclusions and Future Directions 
 
Summary  
The studies presented in Part 1 further demonstrated the importance of 
AM/RAMP/CLR signaling during cardiovascular development and homeostasis, as well as 
AM role to promote tumor lymphangiogenesis and distant metastasis.  Chapter II utilized an 
endothelial-specific Ramp2 transgene to genetically rescue the embryonic lethality 
associated with global loss of Ramp2.  The loss of Ramp2 in non-endothelial cells of these 
mice led to spontaneous hypotension, dilated cardiomyopathy, and multi-organ 
inflammation.  All these phenotypes potentially diverge for canonical AM/CLR signaling, 
indicating potential in vivo functions of the interaction between Ramp2 and the glucagon and 
parathyroid hormone receptors.  Chapter III demonstrated that tumor-derived AM has a 
functional role in tumor lymphangiogenesis and metastasis, independent of tumor growth 
and angiogenesis.  These data further support the importance of AM signaling in adult 
lymphatics and its detrimental effects on tumor metastasis through lymphatics.   
 
Current State of the Field – RAMPs, Cardiac Development and Disease, and Tumor 
Lymphatics 
RAMPs Biochemistry to Cardiovascular Physiology 
GPCRs remain one of the best pharmacological targets with approximately 35% of 
all approved human drugs targeting a small number of the GPCRome.272  There is 
significant interest to understand unique GPCR interfaces and pharmacology in order to 
develop novel compounds that have selective therapeutic functions without adverse side 
86 
 
effects.  GPCR ligand selectivity and divergent signaling through different G proteins or -
arrestin coupling is at the forefront of GPCR pharmacological research.273, 274  One such 
unique mechanisms of GPCR signaling was the discovery and biochemical characterization 
of the RAMPs.7, 191  The majority of family B GCPRs have been shown to interact with 1-3 of 
the identified mammalian RAMPs.275  RAMPs have been shown to facilitate numerous 
different aspects of GPCRs function, including trafficking to the plasma membrane, ligand 
selectivity, G protein- or -arrestin-coupling, and receptor recycling.  The majority of the 
literature has focused on the CLR/RAMP1 and CLR/RAMP2 interactions, which control 
ligand specificity for the hypotensive peptides CGRP and AM, respectively.  For drug design 
purposes, there has been a huge amount of biochemical research to understand the specific 
amino acids involved in the CLR/RAMP interactions.275  This work culminated with the 
crystallization of the ectodomains of CLR/RAMP1, CLR/Ramp2, and CLR/Ramp3 
complexes.276, 277  These crystal structures provided a more thorough understanding of the 
ligand binding pocket and how to target the CLR/RAMP interfaces.  Structural models also 
predict how RAMPs interact with other GPCRs.191  Beyond CLR, it was recently shown that 
RAMP2 could alter ligand selectivity and G-protein coupling of the GCGR, which could have 
major implications on glucagon pharmacology and its regulation of blood glucose 
homeostasis.223  This study demonstrated that RAMP2 is not essential for the plasma 
membrane localization of GCGR or its affinity for glucagon.  However the presence of 
RAMP2 strengthens Gs while inhibiting Gi response to glucagon.  Without RAMP2, the 
GCGR is no longer selective for glucagon and can bind the related peptide, GLP-1, which 
has opposing functions to that of glucagon.  The physiologic consequences of GLP-1 
binding the GCGR or interactions between RAMPs and other GPCRs, such as 
PTHR1/RAMP2, have not been functionally characterized.  With the exception of CLR, the 
physiologic consequences of the majority of these reported biochemical interactions have 
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not been studied.  While it’s apparent that the GPCR/RAMP interface can be a 
pharmacological target, further analysis of the in vivo functions of these interactions is 
required to better understand their viability as drug targets. 
The physiologic functions of CLR/RAMP2 have been extensively studied by our lab 
and others and are previously discussed in this dissertation (See Chapter I, II, and IV).  In 
addition to lymphatic developmental issues, these KO mice also have small disorganized 
hearts with altered trabeculation and thin vSMC walls (Chapter II).22, 33  The proliferation and 
maturation of the myocardium is dependent on numerous mitogenic factors, including IGF 
and FGFs, which are secreted from the epicardium.278, 279 Recently our group demonstrated 
that epicardial-derived AM was responsible for cardiomyocyte hyperplasia observed in the 
AdmHi/Hi OExp mouse model.200  Cardiomyocyte-specific deletion of Calcrl by MHC-Cre or 
SM22-Cre (Table 2-S3) did not cause embryonic lethality and adult mice with cardiac Calcrl 
had no apparent heart deficiencies.  Together these data suggest that epicardial-AM may 
not be acting directly on CLR on cardiomyocytes, but rather is acting indirectly though other 
secreted mitogens, such as FGF, to regulate myocardium proliferation.  In addition to the 
epicardium, there is cross-talk between the endocardium and myocardium, specifically by 
the BMP, EphrinB2, and Notch pathways, to regulate myocardial proliferation and 
trabeculae differentiation.280-283  Interestingly, it has been reported that sonic hedgehog and 
calcrl signaling are upstream of ephrin-B2, Notch, and VEGF pathways during arterial 
development in zebrafish.55  This suggests that endocardial CLR signaling may be upstream 
of these pathways during cardiac development.  These same signaling pathways, in addition 
to PDGF and TGF-signaling, are all involved in vSMC development and maturation.284, 285  
To my knowledge, CLR/RAMP2 signaling has not been directly linked to these pathways 
during vSMC development, but Calcrl-/- embryos had decreased aortic vSMC proliferation 
and survival.33  Together, these studies suggest that the AM/CLR/RAMP2 signaling pathway 
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is either directly or indirectly involved in regulating embryonic maturation of both the 
myocardium and vSMCs, but the specific signaling mechanisms have yet to be elucidated. 
Due to the embryonic lethality of both Calcrl and Ramp2 KO animals,33, 34 not much 
is known about how the loss of these genes alters cardiovascular homeostasis during 
adulthood. Conditional ubiquitous ablation of Calcrl during adulthood leads to dysfunctional 
lymphatics, similar to those observed in human lymphangiectasia.199  However, further 
cardiovascular phenotyping of these mice was not reported.  Cardiomyocyte-specific loss of 
Calcrl during development did not manifest in any noticeable cardiomyopathies during 
adulthood, either basally or when challenged with hypertensive models (Table 2-S3) 
(Dackor RT and Caron KM, Unpublished [2016]).  However, loss of cardiomyocyte Ramp2, 
in the Ramp2-/- Tg mice or the cardiomyocyte-specific MHC-MerCreMer Ramp2 KO mice, 
caused a DCM-like phenotype.222  DCM is a complex multifactorial disease that primarily 
arises from alterations in cytoskeletal proteins or mitochondrial dysfunction and oxidative 
stress-induced myocardial damage.211, 286, 287 Cardiomyocyte loss of Ramp2 caused cellular 
and expressional changes that are common in DCM pathogenesis.  However, it has been 
reported that the MHC-MerCreMer mouse line, independent of Ramp2, can cause a 
reversible DCM phenotype with high TAM concentrations.222, 288, 289  While the Ramp2-/- Tg 
mice likely have complex systemic changes that may be indirectly involved in DCM 
pathogenesis, the Ramp2-/- Tg represents the first model to implicate Ramp2 as being 
protective against DCM-like phenotype.  Furthermore, this DCM phenotype appears to be 
independent of AM/CLR, which supports the involvement of other RAMP2-associated 
GPCRs.   
 A direct link between the cardiac functions of GCGR or PTHR1 and DCM 
pathogenesis has not been, to my knowledge, characterized.  Glucagon can change calcium 
signaling in cardiac cells and a glucagoma is capable of causing a reversible DCM-like 
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phenotype in humans.290, 291 Glucagon is detrimental cardiac function and survival follow 
myocardial infarction.215  However, GLP-1 agonists can improve myocardial glucose uptake 
and have been used to treat DCMs in canines.224  Hypoparathyrodism, hypocalcemia, or low 
levels of vitamin D have all been shown to be associated with reversible DCM in humans.225, 
226  While the disease pathogenesis differs slightly, postpartum DCM is caused by alteration 
in circulating prolactin isoform.211, 286  Interestingly, Ramp2+/- females have been shown to be 
hyperprolactinemic, both basally and during pregnancy.198 High levels of prolactin with 
Ramp2 loss, if cleaved by cathepsin D, could be a novel mechanism in the pathogenesis of 
DCM and/or postpartum cardiomyopathy.  In addition of RAMP2, it was recently reported 
that RAMP3 interacts with an estrogen receptor, GPR30, which is important for sex-
dependent cardioprotection from hypertension.193, 196 More specifically, the loss of Ramp3 
led to worst cardiac damage induced by angiotensin II in male mice when compared to 
female mice.  Additionally, Ramp3 is required for therapeutic success of a cardioprotective 
GPR30 agonist.  Together, these studies illustrate the important of RAMPs in cardiovascular 
development and the pathogenesis of cardiac diseases.  The identification that RAMP3 can 
interact with a family A GPCR, GPR30, opens the door to further explore novel 
RAMP/GPCR interactions that could be important in cardiovascular homeostasis and 
disease. 
 
Tumor Lymphangiogenesis and Metastasis 
 
 Tumor metastasis to distant sites is a multistep process that involves invasive tumor 
cells entering the circulation, evading immune surveillance, leaving the circulation, and 
surviving in a new microenvironment.292-294 The molecular mechanisms and factors involved 
in this process have not been fully characterized, which has led to the inability to prevent 
metastasis.  While the metastatic process initiates locally within the primary tumor, it is a 
systemic disease where both tumor-derived and systemic factors influence metastasis.  The 
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inhibition of tumor angiogenesis, primarily by targeting the VEGF pathway, continues to be o 
of the main strategies to prevent tumor metastasis.  Unfortunately, tumors are adaptable 
and heterogeneous and able to selectively develop mechanisms to circumvent VEGF 
inhibition, which has ultimately led to a failure of these inhibitors to significantly improve 
patient survival.295-297 Metastases is not restricted to the blood vasculatures and numerous 
tumors can disseminate through the parallel, less understood lymphatic vasculature.235, 298  It 
is essential to target both lymph and blood vasculatures simultaneously to inhibit metastasis. 
Therefore, identifying and understanding both the tumor-derived and systemic factors 
involved in tumor lymphangiogenesis and metastasis remains an intense area of research.   
 Our understanding of the factors that drive tumor lymphangiogenesis lags 
significantly behind those factors driving angiogenesis.  Similar to angiogenesis field, 
research to understanding mechanisms of lymphangiogenesis have focused on the VEGF 
family, specifically VEGFC and VEGFD that both signal through VEGFR3.  Both VEGFC 
and VEGFD have been shown to be involved in almost every phase of tumor and lymph 
node lymphangiogenesis, both of which facilitate lymphatic metastasis. 235, 240, 263  Likewise, 
the angiopoietin family, which also work through Tie receptors as well as VEGFR, have also 
been heavily studied as potential lymphangiogenic targets.299 Targeting the VEGF pathway, 
either through ligand traps or tyrosine kinase receptor blockers, has been shown to be a 
viable target to limit lymphangiogenesis in mice.298, 300  However, the lower-than-predicted 
success rates of VEGF inhibitors against angiogenesis suggest that targeting the VEGF 
pathway is not the sole solution to prevent metastasis.297  Additional targets and strategies 
to prevent lymphangiogenesis and other steps of the metastatic process are needed. 
Given its role in lymphangiogenesis, one alternative pathway to target is 
AM/CLR/RAMP2 signaling.  Elevated AM levels have been reported in human melanoma, 
breast, pancreatic, prostate, ovarian, and colon cancers.249  While AM is produced by tumor-
associated macrophages, AM can act back on these macrophages to alter their cytokine 
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secretion. 253, 292, 301, 302  In vitro studies showed that AM can promote tumor cell proliferation, 
invasiveness, and survival.103, 104  Xenograft mouse studies indicate that AM can enhance 
tumor growth and angiogenesis and AM inhibition can reduce tumor growth.56, 102, 303, 304  A 
genomic study comparing primary breast tumors with regional and distant metastasis 
identified AM as part of a 13-gene signature that is associated with distant metastasis and 
poor patient outcome.250  We showed that tumor-derived AM can promote primary tumor 
and lymph node lymphangiogenesis and enhance metastasis of LLC cells to the lungs 
(Chapter III).305  As a follow up, Karpinich et al. demonstrated that AM can act directly to 
LECs to alter gap junctions to facilitate the adhesion and transmigration of tumor cells 
through an LEC monolayer.306 Not only did this provide a potential mechanism behind the 
enhanced metastasis with high AM, but it also demonstrated the importance of gap junctions 
between LECs in regulating lymphatic metastasis. It has been reported that pregnancy can 
increase melanoma lymphangiogenesis and suppress the cytotoxic immune system allowing 
tumor cells to evade the immune surveillance.292, 294, 307-310  Considering AM is highly 
expressed during pregnancy (Figure 1-1), AM may be an important pregnancy-associated 
factors that is able to enhance the lymphatic metastasis. With the incidence of melanoma on 
the rise for decades, it is important to further understand this process.  
The RAMPs have not been heavily implicated in tumor growth or metastasis, which 
requires further studies.  It has been reported that Ramp3 shRNA reduced breast cancer 
growth, angiogenesis, and invasiveness downstream of epithelial to mesenchymal mediator 
lysyl oxidase-like protein 2.311 A recent study found that an amylin analogue, currently used 
to treat diabetes, acted through the calcitonin receptor/Ramp3 interface to cause rapid 
regression of p53-deficient lymphoma.312 These data implicate RAMP3 with tumor 
progression and demonstrate Ramp3 as a viable target against p53-deficient cancers.  
Additional studies regarding RAMPs and tumor progression are needed.   
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Future Directions 
New Models to Study AM/CLR/RAMP Biology 
One major limitation of studying the AM/CLR/RAMP system is that the spatial and 
temporal expression pattern of these proteins has not been well characterized.  Determining 
the expression pattern of these genes is limited to RT-PCR and/or in situ hybridization (ISH) 
and protein analysis is confounded by unreliable antibodies that have not been properly 
verified in KO tissue.  The use of RT-PCR, usually in whole tissue, has led to numerous 
assumptions of the specific cell types that express these genes.  The generation and 
expressional characterization of Calcrl, Ramp1, Ramp2, and Ramp3 reporter mice (gene 
targeted or BAC transgenic) would be invaluable to the field.  This would take the “guess 
work” out of when and where these genes are expressed.  The use of fluorescent reporters 
would allow a further understanding of the GPCR/RAMP colocalization and provide an 
opportunity to isolation specific cell types using FACS for ex vivo experiments.  Zebrafish 
transgenic models would also be a useful tool to study AM and RAMP/GCPR interactions in 
vivo.  Besides calcrl,55 zebrafish models of the RAMPs, to my knowledge, do not exist. 
Another useful mouse model for the field would be a doxycycline-inducible AM 
mouse.  Current models utilizing Adm+/- and AdmHiHi have developmental and adult 
phenotypes that confound phenotype interpretation in these models, such as heart defects 
or altered hemodynamics within blood and/or lymphatic vessels.22, 30, 79, 200, 313  The use of 
Cre-recombinase to conditionally excise Calcrl in adult animals is irreversible.  Considering 
AM levels are elevated in a variety of disease states (Figure 1-1), these doxycycline-
inducible AM mice would allow additional insight into the protective or detrimental roles of 
AM during adult homeostasis and disease.  A Tet ON/OFF switch would not only provide an 
opportunity to study how loss of AM alters homeostasis and disease pathogenesis, but 
would also allow the reintroduction of AM to attempt to resolve any phenotypes.  Temporal 
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control of AM loss- or gain-of-function would be beneficial considering the numerous 
confounding phenotypes associated with different dosages of AM during development. 
While our lab has a thorough repertoire of mouse models to study AM/RAMP/CLR 
signaling, another method to alter levels of these proteins is to focus on their transcriptional 
regulation, posttranscriptional modifications, and degradation.  With CRISPR/Cas9 
technology, it is possible to generate mice where Adm is not regulated by estrogen or 
hypoxia.314-316  Specific mutations could be introduced to further understand the functional 
consequences of these mutations in vivo.  While AM was overexpressed use alter an altered 
3’ UTR in the AMHiHi mice,200, 313 another mechanism to elevate circulating AM levels is to 
target the enzyme(s) that are involved in the rapid breakdown of mature AM peptide, such 
as PAM. PAM-/- mice have similar developmental defects as Adm-/-,35 so a conditional PAM 
allele could be used to prevent AM amidation and breakdown in adult mice.  The 
mechanisms involved in AM, CLR, and RAMP processing and breakdown are not well 
understood.  With further biochemical knowledge, it could be possible to generate RAMP 
mice that are unable to bind or traffic specific GPCRs to the membrane or impair 
GPCR/RAMP ligand selectivity.   
 
Roles of Ramp2 during Development and Reproductive Biology 
It is clear that endothelial expression of Ramp2 is essential for normal murine 
development (Chapter II), but the timing, location, and levels of Ramp2 expression are less 
well understood.18, 22, 198, 206  For instance, 40% of Ramp2-/- Tg mice survive to adulthood with 
no obvious edema while the other 60% of Ramp2-/- Tg have severe hydrops fetalis and are 
stillborn (Figure 4-1A-C and Chapter II).  The stillborn Ramp2-/- Tg pups are predominately 
male, indicating potential sex-dependent differences between Ramp2 (and/or the Cdh5-
driven Tg) expressional requirements during development.  One could assess both Ramp2 
and Cdh5 expression levels in male and female mice at different developmental time points 
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to further address this hypothesis.  The Tg expression could be mosaic and differences in 
the Ramp2-/- Tg lethality could be caused by low levels of Cdh5 expression in lymphatics at 
a crucial development time point.  Low levels of Ramp2 or AM signaling could be sufficient 
to extend the Ramp2-/- survival (e14.5 to e18.5), but not fully rescue the lethality.  This was 
previously observed in both endothelial-specific deletion of Calcrl and Ramp2 mice of which 
both die approximately 4 days after global KO embryos (Calcrl e12.5-e16.5 and Ramp2 
e14.5-e18.5).22, 206  These data suggest that there is a threshold of AM signaling required for 
survival and this threshold is not sufficient in the majority of Ramp2-/- Tg mice.  Edema score 
at e14.5 likely correlates with survival outcomes in that mild edema is resolved and Ramp2-/- 
Tg embryos survive compared to severe edema ultimately leading to lethality (Figure 2-1).   
Considering 100% of Calcrl and 95% of Ramp2 endothelial KOs die during development 
supports that the endothelium is the main cell type required for Ramp2 null survival and low 
Ramp2 endothelial expression is sufficient to improved survival to 40% in Ramp2-/- Tg mice 
(Table 2-1). 22, 206  Further investigation of the spatial (blood vs. lymphatic) and temporal 
levels of AM signaling required for embryonic survival are still needed. 
AM/CLR/Ramp2 signaling is important for normal pregnancy with Adm+/-, Calcrl+/-, 
and Ramp2+/- female mice all having fertility defects34, 68, 198, 313, 317, 318  Both maternal and 
fetal AM/CLR/Ramp2 signaling is essential for placental development and function (Kadmiel 
M and Caron KM Unpublished [2016]).313  The Ramp2-/- Tg mice provide another model to 
investigate the roles of this signaling pathway during pregnancy, considering the complex 
placental microenvironment.  The Ramp2-/- Tg mouse could be used to investigate how non-
endothelial cells (uterine epithelium, stroma, immune cells) contribute to the Ramp2+/- 
placental remodeling defects.313, 319, 320  Late gestation Ramp2-/- Tg with severe non-immune 
hydrops fetalis (Figure 4-1B) have impaired fluid drainage in placenta compared to Ramp2+/+ 
Tg controls (Figure 4-2A).  These mice could be further used to study the pathologic 
consequences of placental edema downstream of hydrops fetalis. 
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It is currently unknown whether adult females lacking Adm, Calcrl, or Ramp2 can 
undergo normal pregnant.  Ramp2+/- ntg males were crossed with Ramp2-/- Tg females in 
order to determine whether Ramp2-/- Tg females could get pregnant, deliver viable embryos, 
and/or foster pups.  The litter sizes from Ramp2-/- Tg dams were significantly smaller 
compared to litters from Ramp2+/- Tg dams (Figure 4-2B).  However, Ramp2-/- Tg females 
are able to undergo implantation and maintain pregnancy to term.  I observed a lot of dead 
pups at birth which was partially due to stillborn Ramp2-/- Tg pups, but was also observed in 
a number of Ramp2+/-.  A number of viable pups were present at weaning indicating the 
Ramp2-/- Tg dams are physically capable to care for their offspring.  The reduced litter size is 
indicative of a subfertility phenotype associated with Ramp2 heterozygosity, which occurred 
in the presence of endothelial Ramp2 expression in these Ramp2-/- Tg females. This data 
supports the assertion that normal fertility requires maternal Ramp2 expression in the uterus 
and/or placenta independent of the endothelium.  Additional studies are needed to further 
understand the cell type specific functions of Ramp2 during pregnancy, which could possibly 
be accomplished using a Ramp2flox/flox or the Calcrlflox/flox animals crossed to different Cre 
lines to study the roles of AM/CLR/Ramp2 signaling in different cell types.  It remains to be 
determined whether complete loss of maternal Ramp2 or AM/CLR/Ramp2 signaling is 
essential to undergo a successful pregnancy. 
 
Sex-dependent Mechanisms of RAMPs to regulate Blood Pressure and Heart Disease 
The Ramp2 Tg partially rescued the global Ramp2 deficiency, but this mouse model 
could also be used to study roles of Ramp2 endothelial overexpression.  We observed no 
significant phenotypes in embryonic survival, body weight, blood pressure, heart function, 
inflammation, and/or gene expression in the Ramp2+/+ Tg compared to controls (Chapter II).  
The lack of basal phenotypes is most likely due to feedback mechanisms to compensate for 
higher endothelial expression of Ramp2 and the associated vasodilatory effects of increased 
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AM/CLR/Ramp2 signaling.  It would be interesting to investigate how (lymph)angiogenesis is 
altered in the Ramp2+/+ Tg mice using either retinal or tumor angiogenesis assays. 
While the vasodilatory effects of AM are well established, the majority of genetic 
mouse models with alterations in this pathway do not alter basal blood pressure.  For 
example, neither loss-of-function animals, including Adm+/- , Calcrl+/-, Ramp2+/-, Ramp3-/- 
Calcrlflox/flox; SM22-Cre+ (Table 2-S3) or gain-of-function animals, including Ramp2+/+ Tg 
(Figure 2-2), AdmHi/Hi and SM22-Ramp2 Tg had significantly altered blood pressure.33, 34, 47, 
79, 196, 200  The Ramp2-/- Tg animals (Figure 2-2), Ramp2flox/flox; Cdh5-Cre, and Ramp1-/- are, to 
my knowledge, the only AM/CLR/Ramp2 mouse models with altered blood pressure.197, 206  
While Ramp2-/- Tg have developmentally thinner aortic vSMC walls and DCM-like 
phenotypes (Chapter II), it is unclear why these mice develop hypotension.  Administration 
of phenylephrine revealed that the vSMC are capable of vasoconstriction similar to that 
observed in controls.  The duration of the elevated blood pressure appeared slightly shorter 
in Ramp2-/- Tg mice compared to controls which could partially explain the hypotension, but 
these results and conclusions need to be confirmed.  Additional pharmacological challenges 
could help tease apart the mechanisms of endothelial-mediated vSMC relaxation through 
nitric oxide or direct vSMC relaxation.   
Loss of Ramp2 could lead to higher circulating AM, which has been shown to signal 
through CLR/Ramp1 heterodimer. We recently reaffirmed that exogenous AM administration 
had no significant blood pressure effect in Ramp1-/- mice, likely indicating that Ramp1 is 
essential for AM vasodilation (Pawlak J and Caron KM Unpublished [2016]).  This 
vasodilation through CLR/Ramp1 could be another potential mechanism of hypotension in 
Ramp2-/- Tg mice in circulating AM is elevated. It would be interesting to determine how 
chronic AM administration, either by AM minipumps or genetic overexpression using the 
AMHiHi mouse, alters blood pressure in Ramp2+/-, Ramp2-/- Tg, Ramp2+/+ Tg, Ramp1-/-, 
Ramp3-/-, Ramp1-/-; Ramp3-/- animals.  Furthermore, our lab has developed and utilized the 
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renin transgenic hypertensive mouse model, which could be crossed to Ramp2+/+ Tg, 
Ramp2-/- Tg, Ramp2fl/fl, or Calcrlfl/fl mice in order to study how these mouse models respond 
to chronic hypertension challenge.   
Interestingly, the basal hypertension observed in Ramp1-/- animals was only in male 
mice.197  Likewise, when challenged with renin-induced hypertension, male Ramp3-/- mice 
had a more severe phenotype than the female Ramp3-/- mice and Ramp3 was required for 
GPR30-induced cardioprotection only in male mice.193, 196  Conversely while the Ramp2-/- Tg 
females had spontaneous hypotension, it does not appear that Ramp2-/- Tg males have 
significant hypotension (Figure 4-3).  Similarly, male Ramp2-/- Tg males do not appear to 
have a DCM-like phenotype either, but additional male animals are needed to confirm these 
results.  These sex-dependent phenotypes are not too surprising considering that Ramp2+/- 
females have a number of endocrine phenotypes not observed in Ramp2+/- males.198   
Another hypothesis worth testing is whether the genetic loss of Ramp2 is involved in 
the pathogenesis of postpartum DCM.  As previous mentioned, Ramp2+/- female mice have 
endocrine phenotypes including basal hyperprolactinemia.198  It has been shown that 
oxidative stress due to mitochondrial dysfunction can lead to the production of cathepsin D, 
which can cleave circulating prolactin into a harmful prolactin isoform that causes further 
cardiac and vascular damage.211, 286 While prolactin levels need to be confirmed, heightened 
basal prolactin could contribute to the observed DCM phenotype in the Ramp2-/- Tg females.  
It would be interesting to compare hearts from virgin vs. postpartum Ramp2-/- Tg females to 
see if the DCM phenotype is exacerbated.  Looking at serum prolactin isoforms would 
further confirm whether the mechanism of Ramp2-/- Tg postpartum cardiomyopathy is similar 
to previously reported results.  This would represent a novel sex-dependent mechanism of 
Ramp2 loss.  Further investigation of the sex-dependent mechanisms of RAMPs to regulate 
blood pressure and cardiac homeostasis are needed to understand how the RAMP family 
members could be used therapeutically in a sex-dependent manner.   
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Roles of AM and GCGR/RAMP2 and PTHR1/RAMP2 Interfaces in Endocrine Diseases 
AM has been reported to be expressed in pancreatic islets and functions to inhibit 
insulin secretion in vivo and in isolated islets.321, 322  The roles of AM in glucose homeostasis 
and diabetes need to be further verified.  Loss of Ramp2 during development led to 
decreased cardiac Gcgr expression throughout life (Figure 2-6).  Biochemical studies 
demonstrated that GCGR, but not GLR-1R or GLP-2R, interacts with RAMP2.191  Weston et 
al. recently demonstrated that RAMP2 alters GCGR G protein-coupling and signaling.  
Additionally, RAMP2 dictates the ligand selectivity of the GCGR.223  More specifically, the 
GCGR/RAMP2 heterodimer is selective for glucagon, but the GCGR without RAMP2 can 
bind both glucagon and GLP-1.  The physiological consequences of GLP-1 as a partial 
agonist of the GCGR are unknown.  Glucagon and GLP-1 typically have opposing functions 
in regulating glucose and cardiac homeostasis.  Glucagon increases blood glucose 
concentrations by activating liver gluconeogenesis and is detrimental to cardiac function 
following ischemic injury.  Conversely, GLP-1 increases insulin to decrease blood glucose 
levels and is cardioprotective following ischemic injury.215, 323, 324  Using Ramp2 mouse 
models, such as the Ramp2-/- Tg or Ramp2flox/flox mice, it would be interesting to investigate 
the physiological consequences of altered Gcgr ligand selectivity and signaling in the in the 
heart, pancreas, and liver.  One could measure fasting glucose, insulin, glucagon, and GLP-
1 levels as well as perform glucose tolerance tests to assess dysregulation in glucose 
homeostasis.  Serum glucose was not altered basally in Ramp2-/- Tg mice (Table 2-S2), but 
the these mice could be challenged with type I or type II diabetic models.  Exogenous 
glucagon and GLP-1 administration usually have opposing effects, which could be tested in 
Ramp2 null adults to help determine how Ramp2 alters these peptides functions in vivo.  
These Ramp2 null mice could be fed a high fat diet to assess how obesity and insulin 
resistance affects their glucose homeostasis and overall health.  Gcgr-/- dams had significant 
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perinatal lethality due to lower glucose levels in pregnant females,325 which could partly 
explain Ramp2-/- Tg perinatal lethality and should be further examined.   
Ramp2 loss led to altered Pthr1 levels (Figure 2-6) and RAMP2 has been shown to 
traffic PTHR1 to the membrane, but the functions of this interaction is unknown.191  Using 
Ramp2 gain- and loss-of-function mice it would be interesting to test how decreased Pthr1 
expression in heart and kidney alters the parathyroid hormone signaling axis to regulate 
vitamin D and serum calcium homeostasis.  Serum calcium levels in Ramp2-/- Tg were 
unchanged (Table 2-S2), but it is possible that serum vitamin D and bone resorption in these 
animals acts as a compensatory mechanism to maintain serum calcium, which requires 
further investigation.  Bone resorption has been reported in Ramp2+/- females.198  To my 
knowledge, cardiac-specific Pthr1 functions have not been assessed and could be 
informative to understand the DCM-like phenotype in Ramp2-/- Tg mice.  Additionally, a 
combined Pthr1+/-; Gcrg+/- mouse could also be informative since Pthr1 and Gcgr are at 
heterozygous levels in Ramp2-/- Tg mice.  Vitamin D deficiency and hypocalcaemia have 
been shown to correlate with DCM in humans, which represent another potential 
mechanism for the DCM phenotype in the Ramp2-/- Tg mice.  It would be interesting to test if 
calcium, vitamin D, GLP-1, and/or antioxidant administration could rescue the DCM 
phenotype.  Together, additional studies are needed to shed further light on the 
physiological consequences of the RAMP2 interaction with both GCGR and PTHR1.  These 
studies would provide insight into how these interactions are involved in cardiac and 
endocrine diseases, providing a novel understanding of how to target these diseases 
therapeutically.    
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Determine if tumor-derived AM promotes tumor lymphangiogenesis indirectly through 
macrophage activation, and/or transdifferentiation   
We showed that tumors-derived AM dosage is correlated with tumor 
lymphangiogenesis (Figure 3-4), but the mechanism is unclear.305  The study in Chapter III 
concluded that the increased lymphangiogenesis caused by AM was through AM signaling 
directly on LECs to increase proliferation of preexisting lymphatic vessels.  AM could also be 
acting indirectly through macrophages to alter lymphangiogenic factor secretion.  Tumor-
associated macrophages, which secrete numerous lymphangiogenic factors, need to be 
further interrogated in the AM-dosed tumors.  AM dosage does not appear to alter 
macrophage infiltration by IHC (Figure 3-5).305 This result should be confirm using 
quantitative flow cytometry to count macrophages (F4/80+ or CD11b+) from dissociated 
tumors.  Additionally, the expression of Vegfa, Vegfc, or Vegfd lymphangiogenic genes was 
unchanged (Figure 3-5), but this was done using whole tumor RNA which could mask 
expressional changes in less abundant cell types within the tumor microenvironment.  RT-
PCR or genome-wide array expression analysis from specific cell types, including LLCs, 
macrophages, Lyve1+ macrophages, and endothelial cells would provide additional insight 
into how AM induced lymphangiogenic changes within the microenvironment. 
Macrophages have been reported to transdifferentiation into LECs and incorporate 
directly into lymphatic vessels.253, 254, 326-328  There appeared to be a potential correlation 
between tumor-derived AM and the number of these specialized Lyve1+; F4/80+ 
macrophages (Figure 3-5).305 Lyve1+; F4/80+ macrophages should be quantified in Adm 
dosed tumors using both IHC and flow cytometry as well as analyzed for evidence that 
these macrophages are able to incorporate into lymphatic vessels, similar to that recently 
reported CD31+ tumor cell vascular mimicry.295  It would be interesting to determine whether 
AM treatment can alter the pro- or anti-inflammatory cytokines and lymphangiogenic 
peptides secretion profile from cultured Lyve1+; F4/80+ or Lyve1-; F4/80+ macrophages.301, 
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328  To tease apart the macrophage-specific effects on LLC lymphangiogenesis, 
macrophages could be depleted using clodronate liposomes,327 which would further confirm 
that AM is not acting indirectly through macrophages to effect LECs proliferation. 
 
Determine how systemic AM dosage alters tumor lymphangiogenesis and metastasis   
The results of Chapter III demonstrated that tumor-derived AM dosage alters tumor 
lymphangiogenesis and metastasis.305 A follow up experiment is to test whether systemic 
AM also plays a role in tumor lymphangiogenesis and metastatic potential.  Systemically 
high AM is relevant because occurs during numerous diseases and during normal 
pregnancy (Figure 1-1).  Numerous reports have demonstrated that pregnancy can enhance 
tumor lymphangiogenesis and metastasis, particularly in early onset melanoma.307, 309, 310, 329  
The mechanisms behind pregnancy-associated enhanced metastasis is not well 
understood, but involves the complex interaction of the immune system, sex hormones, and 
other circulating factors.292, 294, 308, 310, 330  To determine whether AM is one of those 
circulating pregnancy-associated factors; tumors could be implanted into both pregnant and 
virgin mice and assessed for growth and metastasis.  However, this elevated AM during 
pregnancy returns to normal quickly following delivery, which is not conducive to the time 
course metastasis in murine implanted tumor models. Additionally, other pregnancy-
associated factors confound the AM-specific roles in this process.  Alternatively, the AdmHi/Hi 
mouse model is ideal to study how elevated systemic AM levels affect tumor metastasis 
independent of the other hormonal alterations that occur during pregnancy.  The AdmHi/Hi 
mice have similar elevated AM levels observed during normal human pregnancy.  This 
model could be compared to genetic models of low (Adm+/-) and normal (Adm+/+) AM levels. 
B16F10-GFP melanoma cells (kindly provided by Dr. Andrew Dudley) were 
implanted subcutaneously in immunocompetent wild-type and AdmHiHi mice and allowed to 
grow for 17 days (Figure 4-4A).  Primary tumors expressed GFP tumor cells and systemic 
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AM did not alter tumor growth (Figure 4-4B-C).  CD31 (blood) and Lyve1 (lymphatic) stained 
primary tumors sections revealed no preliminary differences in either the number or dilation 
of blood or lymphatic vessels in wild-type or AdmHiHi primary tumors (Figure 4-4D-E).  There 
appeared to be an increased number of GFP+ tumor cells in the draining lymph nodes and 
lungs of the AdmHiHi mice compared to control following 17 days (Figure 4-4F).  Preliminary 
quantification revealed a trending increase in GFP+ tumors cells in AdmHiHi lung sections 
(Figure 4-4G), but this quantification should be further confirmed by flow cytometry.  To 
further determine if metastasis was occurring independent of changes in tumor vasculature, 
1.5x105 B16F10-GFP cells were injected into the tail-vein of these mice and assessed 21 
days post-injection (Figure 4-5A).  After whole mouse necropsy, detectable GFP+ foci were 
visible in the liver and lungs (Figure 4-5B), as well as a few foci in the ovaries, spine, and 
kidneys.  While preliminary (N=4), GFP+ foci appeared more consistently and in greater 
numbers in the AdmHiHi mice compared to wild-type controls (Figure 4-5C-D).  This was 
apparent both macroscopically and microscopically in the lungs (Figure 4-5E).  Together 
these preliminary in vivo experiments suggest that metastasis is slightly increased in the 
AdmHiHi animals, which appeared to be independent of primary tumor vasculature.  I 
speculate that this increased metastasis is due to differences in either tumor cell adherence 
or through the suppression of the cytotoxic immune system.  More experiments are needed 
to validate and confirm these hypotheses and conclusions. 
The potential of AM as a therapeutic target against cancer has not been well studied 
in vivo.  It would be interesting to investigate how vascular or lymphatic-specific deletion of  
Calcrl, which have impaired lymphatic and presumably blood vasculatures,199 alters tumor 
growth and metastasis.  These mice challenged with LLC-Adm RNAi and LLC-Adm OExp 
tumors would further define the cell autonomous effects of tumor-derived AM in the tumor 
microenvironment.  The most common lymphangiogenic peptide shown to enhance 
lymphatic metastasis is Vegfc.44, 240-243  Vegfc not only potently induces lymphatic vessel 
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proliferation and growth, but it also makes vessels extremely leaky.  Meanwhile AM has 
been shown in vitro and in vivo to tighten endothelial junctions making them less leaky.25, 199, 
306, 331, 332  It would be interesting to investigate the vessel number, integrity, and metastatic 
potential in mice that overexpress both Adm and Vegfc.  Potentially a dual target approach 
involving both CLR and VEGFR3 would be more successful therapeutic target than VEGF 
inhibitors alone. 
 
AM Functions on Immune Cell Adhesion, Activity, and Cytotoxic Surveillance 
AM has been shown to have acute anti-inflammatory functions and is largely 
considered an anti-fibrotic and protective peptide.32, 333-335  However, the consequences of 
chronically elevated AM, to my knowledge, have not been thoroughly addressed.  In the 
context of tumors or chronic infections, AM could have unintended consequences of 
suppressing the cytotoxic immune system which would allow tumors cells or infections to 
persist in the circulation.  Furthermore, loss of Ramp2 in adult mice leads to multi-organ 
vasculitis, which has been attributed to either vascular congestion secondary to DCM and 
hypotension in the Ramp2-/- Tg mice (Figure 2-5) or due to increased adherence of immune 
cells to endothelium lacking Ramp2.206  It remains unclear how overexpression of 
endothelial Ramp2 has the same inflammatory phenotype as deletion of endothelial Ramp2. 
Hemodynamic stasis downstream of hypotension or DCM could increase immune cell 
adherence and transendothelial migration or could increase compensatory circulating 
vasoconstrictors that can indirectly cause tissue damage and inflammation.  Interestingly, 
both Ramp2 mouse models have evidence of increased Adm expression, which is likely 
elevated due to homeostatic response caused by loss of Ramp2 or indirectly due to 
pathologic conditions.  Surprisingly, adult AdmHiHi mice also have a significant number of 
inflammatory foci in their livers (Figure 4-6A), kidneys (Figure 4-6B) and lungs (Figure 4-6C), 
which is progressive with age.  The AdmHiHi adult mice also have significantly larger spleens 
104 
 
than Adm+/+ gender aged match mice (Figure 4-7B).  These data further support that 
chronically high AM may be involved in the multi-organ inflammation phenotype.   
 There are mechanistic similarities by which immune and tumor cells adhere and 
migrate through endothelial monolayers.336  A recent study from our group demonstrated 
that AM enhanced tumor cell adherence and transmigration through LEC monolayer, which 
was facilitated through gap junctions.306  These results were accomplished through either 
genetic overexpression of AM in the LLC Adm OExp tumor cell model (Figure 3-1) or by 
exogenous AM treatment of other mouse and human tumor cell lines.  Furthermore, LLCs 
Adm RNAi, AM inhibitor, or gap junction inhibitors all reversed this process.  I hypothesize 
that chronically elevated AM can enhance immune cell adherence and migration through 
endothelial monolayers and could be an underlying mechanism behind the observed multi-
organ inflammation in the Ramp2 mouse models.  One could utilize similar in vitro 
adherence and transmigration assays as previously published in order to confirm these 
results using primary mouse or human immune cells instead of tumor cells.306  Both BEC 
and LEC monolayers could be tested, as well as different immune cell populations collected 
from Adm+/-, Adm+/+, and  AdmHiHi  mice.  If inflammation is progressive with age, different 
aged mice could be used to study how AM alters the immune system composition and 
function over time.  Specific isolated immune cells could be further tested for altered 
cytokine production.  These experiments could also be performed in activated immune cells, 
from inflamed mice, or with isolated human immune cells treated with AM.  
Preliminary results suggest that high systemic AM in the AdmHiHi mice can potentially 
increase melanoma cell metastasis, independent of blood and lymphatic vasculatures in the 
primary tumor (Figure 4-4 and 4-5).  I hypothesize that high AM inhibits the cytotoxic 
immune system, specifically peripheral natural killer (pNK) cells considering AM dosage 
alters uterine NK cells recruitment and cytokine release.313  A CD49b+ pNK cell enriched 
population was isolated using dissociated wild-type spleens and MACS (Figure 4-7A).  To 
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assess the ability of AM to activate or inhibit pNK cell function, isolated pNK cells were 
treated with AM, prostaglandin E2 (PGE2), or Forskolin.  All treatments increased cAMP 
production (Figure 4-7C).  pNK expressed modest levels of Calcrl (Figure 4-7D), suggesting 
AM can act directly on NK cells.  It has been shown that PGE2 and increased cAMP 
production inhibits pNK cell cytotoxicity.337, 338  To assess cytotoxicity directly, pNK cells 
were co-cultured with fluorescently labelled lymphoma cells (Yac1) and treated with a 
cytotoxic activator IL-2,339 an inhibitor PGE2, and/or AM.  Specific fluorescent tumor cell 
death was assessed by flow cytometry (Figure 4-7E).  As expected IL-2 activated pNK cells 
killed a significant number of tumor cells, which was blocked by PGE2 treatment (Figure 4-
7F).  AM treatment was not able to inhibit IL-2 activated pNK cell cytotoxicity (Figure 4-7F).  
These initial experiments indicate that AM can act directly on pNK cells, but does not inhibit 
NK cell cytotoxicity.  Therefore while high AM appears to increase metastasis, it is likely not 
caused by the direct inhibition of pNK cytotoxic surveillance.  It has been shown that 
lymphangiogenic factor, VEGFD, can increase serum prostaglandin levels indirectly through 
LECs.263  AM could indirectly regulate pNK cell function through prostaglandins or by 
altering various aspects of the cyclooxygenase pathway, which has been reported 
previously in murine arthritis models (Figure 4-8A).334, 340  Alternatively, AM could increase 
tumor cell survival by inhibiting other cytotoxic cells, including macrophages,301 myeloid-
derived suppressor cells,310 regulatory T cells,334 or mast cells105 directly (Figure 4-8B).  AM 
could act indirectly through these cells to suppress pNK cell function (Figure 4-8C).  It is also 
possible that the number of pNK cells and/or other cytotoxic cells is altered in the AdmHiHi 
enlarged spleens.  Investigating the cytokine profile and activity of NK cells isolated from 
different mouse lines would be informative.  To my knowledge, it has not been reported how 
AM affects pNK cell function or immune surveillance AM during tumor metastasis.  These 
studies would be informative to further understand AM roles during inflammation and 
cancer.  
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Concluding Remarks 
   Through the studies in Part I, I opened the door to further studies to investigate 
Ramp2 and its specific, possibly sex-dependent, roles to regulate blood pressure and 
cardiac homeostasis.  This novel transgenic rescue could potentially act as a therapeutic 
strategy to treat non-immune hydrops fetalis and potentially other lymphatic diseases.  It 
also expands Ramp2 functions to other GPCR pathways essential for endocrine 
homeostasis.  While AM is typically considered protective, it is detrimental in tumor context 
and could represent a novel target against tumor metastasis.     
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Figures 
 
Figure 4-1:  Edema and late gestational lethality-associated with some Ramp2-/- Tg 
pups.  Representative (A) PCR from (B) e18.5 viable Ramp2+/+ ntg, Ramp2+/+ Tg, and 
Ramp2-/- Tg embryos.  Magnifications are equivalent between panels.  (C) Representative 
images of still-born Ramp2-/- Tg P1 pups compared to viable Ramp2+/- littermates.  
 
 
 
 
 
 
 
 
108 
 
 
Figure 4-2:  Ramp2-/- Tg dams can get pregnant but have reduced litter size.  (A) 
Representative H&E images of Ramp2+/+ Tg and edematous Ramp2-/- Tg placentas from 
e18.5 embryos.  (B) Average litter size of Ramp2+/- ntg male crossed to either Ramp2+/- Tg 
or Ramp2-/- Tg females.  N = 3 litters from 2-3 different dams.  Significance determined by 
student T-test with *p<0.05. 
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Figure 4-3:  Ramp2-/- Tg spontaneous hypotension is sex-dependent.  Intra-arterial 
blood pressure measurements from anesthetized Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2-/- 
Tg (A) female and (B) male mice.  Data represented as average MAP in a minute of 
continuous baseline measurements. N = 2 mice per genotype per sex. 
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Figure 4-4:  Systemic elevated AM led to increased metastasis independent of tumor 
growth or (lymph)angiogenesis.  (A) B16F10-GFP melanoma cells were injected 
subcutaneously into immunocompetent Adm+/+ and AdmHiHi adult female mice.  (B) 
Representative sections from primary tumors with GFP+ (green) tumor cells and GFP- host-
derived cells.  (C)  Tumor volume after 17 days of growth measured by calipers from Adm+/+ 
and AdmHiHi mice.  Quantification of tumor-associated, both peritumoral and intratumoral (D) 
blood and (E) lymphatic vessels from Adm+/+ and AdmHiHi primary tumor sections.  Dilation 
was defined by visibly open vessel lumens.  Blood vessels were visualized using CD31 and 
lymphatic vessels by LYVE-1.  (F) Representative images of GFP+ tumor cells (green) in 
both the draining sentinel lymph node and lung from B16F10-GFP injected Adm+/+ and 
AdmHiHi mice after 17 days.  (G) Quantification of GFP+ cells per lung sections in 3 mice per 
genotype. 
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Figure 4-5:  Increased tumor cell seeding in AdmHiHi mice independent of primary 
mass.  (A) B16F10-GFP melanoma cells were injected into the tail-vein of 
immunocompetent Adm+/+ and AdmHiHi adult female mice.  (B) Representative bright field 
and fluorescence whole mount lungs and livers demonstrating visible GFP+ (green) tumor 
mass 21 days following injection.  Quantification of (C) the percentage of mice with visible 
GFP+ foci in different organs and (D) number of GFP+ foci per lobe of lung.  (E) 
Representative lung sections with GFP+ cells (green) from Adm+/+ and AdmHiHi mice 21 days 
post-injection. N = 4 mice per genotype. 
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Figure 4-6:  Chronically elevated systemic AM causes multi-organ inflammation. 
Representative H&E images and quantification of inflammatory foci in (A) livers, (B) kidneys, 
and (C) lungs from Ramp2+/+ ntg, Ramp2+/+ Tg, Ramp2-/- Tg, aged-matched AdmHiHi, and 
older (> 1 year) AdmHiHi mice.  Data represented as averages ± SEM from N = 3-4 mice per 
genotype.   
 
 
113 
 
 
Figure 4-7:  AM does not directly alter NK Cell Cytotoxicity.  (A) Flow cytometry of non-
sorted splenocytes and enriched CD49b+ peripheral NK cell fraction following MACS 
isolation.  (B) Spleen weights normalized to body weight from Adm+/+ wild-type and AdmHiHi 
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adult mice. N = 4-6 mice per genotype.  (C) cAMP concentrations of cultured CD49b+ NK 
cells following water, AM, PGE2, or Forskolin treatments.  (D) Relative expression of AM 
receptor, CLR in splenocytes, CD49b positive and negative fractions, as well as whole lung.  
(E) Fluorescently labeled lymphoma Yac1 cells were cocultured for 4 hours with CD49b+ NK 
cells treated with water, IL-2, IL-2 and AM, IL-2 and PGE2, AM and PGE2, or Triton.  (F) NK 
cell cytotoxicity assessed by percentage of viable (7-AAD-) vs dead (7-AAD+) Yac1 (GFP+) 
tumor cells using flow cytometry.  Representative data from independent experiments 
repeated three times with each condition in triplicate. 
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Figure 4-8:  Effect of high systemic AM on tumor metastasis through suppression of 
cytotoxic immune system.  (A) Increased tumor cells in the lungs of mice with high 
systemic AM levels compared to wild-type mice. (A-C) Hypothetical mechanisms by which 
AM is able to suppress immune surveillance. (A) AM acts indirectly through endothelial cells 
to increase PGE2 synthesis leading to decreased NK cell cytotoxicity.  (B) AM directly 
suppresses function of other cytotoxic cells, such as T cells, leading to increased 
metastasis.  (C) AM acts indirectly through other immune cells to ultimately suppress NK cell 
cytotoxicity.  
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Chapter V: The History of AM Receptors:  The Forgotten GPCRs 
 
Overview   
Before the discovery of the receptor activity-modifying proteins (RAMPs), 
adrenomedullin (AM) was thought to bind and signal through three GPCRs, including 
calcitonin receptor-like receptor (CLR), RDC-1, and G10D. G10D became known as the AM 
receptor, or Admr.  However, the pharmacology of RDC1 and Admr was disputed and Admr 
was orphanized and became known as Gpr182.  Since the RAMPs discovery confirmed 
CLR as the canonical AM receptor, the historical evidence that AM can bind and/or signal 
through these other two GPCRs was largely forgotten.  However, recent studies have 
demonstrated the importance of these receptors during development and adulthood and the 
possibility of them being AM receptors needs to be revisited. 
 
The Rise and Fall of AM and CGRP Receptors prior to RAMP Discovery 
Adrenomedullin (AM) was initially identified in an isolated human adrenal 
pheochromocytoma and could activate cAMP in platelets.76, 341  It quickly became apparent 
that both AM and related calcitonin gene-related peptide (CGRP) had potent vasodilatory 
effects in rat mesenteric vascular beds.76, 131, 255  This discovery quickly sparked significant 
interest to discover the receptors of AM and CGRP in vascular smooth muscle cells (vSMC) 
that could potentially be targeted therapeutically to treat hypertension and other diseases.  
Using primarily radiolabeling experiments with rat 125I-AM and rat 125I-CGRP, numerous 
reports showed that AM and CGRP could bind rat vSMC and stimulate cAMP production.342, 
343  It was later demonstrated that AM could activated cAMP production in bovine aortic 
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endothelial cells, Swiss 3T3 fibroblasts, and rat skeletal muscle, as well as elevated 
intracellular calcium in bovine adrenal medullary cells and aortic endothelium.344-348  It was 
also shown that AM was expressed in pancreatic -cells and inhibited insulin secretion in 
vivo and in cultured pancreatic islets,321 further demonstrating the potential to use AM 
receptors as a therapeutic target to regulate blood glucose homeostasis.  It became 
apparent that AM and CGRP interacted with the same or similar receptors.349 
In the early 1990s, three distinct GPCRs were cloned that would eventually be 
thought to be the functional AM and/or CGRP receptors.  The first was RDC1, which was 
cloned from canine thyroid.350  A few years later, the rat and human calcitonin receptor-like 
receptor (CLR) were cloned and shown to elicit a cAMP response with CRF treatment.351-353  
The third distinct GPCR, G10D was cloned from rat liver and was expressed in lung, 
adrenal, liver, kidney, aorta, heart, spinal cord, gut, and testis.354  Sequence alignment found 
that canine RDC1 was the closest known G10D paralog with the majority of similarity in the 
transmembrane domains.  Unlike Class A RDC1 and G10D, CLR is a Family B GPCR with 
similar sequence to the calcitonin receptor.  A few years later, three other groups 
independently cloned rat and human GPCRs identical to G10D, which were named L1 and 
adrenomedullin receptor, respectively.355-357    
The initial characterization of G10D was unsuccessful in identifying a functional 
ligand.354 G10D cDNA was transfected into COS-1 cells and a variety of radiolabeled ligands 
failed to bind, including angiotensin II, naloxone, leukotriene C4, leukotriene D4, bradykinin, 
or galanin. Additionally no significant calcium activated-chloride current was detected in 
Xenopus oocytes injected with G10D mRNA and treated with angiotensin II, bradykinin, IL-8, 
MCAF, MIP-1, RANTES, TNF-, ATP, leukotriene C4 or D4.  In a later study, Kapas et al. 
transfected Admr (G10D/L1) cDNA into COS-7 cells and found that AM treatment, but not 
CGRP, activated cAMP response (EC50 = 7 nM).
356  Additionally, rat 125I-AM bound these 
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cells with high affinity (KD=8.2 nM).  Furthermore, Admr/L1/G10D mRNA expression sites 
closely matched known 125I-AM binding sites in rat tissues.358.  Northern blots revealed 
human Admr relative expression in a number of tissues (listed highest to lowest expression), 
including heart, skeletal muscle, liver, lymph node, adrenal medulla and cortex, stomach, 
spleen, kidney, thyroid, bone marrow, small intestine, testis, brain, and lung.357 This 
expression pattern mirrored earlier reports of rat G10D expression pattern.354 
Since RDC1 was the closest paralog of Admr/L1/G10D, RDC1 was also assessed as 
an AM and/or CGRP receptor.359  RDC1 was transfected into COS-7 cells, where rat CGRP 
(KD = 9.2 nM, EC50 = 3 nM) and AM (KD = 190 nM, EC50 10 nM) could bind these cells and 
activate cAMP response, while amylin did not bind.  A competitive inhibitor CGRP(8-37) did 
not block the AM induced cAMP response in COS-7 cells likely indicating an alternative 
binding site or non-specific binding.  They concluded that RDC1 was primarily a CGRP 
receptor, with lower affinities for AM.  To try and determine which AM receptor was 
responsible for vasodilatory effects, Autelitano et al. looked at the expression of L1, CLR, 
and RDC1 in lungs and a vSMC cell line and found that all three receptors were expressed 
in the lungs, but only RDC1 was detected in vSMC.360 
Entzeroth et al. showed that CLR was also responsive to CGRP and AM and was 
responsible for their vasodilatory effects.361 Using SK-N-MC neuroblastoma cells they 
demonstrated that human CGRP (EC50 = 9.65) and AM (EC50 = 7.75) were able to elicit 
increased cAMP levels. These responses were blocked by the CGRP[8-37] antagonist 
indicating a specific interaction. CGRP or AM infusion into isolated rat hearts caused 
vasodilation with EC50 ~ 0.5 nM or 3 nM, respectively.  This effect could be blocked with a 
CGRP inhibitor further demonstrating that AM and CGRP vasodilation is through a common 
receptor.  Other groups using different human cell lines also demonstrated CLR as a CGRP 
receptor.349, 362  Together, CLR and to a lesser extent RDC1 were thought to be nonselective 
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AM and CGRP receptors, while G10D/L1/Admr was thought to be the AM selective receptor 
(Figure 5-1).   
In 1998, Kennedy et al. attempted to validate the previous finding that the rat and 
human Admr were in fact AM-specific receptors.356, 363  This study transfected COS-7 with 
either mock pcDNA3 or rat Admr-FLAG and confirmed the surface expression of FLAG 
epitope in non-permeabilized cells.363 This study found that rat or human 125I-rAM bound 
identically in both mock and Admr-FLAG transfected cells.  Human AM did not displace 125I-
AM bound to COS-7 cells.  Furthermore, neither rat nor human Admr activated cAMP 
response with AM treatment in COS-7 or HEK293T cells, but did elicit cAMP response a 
positive control Swiss 3T3 cell line.  Together, these data demonstrated that the AM binding 
in COS-7 cells previously reported was likely independent of Admr expression.  Therefore 
Admr is likely not the AM receptor and thus was reclassified as an orphan receptor, Gpr182.  
Additional studies found that L1/Admr/Gpr182 expression was not detected in uterus, rat 
fibroblasts, or rat vSMCs, which all clearly label with AM, further supporting that Admr does 
not bind AM in these cell types.344, 360, 364 
Shortly after Admr was debunked as the AM receptor, McLatchie et al. published a 
seminal manuscript demonstrated that CLR interacts with novel receptor activity-modifying 
proteins (RAMPs) in Xenopus oocytes and transfect HEK293T cells.  This interaction was 
required for CLR trafficking to plasma membrane and when CLR heterodimerized with 
Ramp1 it bound and signaled with CGRP with high affinity.  Conversely, the CLR/Ramp2 
complex acted as the AM receptor.7  It was later shown that cAMP induced by AM in vSMC 
was through CLR/RAMP2 complex.365  The identification of the RAMP proteins, along with 
the orphanization of Admr to Gpr182, largely resolved the controversy of the canonical 
CGRP and AM receptors.  Both RDC1 and Gpr182 were largely discredited as putative AM 
receptors and forgotten about in regards to AM signaling (Figure 5-1).  
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CLR, Cxcr7, and Gpr182 in a RAMP World  
The first in vivo confirmation that CLR/Ramp2 was the canonical AM receptor came 
from the phenotypic similarities between genetic knockout mice of Adm, Calcrl, and 
Ramp2.22, 30, 33  As discussed in Part I, all the knockout mice had midgestational lethality 
attributed to cardiovascular and lymphatic developmental defects demonstrating this 
signaling paradigm is required for survival.  Mice with genetic loss of CGRP, Ramp1, and 
Ramp3 were born in normal Mendelian ratios and had no obvious developmental defects.34, 
194, 197  These data indicate either these genes are dispensable during development, CGRP 
has compensatory isoforms, and/or that CGRP can signal through Ramp2.  The functional 
characterization of AM and CLR was discussed extensively in Part I and recent reviews.366, 
367   
Cxcr7 knockout animals have early postnatal lethality associated with cardiomyocyte 
hyperplasia, cardiac enlargement, and valve defects.368-370  There is a huge amount of 
literature regarding Cxcr7 in the cardiovascular, neural, and immune systems, as well as 
during cancer.  Cxcr7 mainly acts to control chemotactic gradients of SDF-1 availability for 
Cxcr4-induced migration.371-375  Cxcr7, like most chemokine receptors, is promiscuous and 
can bind numerous ligands, including SDF-1, ITAC, and an adrenal opioid proenkaphalin 
A.376-378  In addition to cardiac development, Cxcr7 is also important for developmental 
lymphatic proliferation, potentially through sequestering AM ligand availability.332, 379  
Whether or not Cxcr7 is able to directly bind AM and CGRP, as previously reported is 
controversial.7, 248, 359  It appears clear that AM and Cxcr7 are transcriptionally linked and 
have some developmental similarities,200, 332, 368 but the lymphatic functions of SDF-1 and 
Cxcr4, as well as how Cxcr7 affects CLR expression needs to be elucidated before the 
lymph-associated phenotypes can be attributed solely to AM (or CGRP).   
While CLR and Cxcr7 have been relatively extensively studied since 1998, the third 
historical AM receptor, Gpr182 was largely forgotten by the research community, with a 
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PubMed search for “Gpr182” in June 2016 yielding one publication.201  Gpr182 remains a 
Class A orphan receptor with unknown ligand or downstream signaling.  Additionally, 
browser searches for “adrenomedullin receptor” typically do not distinguish Gpr182 from 
CLR/RAMP2.  The historical nomenclature of Admr continues to confuse the research 
community, who identify Admr as part of genome-wide arrays and hypothesize that it 
functions as the receptor for AM.102, 248, 380, 381    Gpr182/Admr was identified as a novel 
vascular endothelial marker during zebrafish and mouse development and Gpr182 
expression is upregulated in mammary tumor endothelium.201, 381, 382  To date the scientific 
literature regarding G10D/L1/Admr/Gpr182 has focused on expression by whole tissue 
Northern blot, RT-PCR, or whole genome expression pattern, with very limited tissue 
localization by in ISH or unvalidated antibodies.  Considering the lack of a ligand, knowledge 
of downstream signaling, and research tools, there are currently no published studies 
elucidating the specific functions of Gpr182 in vivo.  The following Chapter VI addresses 
Gpr182 spatial and temporal expression patterns and identifies novel functions of Gpr182. 
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Figure 
 
 
 
Figure 5-1:  Historical perspective of AM pharmacology.  Schematic summarizing the 
AM and CGRP receptors prior to and following the characterization of RAMPs in 1998.  
Known ligands are represented by solid circles and other partial agonists or theoretical 
ligands are represented by dotted circles.  Cxcr7 and Gpr182 are Class A rhodopsin-like 
GPCRs and CLR is a Family B secretin-like GPCRs. 
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Chapter VI: Gpr182 inhibits intestinal proliferation during regeneration and adenoma 
formation4 
 
Overview   
Orphan G protein-coupled receptors (GPCRs) provide an untapped opportunity for 
identification of novel pharmacological targets, yet their expression patterns and 
physiological functions remain challenging to elucidate.  Using a genetically-engineered 
knock-in reporter mouse, we mapped the expression pattern of the orphan GPCR, Gpr182, 
during development and adulthood.  Notably, Gpr182 is robustly expressed at the crypt base 
throughout the small intestine, where it is enriched in the crypt base columnar stem cells—
one of the most active stem cell populations in the body.  Knockdown of Gpr182 expression 
in mice had no effect on homeostatic intestinal proliferation, but led to significantly increased 
stem cell proliferation during intestinal regeneration following irradiation-induced injury.  
Furthermore, when combined with the mutant ApcMin mouse model, reduced Gpr182 led to 
significantly more adenomas throughout the intestine and decreased survival of these mice.  
Reduced Gpr182 led to increased activation of Erk1/2 in basal and challenge models, 
demonstrating a key role for this orphan GPCR in controlling negative proliferative signals 
within the intestine.  Importantly, we further show that GPR182 expression is significantly 
reduced in numerous human carcinomas, including colon adenocarcinoma.  Together these 
results provide new expression analysis of Gpr182 in vivo and are the first to implicate 
                                                          
4 This work is currently [2016] in revision for publication in Journal of Clinical Investigation. 
Permission for re-printing will be obtained upon publication. Contributing authors include: 
Daniel O. Kechele, R. Eric Blue, Amanda T. Mah, Scott T. Espenschied, Marni B. Siegel, 
Charles M. Perou, Scott T. Magness, P. Kay Lund, and Kathleen M. Caron.  
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Gpr182 as a negative regulator of intestinal MAPK signaling-induced proliferation during 
regeneration and adenoma formation. 
 
Introduction 
G protein-coupled receptor 182, Gpr182 (formerly known as G10D or Admr354, 356), is 
a class A orphan GPCR with nearly nothing known about its expression, function, regulation, 
or pharmacology.  Gpr182 is grouped within the chemokine receptor family by phylogeny, 
with the atypical chemokine receptor 3 (Ackr3, formally known as Cxcr7 or RDC1) as its 
closest paralog, despite the two sharing a modest <30% sequence homology in mice or 
humans.  Gpr182 was previously considered a putative receptor for the multifunctional 
peptide adrenomedullin,356 however these initial findings were not consistent among 
laboratories363 and it was later shown that adrenomedullin signals through a different GPCR 
complex.7  Unfortunately, the former Admr (adrenomedullin receptor) nomenclature is 
sometimes still employed, which leads to confusion in the field.  For example, GPR182 was 
reported to be highly expressed in numerous human pancreatic cancer cell lines and 
knockdown of GPR182 in these cells decreased xenograft tumor growth, which the authors 
concluded was due to a loss of adrenomedullin signaling.102, 380 Anatomical expression 
profiling of the GPCRome demonstrated the relative ubiquitous expression of Gpr182 in 
most mouse tissues.383  More recently, Gpr182 was found to be highly expressed in 
developing murine endothelium and enriched in mammary tumor endothelium compared to 
normal mammary endothelium.201, 381  Additionally, Gpr182 was identified among a group of 
factors that are significantly altered in a zebrafish model of myeloid leukemia.384  Thus, a 
significant advance of the current study is the complete expressional profile of Gpr182 using 
an in vivo mammalian reporter model, where we observed robust expression within the 
gastrointestinal tract epithelia.   
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The epithelium of the gastrointestinal tract is one of the most dynamic tissues in the 
adult body, primarily responsible for the absorption of dietary nutrients, and also for fulfilling 
important endocrine, immune and protective barrier functions.  To maintain its proper 
functions, the intestinal epithelium must continuously turnover, with the entire small intestinal 
epithelium renewing every week in humans and in mice.  This constant renewal is driven by 
an active population of intestinal stem cells (ISCs) that are located at the base of the crypts 
of Lieberkühn, where they give rise to rapidly dividing daughter transit-amplifying progenitor 
cells that differentiate into the absorptive or secretory lineages responsible for functions of 
the intestine.385-388  Current views are that two distinct pools of ISCs exist in the intestinal 
epithelium:  the crypt base columnar (CBC) ISCs which are positioned between 
differentiated Paneth cells and mediate normal homeostatic renewal, and “damage-
resistant” ISC that act as a reserve ISC activated following injury.385, 386, 388, 389  With the 
discovery of numerous ISC-specific markers including Lgr5, Lrig1 Ascl2, Olfm4, Hopx, Bmi1, 
and Sox9, our understanding of both these ISC populations has drastically expanded over 
the past decade.390-396  It is evident that the activity and proliferation of these ISCs must be 
tightly controlled by numerous signaling pathways and redundant mechanisms in order to 
maintain homeostasis in the dynamic gut microenvironment.385, 397  Furthermore, oncogenic 
mutations specifically in ISCs can drastically enhance adenoma formation in mice.391, 398  
Thus, defining factors that regulate ISC proliferation or survival is critical to better 
understand their functions during homeostasis, damage repair, and cancer, in order to better 
therapeutically target these ISCs. 
In this study, we aimed to identify novel functions of the orphan Gpr182 in vivo by 
first mapping the murine Gpr182 expression pattern during development and in adulthood, 
and then by secondly elucidating the effects of Gpr182 reduction on intestinal homeostasis, 
regeneration, and adenoma formation.   
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Methods 
Experimental Animals 
The Gpr182tm2a(KOMP)Wtsi/+ (knockout First/promoter driven) mice used in this research 
project were created from ES cell clone (EPD0365_4_C08) obtained from the NCRR-NIH 
supported Knockout Mouse Project (KOMP) repository and generated by the CSD 
consortium for the NIH funded KOMP.399  The CSD targeted allele has been previously 
published.400, 401  To achieve global deletion, the Gpr182tm2a(KOMP)Wtsi/+ mice were crossed to 
ubiquitous C57BL/6J-CMV-Cre transgenic mice.  For adenoma studies, Gpr182lacZ/+ mice 
were crossed to the C57BL/6J-ApcMin/+/J (Jackson Laboratory 002020) mice. All Gpr182-
associated mouse lines were maintained on an isogenic C57BL/6 background.  Previously 
published Sox9-EGFP BAC transgenic389, 396, 402-404 and Lgr5-EGFP390 mice were used for 
cell isolation and expression confirmation.  Genotyping primers are listed in Supplemental 
Table 1. 
 
Animal Procedures and Dissection 
For irradiation challenge, 10-14 week old female Gpr182+/+ and Gpr182lacZ/lacZ mice 
were subject to abdominal ionizing radiation as previously described.389  Briefly, under 
isoflurane anesthesia, mice received 14 Gy radiation (XRad 320 from Precision X-Ray, 
50cm, F1 Filter) to their abdomens.  Experimental and control mice were irradiated at the 
same time, to ensure equivalent radiation dosages and rates (~2.8 Gy/min for 300 sec).  
Mice were observed and weighed daily to monitor severity of irradiation and overall health.  
Five days post-irradiation, mice were injected intraperitoneally with 4 g of 5-ethynyl-2’-
deoxyuridine (EdU) per 1 g body weight.  Ninety minutes later mice were euthanized and 
gastrointestinal tissue was collected for histology and biochemistry.  For adenoma studies, 
male and female mice were monitored for health (physical appearance, body weight, bloody 
stool) and euthanized for tissue collection at five months.  Some mice had to be sacrificed 
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early due to declining health.  The small intestines and colons were removed and flushed 
with cold PBS.  The entire intestinal length was measured and then separated into 
duodenum, jejunum and ileum.  The small intestines and colons were opened along the 
length, flattened, and macroscopic polyp number and size was quantified from all ApcMin/+ 
mice.  Tissues were then processed for histology, whole mount X-gal staining, and 
biochemistry.  For cryogenic sections, tissue was fixed in 4% paraformaldehyde, 
cryoprotected in 30% sucrose and embedded in OCT before cryosectioning.  For histology 
tissues were fixed in either 4% paraformaldehyde or 10% zinc formalin and then paraffin 
embedded and sectioned. 
 
Whole Mount X-gal Staining 
Whole mount X-gal staining was adapted from previously published protocols.390 
Briefly, whole tissue was fixed in 0.2% glutaraldehyde (Electron Microscopy Sciences) for 24 
hours at 4°C.  Tissue was washed and permeabilized with 0.1% triton and incubated in 1 
mg/mL X-gal (Bioline) staining buffer for approximately 24 hours at room temperature in the 
dark.  Tissue was washed and post-fixed in 4% paraformaldehyde for 24 hours at 4°C.  
Samples were washed, imaged, and paraffin embedded and sections were counterstained 
with 1% Neutral Red (Sigma-Aldrich) or Eosin. 
 
Optical Projection Tomography 
Whole mount X-Gal stained tissues were embedded in 1% LM agarose, dehydrated 
overnight in absolute methanol, and cleared in benzyl alcohol:benzyl benzoate (1:2) as 
previously described.305  Optically cleared specimens were mounted to aluminum chucks 
and scanned with a 3001m Optical Projection Tomography Scanner (BiOPTonics) under 
bright field illumination.  Data sets were reconstructed into 3D models using nRecon 
software, and then visualized using either BiOPTonics viewer or ImageJ (NIH). 
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Immunohistochemistry 
For IHC, cryogenic sections were hydrated, permeabilized, and blocked with 5% 
normal donkey serum.  When required, slides were boiled in citrate buffer for antigen 
retrieval.  Slides were then stained with primary antibodies, including: chicken anti--
galactosidase (1:1500, Aves Labs), rabbit anti-lysozyme (1:1000, Leica Biosystems), rabbit 
anti-phospho-Histone H3 (1:500, Cell Signaling) rat anti-Ki67 (1:30, Dako), rabbit anti--
catenin (1:500, ABCAM), rat anti-CD31 (1:100, ABCAM), Syrian hamster anti-podoplanin 
(1:200, Developmental Studies Hybridoma Bank), overnight at room temperature.  Sections 
were rinsed, blocked, and incubated with secondary antibodies (1:200, Jackson 
Immunoresearch), including:  donkey anti-rabbit Alexa Fluor 488, donkey anti-rabbit Alexa 
Fluor 594  donkey anti-chicken Alexa Fluor 647, donkey anti-chicken Alexa Fluor 594, 
Donkey anti-rat Cy3, Donkey anti-mouse Alexa Fluor 488, Goat anti-Syrian hamster FITC, 
and Hoechst 33258 (1:1000, Sigma-Aldrich) in the dark for 90 minutes at room temperature. 
The Click-iT EdU Alexa Fluor 594 kit (Invitrogen) was used according to manufacturer’s 
instructions. 
 
Imaging and Image Processing 
Whole mount tissue was imaged using a Leica MZ16FA dissecting stereoscope 
outfitted with a QImaging Micropublisher 5.0 RTV color CCD camera.  Paraffin embedded 
H&E and X-gal slides were imaged using a Leitz Dialux 20 with QImaging Micropublisher 
5.0 RTV color CCD camera or an Olympus BX61 microscope equipped with a QImaging 
RETIGA 4000R CCD color camera with Volocity software (Improvision).  Fluorescence IHC 
images were acquired on a Nikon E800 fluorescence microscope with a Hammamatsu Orca 
CCD camera with Metamorph software (Molecular Devices Corp.) or a Zeiss LSM 700 
confocal microscope.  Fluorescent images were pseudo-colored using ImageJ.  Image 
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processing, including cropping, brightness, and contrast adjustments were altered equally 
across comparable images using Photoshop CS4 (Adobe).  
 
Morphometry and Proliferation Quantitation 
Crypt depth was quantified by measuring distance from bottom of nuclei at base to 
top of crypt from all whole open crypts in one cross section from 5 mice per genotype per 
treatment.  Crypt density was assessed by whole mount microscopy.  Three fields per 
intestinal area per genotype were imaged and crypt area from 10 crypts per field was 
measured using ImageJ.  The approximate amount of crypts that would fit into a 1 mm2 area 
was calculated.  Proliferation was assayed by EdU incorporation and the Click-It detection 
kit and analyzed by counting the number of EdU+ cells per open crypt normalized to total 
number of DAPI+ crypt cells and expressed as a percentage.  Researchers were blinded to 
mouse genotype and treatment.  Cell positions of EdU+ cells along crypt-villus axis were 
recorded during quantification.  20-60 individual whole open crypts were included from each 
region of the intestine (duodenum, jejunum, ileum, and distal colon) from 5 mice per 
genotype per treatment.  Polyp dimensions were approximated from all polyps ≥1x1 mm2 
throughout the small intestine in all experimental mice and polyp area was calculated 
assuming elliptical shape.  Individual polyp proliferation was determined by threshold 
quantification of Ki67+ signal as a ratio of DAPI+ signal using ImageJ. 
 
RT-PCR Analysis 
Tissues were either snap frozen in liquid nitrogen or stored in RNAlater (Ambion).  
RNA was extracted using TRIzol reagent (Invitrogen) and a Percellys bead homogenizer 
according to standard procedures, and subsequently DNase1 treated (Promega RQ1) and 
reverse transcribed with M-MLV (Invitrogen) or iScript (BioRad).  Quantitative gene 
expression was assayed with 2x TaqMan Master Mix (Applied Biosystems) and run on a 
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StepOne Plus (Applied Biosystems).  Primers and probes for RT-PCR are listed in 
Supplemental Table 6-S1.  Enriched cell populations were collected using FACS to isolated 
cells based on differential Sox9-EGFP levels as previously described.389, 402  Likewise, the 
Paneth cell enriched population was isolated using a previously published protocol.403 
Relative expression levels were determined by the ΔΔCt and normalized to reference gene 
expression, Gapdh or Rn18S. 
 
Western Blotting and Analysis 
Protein was extracted using Lens Homogenization Buffer with DTT and cOmplete 
protease inhibitor cocktail tablets (Roche) and a bead homogenizer (Percellys) according to 
standard procedures.  Concentrations were determined using Pierce bicinchoninic acid 
(BCA) protein assay kit (Thermo Scientific) read on a Mithras LB 940 (Berthold 
Technologies).  Protein ran on Mini-Protean TGX SDS-PAGE gel (BioRad) and transferred 
onto nitrocellulose (GE Healthcare) membrane.  Blots were blocked and stained in 5% BSA 
diluted in tris-buffered saline with 0.1% Tween 20.  Blots were incubated in primary 
antibodies including, rabbit anti-p42/44 MAPK (Erk1/2) (1:1000, Cell Signaling), rabbit anti-
phospho-p42/44 MAPK (Erk1/2) (Thr202/Tyr204) (1:1000, Cell Signaling), and mouse anti-
Gapdh (1:5000, Novus Biologicals) overnight at 4°C.  Blots were rinsed, blocked in 5% 
nonfat milk, and incubated with secondary antibodies including, goat anti-rabbit Dylight 680 
(1:12,000, Thermo Scientific), goat anti-mouse Dylight 800 (1:12,000, Thermo Scientific) in 
the dark for 60 minutes at room temperature.  An Odyssey CLx (Li-COR) was used for 
imaging.  Image brightness and contrast changes were made equally across all comparable 
images using Image Studio and Photoshop CS4 and p-Erk/Erk quantification by 
densitometry using ImageJ was normalized to Gpr182+/+ controls.  Gapdh was used to 
ensure equal loading. 
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RNA Sequencing Analysis  
RNA Sequencing data was downloaded from the TCGA Data Portal.405, 406  RSEM 
upper-quantile normalized values from Illumina HiSeq_RNASeqV2 from patient-matched 
tumor and normal tissue were log2 transformed.  Samples with expression <3 are 
indistinguishable from background and thus were considered as 0. 
 
Statistics 
Statistical analysis was performed with GraphPad 5.0 and data represented as mean 
± SEM. The unpaired T-test was used for graphs analyzing two groups.  For parametric data 
with >2 comparisons and biological replicates N <10 the 1-way ANOVA with Tukey’s 
Multiple Comparison test was used.  For nonparametric data analyzing >2 groups and 
biological replicates N >10 the 1-way ANOVA with Kruskal-Wallis test and Dunn’s Multiple 
Comparison test was used.  The Mantel-Cox test was used to analyze Kaplan-Meier survival 
data.  Patient-matched tumor and normal tissues were compared with nonparametric 
Wilcoxon matched paired T-test and non-matched tumors were compared using unpaired 
Mann Whitney T-test.  Significant differences are represented as *p < 0.05, **p < 0.01, ***p 
< 0.001.   
 
Study Approval 
All animal studies were in accordance with approved protocols by the Institutional 
Animal Care and Use Committee of the University of North Carolina at Chapel Hill. 
 
Results 
Orphan Gpr182 is widely expressed throughout development and adulthood 
The Gpr182tm2a(KOMP)Wtsi/+ (knockout first/promoter driven), hereafter referred to as the 
Gpr182lacZ/+ mouse, was generated399 and initially used to map murine Gpr182 expression 
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during development and adulthood.  A gene trap cassette bearing an En2 splice acceptor 
upstream of a lacZ reporter was knocked into murine Gpr182 locus immediately downstream 
of exon 1, resulting in expression of lacZ instead of the endogenous protein coding 
sequence in exon 2 (Figure 6-1A).  Gpr182 lacZ expression was detected by -
galactosidase (-gal) activity as early as embryonic day 8.0 (e8.0) in dorsal aorta and 
vitelline veins (Figure 6-1B and Supplemental Figure 6-S1A).  By e13.5, Gpr182 expression 
was observed in numerous organs, including heart, lung, liver, aorta, and carotid arteries 
(Figure 6-1C and Supplemental Figure 6-S1B-C).  Embryonic heart expression was present 
in both atria and ventricles, particularly in the ventricular trabecular region (Figure 6-1D).  At 
e17.5, Gpr182 localization remained prominent in the heart, lungs, and liver, but was also 
observed in the embryonic kidneys, glandular stomach, intestine, spleen, and yolk sac 
vasculature (Figure 6-1E and Supplemental Figure 6-S1D). 
In adult mice Gpr182 was widely expressed throughout the body.  Cardiac 
expression was localized to the endocardium of the atria and ventricles, as well as in the 
heart valves and coronary arteries (Figure 6-1F and Supplemental Figure 6-S1E).  Notably, 
little to no staining was observed in cardiomyocytes, fibroblasts, epicardium, or capillary 
endothelium.  Lungs express high levels of Gpr182 primarily in endothelial cells (Figure 6-
1G and Supplemental Figure 6-S1F).  Though Gpr182 was expressed in renal tubules 
during late gestation (Supplemental Figure 6-S1D), adult renal localization was primarily 
enriched in the glomeruli, where it appears strikingly specific to podocytes (Figure 6-1H and 
Supplemental Figure 6-S1G).  The sinusoidal endothelial cells, rather than hepatocytes, 
were the primary cell type expressing Gpr182 in the liver (Figure 6-1I).  Gpr182 was 
expressed throughout the glandular stomach, including both the fundus and antrum (Figure 
6-1J and Supplemental Figure 6-S1H).  Interestingly, this Gpr182 localization was detected 
in gastric epithelial cells primarily near the base of the glands in both fundus and antrum, 
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although a few Gpr182+ cells are observed higher up the gland in the fundus.  Staining was 
not detected in acid-secreting parietal cells (Figure 6-1J).  Gpr182 X-gal staining was also 
robust in spermatocytes of the adult testis (Supplemental Figure 6-S1I).  Spleen and lymph 
nodes reveal endothelial Gpr182 localization, with little to no detectable staining in mature or 
developing hematopoietic and lymphoid lineages (Supplemental Figure 6-S1J-K).  Also, we 
observed little to no X-gal staining in skeletal muscle, pancreas, brain, spinal cord, or dorsal 
root ganglia of adult mice (Supplemental Figure 6-S1L-O).  This murine Gpr182 expression 
pattern during development and adulthood extends previous microarray data,381, 383 
suggesting that Gpr182 is widely expressed and furthermore demonstrates that it is primarily 
enriched in endothelial cells of most, but not all tissues.  
 
Gpr182 is expressed throughout the intestine and is enriched in small intestinal stem cells 
Notably, although Gpr182 is primarily in endothelial cells of most tissues, the 
gastrointestinal tract expression pattern appears to be restricted to the epithelium.  Whole 
mount X-gal staining and histology revealed the most intense staining in the crypt epithelial 
cells in the small intestine and colon, with a few positively stained cells in the villi of the small 
intestine, but relatively absent in enterocytes (Figure 6-2A-C).  -gal staining was higher in 
the stem cell zone at the base of crypts than in the transit-amplifying cells residing higher up 
the crypt-villus axis (Figure 6-2D, 6-2E). More specifically, -gal stained thin cells with 
elongated nuclei that are intercalated between lysozyme+ Paneth cells (Figure 6-2E), 
closely resembling the pattern of other markers of the active CBC ISCs.390-393 
To further verify Gpr182 enrichment in CBC ISCs, both Lgr5-EGFP and Sox9-EGFP 
BAC transgenic mice were used to isolate different intestinal epithelial cell populations using 
distinct levels of EGFP, as previously described.389, 390, 396, 402-404  Gpr182 transcript is 
enriched in the CBC ISC population (Sox9-EGFPLow) when compared to populations 
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containing transit-amplifying cells (Sox9-EGFPSublow) and mixed enterocyte, goblet cell 
fractions (Sox9-EGFPNegative) (Figure 6-2F).  Gpr182 is expressed at very low levels in 
isolated Paneth cell fractions. Gpr182 was highly enriched in the Sox9-EGFPHigh cell 
population, which is a mixed population of enteroendocrine cells, tuft cells, and activatable 
reserve ISCs,389, 403, 404 consistent with the observation of rare -gal+ cells with morphologic 
similarities to enteroendocrine and tuft cells in the villus region (Figure 6-2B-C).  Gpr182 
transcript was significantly enriched in Lgr5-EGFPHigh CBC ISC population compared to 
differentiated Lgr5-EGFPNegative population (Figure 6-2G).  Together, these data suggest that 
Gpr182 is not a selective CBC marker, but is enriched in CBC ISCs at the crypt base, as 
well as in Sox9-EGFPHigh population that contains activatable reserve ISCs. 
 
Gpr182 reduction does not alter intestinal proliferation during homeostasis 
Gpr182lacZ/lacZ animals have a significant ~85% reduction in endogenous Gpr182 
expression in jejunum compared to Gpr182+/+ mice (Figure 6-3A).  These Gpr182 
knockdown mice are viable and born at expected Mendelian ratios, exhibit normal fertility, 
and live to adulthood with no overt phenotypic abnormalities.  Similarly, when crossed to the 
ubiquitously expressed CMV-Cre mouse, Gpr182/; CMV-Cre+ mice had negligible Gpr182 
expression in the jejunum compared to Cre+ controls (Supplemental Figure 6-S2A).  The 
Gpr182/+; CMV-Cre+ and Gpr182/; CMV-Cre+ mice had similar X-gal gastrointestinal 
expression pattern as Gpr182lacZ/lacZ animals (Supplemental Figure 6-S2B-C).   
To evaluate the potential roles of Gpr182 in ISCs, we first characterized the basal 
homeostatic rate of intestinal proliferation in Gpr182lacZ/lacZ mice and consistent with the 
highly-regulated nature of the ISC niche, we found no significant effects of Gpr182 reduction 
on homeostatic intestinal proliferation.  For example, small intestine and colon lengths were 
unchanged in the Gpr182lacZ/lacZ animals compared to controls (Figure 6-3B, 6-3C).  
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Intestinal crypt density, as a proxy for crypt fission, was unaltered between the genotypes 
(Figure 6-3D).  Crypt depth was also unchanged (Figure 6-3E), consistent with no significant 
differences in basal proliferation, as evidenced by similar numbers of EdU+ cells per crypt, 
across the genotypes in both the small intestine and the colon (Figure 6-3F, 6-3G).  
Likewise, there was no difference in the number of phospho-Histone H3+ cells per crypt in 
the small intestine (Gpr182+/+: 1.26 +/- 0.13 cells/crypt and Gpr182lacZ/lacZ: 1.33 +/- 0.10 
cells/crypt, N = 5).  The -Gal+ cells were primarily located in lowest four cell positions of the 
crypt and there were no significant changes in the position of proliferating transit-amplifying 
zone cells between the genotypes (Figure 3H).  Additionally, whole jejunum expression of 
mitotic Cyclin D1, or stem cell markers Lgr5 or Olfm4 were unchanged in Gpr182/; CMV-
Cre+ mice compared to Gpr182+/+; CMV-Cre+ controls (Supplemental Figure 6-S2D).  
Differentiation also appeared unaltered with all secretory lineages detectable and no relative 
changes in Hes1, CgA, or Lysozyme expression (Supplemental Figure 6-S2D and data not 
shown).    Collectively, these data demonstrate that genetic reduction of Gpr182 does not 
lead to altered intestinal proliferation or growth, which is consistent with the highly-regulated 
control of intestinal proliferation during homeostasis.   
 
Mice with Gpr182 knockdown exhibit intestinal hyperproliferation during intestinal 
regeneration following irradiation injury 
To test whether Gpr182 may be involved with regulating proliferation during intestinal 
regeneration following damage, Gpr182+/+ and Gpr182lacZ/lacZ were exposed to a high dose 
(14 Gy) of ionizing radiation delivered to the abdomen. It is well established that intestinal 
irradiation (IRR) causes apoptosis of actively dividing cells leading to the temporary loss of 
proliferative crypts and villi, with subsequent surviving ISCs expanding and regenerating the 
damaged intestinal epithelium, with peak proliferation occurring five days post-irradiation.389, 
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404, 407, 408   Both Gpr182+/+ and Gpr182lacZ/lacZ IRR animals lost approximately 20% of their 
initial body weight five days post-IRR compared to non-IRR controls (Figure 6-4A).  
Interestingly, the small intestine and colon were significantly longer in the IRR Gpr182lacZ/lacZ 
mice compared to controls (Figure 6-4B-C).  While X-gal stained crypts throughout the small 
intestine in non-IRR Gpr182lacZ/lacZ mice (Figure 6-4D and Supplemental Figure 6-S2B), but 
the vast majority of regenerative crypts in the Gpr182lacZ/lacZ IRR mice were X-gal negative 
(Figure 6-4D).  Gpr182 mRNA expression in whole jejunum decreased at this phase of 
regeneration in the Gpr182+/+ mice compared to non-IRR controls (Figure 6-4E).  Expression 
of the CBC ISC marker Lgr5 was unchanged between genotypes, but decreased at this 
phase of regeneration (Figure 6-4F).   
 During regeneration, the Gpr182lacZ/lacZ IRR small intestines had significant increased 
crypt depth compared to IRR controls (Figure 6-4G).  There were also significantly more 
EdU+ cells per crypt in the regenerating duodenum and jejunum of the IRR Gpr182lacZ/lacZ 
mice compared to IRR Gpr182+/+ controls, with comparable, but not statistically significant, 
trends in the ileum and colon (Figure 6-4H-I).  The increased percentage of EdU+ cells were 
located in the bottom third of the regenerating crypt (Figure 6-4J).  The number of phospho-
Histone H3+ cells per crypt was also significantly increased in the irradiated Gpr182lacZ/lacZ 
duodenum (Gpr182+/+: 2.51 +/- 0.39 cells/crypt and Gpr182lacZ/lacZ: 3.74 +/- 0.18 cells/crypt, N 
= 4-5; *p<0.05).  Together, these data indicate a role for Gpr182 in regulating proliferation 
during intestinal epithelial regeneration. 
 
Mice with reduced Gpr182 carrying ApcMin/+ allele exhibit increased intestinal adenoma 
burden and decreased survival 
Since Gpr182 acts to inhibit proliferation during regeneration, we reasoned that 
Gpr182 levels may also be important in deregulated proliferation during disease, such as 
intestinal adenoma and carcinoma.  Gpr182lacZ/lacZ adults up to two years of age did not 
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develop spontaneous intestinal adenomas (data not shown).  Thus, to investigate whether 
Gpr182 is involved in intestinal adenoma initiation and progression, Gpr182lacZ/lacZ mice were 
crossed with the well-characterized ApcMin mouse model, which develops spontaneous 
intestinal and colon adenomas due to aberrant activation of the Wnt/β-catenin signaling 
pathway.409, 410  Both male and female five-month-old Gpr182lacZ/+; ApcMin/+ and 
Gpr182lacZ/lacZ; ApcMin/+ mice were characterized for adenoma formation and compared to 
Gpr182+/+; ApcMin/+ controls.  The majority of Gpr182+/+; ApcMin/+ (44/47) and Gpr182lacZ/+; 
ApcMin/+ (30/32) animals survived the five month experimental period (Figure 6-5A).  
However, significantly fewer Gpr182lacZ/lacZ; ApcMin/+ (29/45) mice survived to five months, 
indicating that genetic reduction of Gpr182 exacerbates the lethality of C57BL/6-ApcMin/+ 
mice.  Furthermore, both Gpr182lacZ/lacZ; ApcMin/+ male and female mice had significantly 
lower body weights at five months compared to gender-matched controls (Figure 6-5B).  The 
spleens weighed significantly more in both Gpr182lacZ/+ and Gpr182lacZ/lacZ animals when 
compared to controls (Figure 6-5C). The small intestines were also significantly longer in the 
Gpr182lacZ/lacZ; ApcMin/+ animals compared to controls (Figure 6-5D), which is similar to the 
irradiation response (Figure 6-4C). Together these data suggest that attenuated Gpr182 
expression is detrimental to the health and survival of ApcMin/+ animals. 
For both sexes, macroscopic polyp number and sizes throughout the intestine were 
three- to four-fold higher in Gpr182lacZ/lacZ; ApcMin/+ mice compared to Gpr182+/+; ApcMin/+ 
controls (Figure 6-5E-F).  Moreover, the haploinsufficient Gpr182lacZ/+; ApcMin/+ mice also 
showed significantly more polyps in the small intestine compared to Gpr182+/+; ApcMin/+ 
controls, further supporting a genetic dose-dependent inverse correlation between Gpr182 
levels and polyp formation.  Although the relative size distribution of polyps was unchanged 
between genotypes, we found a statistically significant increase in the number of polyps of 
all sizes in Gpr182lacZ/lacZ; ApcMin/+ mice compared to Gpr182+/+; ApcMin/+ controls (Figure 6-
5G).   
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The ApcMin/+ model exhibits fewer and more sporadic polyps in the colon after five 
months.  Consistently, colon polyps occurred in 66% of Gpr182+/+; ApcMin/+ assessed, while 
the incidence of colon polyps was 84% in Gpr182lacZ/lacZ; ApcMin/+ mice.  Moreover, there was 
a two-fold increase in the number of colon polyps in the Gpr182lacZ/lacZ; ApcMin/+ animals 
compared to Gpr182+/+; ApcMin/+ controls (2.0 +/- 0.3 versus 1.0 +/- 0.2 polyps, respectively; 
*p<0.05).  Together, these data indicate that decreased Gpr182 expression is sufficient to 
exacerbate the ApcMin/+ adenoma formation and burden throughout the intestine, further 
supporting that Gpr182 has a role in negatively regulating intestinal proliferation.   
 
Mosaic Gpr182 expression within adenomas correlates with proliferative heterogeneity 
While adenoma formation was increased in Gpr182lacZlacZ; ApcMin/+ animals, no 
morphological differences were observed in Gpr182lacZ/lacZ polyps compared to Gpr182+/+ 
polyps (Figure 6-6A).  Furthermore, there were no qualitative or quantitative differences in 
overall proliferation within individual polyps between the Gpr182+/+ and Gpr182lacZ/lacZ 
animals (Figure 6-6B-C), although the polyp proliferation in the Gpr182lacZlacZ; ApcMin/+ mice 
appeared more heterogeneous.  Overall Gpr182 expression was unchanged in ApcMin/+ 
polyps compared to normal wild-type jejunum (Figure 6-6D).  Macroscopic and histologic 
analysis of Gpr182-associated X-gal and -gal antibody revealed a mosaic staining pattern 
between polyps and within individual polyps (Figure 6-6E-H).  Abundant X-gal stain was 
consistently observed in microadenomas (Figure 6-6G).  Interestingly, within individual 
polyps Ki67-labeled proliferation consistently appeared inversely correlated with Gpr182 -
galstaining (Figure 6-6H).  From this data, we conclude that areas with high Gpr182 
reporter/promoter activity exhibit lower proliferation than areas with low Gpr182 
reporter/promoter activity, further supporting a function of Gpr182 in inhibiting proliferation. 
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Decreased Gpr182 leads to aberrant Erk1/2 activation during homeostasis, regeneration, 
and adenoma 
Class A GPCRs commonly activate or inhibit the MAPK signaling cascade, which 
has numerous downstream effects on cell proliferation and survival.  Although the signal 
transduction pathways of the orphan Gpr182 have yet to be characterized, we found 
significantly increased phosphorylated Erk1/2 (Thr202/Tyr204) in Gpr182lacZ/lacZ   jejunum 
compared to Gpr182+/+ controls, which was consistently observed in Gpr182lacZ/lacZ  jejunums 
during homeostasis, regeneration, and in ApcMin/+ polyps (Figure 6-7A).  Therefore, 
decreased Gpr182 leads to increased Erk1/2 signaling, which is consistent with increased 
proliferation during regeneration and increased polyp formation observed in the 
Gpr182lacZ/lacZ mice (Figure 6-7B).   
 
GPR182 expression is reduced in numerous human carcinomas, including colon 
adenocarcinomas 
Considering the proliferative phenotypes observed in the Gpr182 knockdown mice, 
we sought to determine whether GPR182 expression levels are changed in human 
carcinomas.  First, we found that GPR182 expression is low in numerous human colorectal 
carcinoma cell lines, including CaCo2, HT29, Colo205, and SW480 (Figure 6-8A).  
Secondly, RNA Sequencing data from The Cancer Genome Atlas (TCGA)405, 406 confirmed 
that GPR182 expression is significantly lower in colon adenocarcinoma when compared to 
patient-matched normal colon tissue (Figure 6-8B, top panel) and non-matched samples 
(normal colon: 0.86 ± 0.17, N = 41; colon adenocarcinoma: 0.24 ± 0.04, N = 285; 
***p<0.0001 Mann Whitney T-test).  GPR182 expression is also significantly downregulated 
in numerous carcinomas in tissues other than the colon, including breast, kidney, liver, lung, 
pancreas, and thyroid carcinomas (Figure 6-8B).  These data further support that low 
GPR182 expression in mice and humans is inversely correlated with high proliferation.   
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Discussion 
Deorphanization of GPCRs remains an active area of research, especially 
considering that approximately 40% all approved drugs for humans target only a small 
fraction of the GPCRome.272, 411  In addition to elucidating the pharmacology of orphan 
GPCRs, it is crucial to characterize the anatomical locations and physiological functions of 
these receptors in vivo.  To this end, we generated and employed a genetic Gpr182-lacZ 
knock-in mouse model to gain insights into the expression pattern and physiological 
functions of Gpr182.  The intestinal expression pattern – particularly the crypt localization – 
piqued our interest and became the focus of this study.  However, it is worth emphasizing 
that Gpr182 expression is enriched in an interesting variety of tissues and cell types, which 
will certainly entice additional physiological studies.   Furthermore, these types of 
physiological in vivo studies may prove instructive towards the eventual “deorphanziation”, 
or identification of endogenous ligand(s), of Gpr182, which currently remains unknown.  
Our study shows that Gpr182 is robustly expressed in the epithelium throughout the 
gastrointestinal tract and is particularly enriched in the CBC ISCs of the small intestine, yet 
genetic reduction of Gpr182 did not alter intestinal morphology or proliferation during 
homeostasis.  The lack of a basal phenotype in intestinal tissue is not surprising, 
considering the tightly regulated control of epithelial proliferation for maintaining intestinal 
health.  However, under conditions of stress-induced proliferation, such as regeneration 
following injury or ApcMin mutation, the reduction of Gpr182 caused increased proliferation 
likely due, in part, to enhanced Erk1/2 signaling.  These results indicate that Gpr182 is 
normally functioning to inhibit MAPK-induced intestinal proliferation.  This conclusion is 
further supported by our findings of low GPR182 expression in human colorectal carcinoma 
cell lines and several human carcinomas, including colon adenocarcinomas—a novel finding 
which significantly expands the growing cadre of negative regulators of proliferation recently 
shown to be downregulated during colorectal tumorigenesis.391, 412-415    
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MAPK-signaling can play many critical roles during tumorigenesis.  For example, 
Erk1/2 activation through surface receptors, such as TLR and/or Egfr is required for 
adenoma formation in ApcMin/+ mice, which can be blocked by Mek/Erk inhibitors.416, 417  In 
addition, loss of the receptor tyrosine kinase negative regulator Lrig1 leads to constitutively 
active Egfr and other ErbB receptors leading to increased Erk1/2 signaling, 
hyperproliferation, and tumorigenesis.391, 418  Most commonly, oncogenic mutations in Kras 
activates numerous downstream kinases, including Erk1/2, which rarely initiate 
tumorigenesis alone, but when combined with Apc inactivation, lead to increased adenoma 
formation and progression.414, 419-423  Finally, an activating mutation in Gs (GNAS R201C) 
leads to increased cAMP and Erk1/2 activation, which also increased adenoma formation 
when crossed to the ApcMin/+ mice.424  Interestingly, the number of polyps and relative Erk1/2 
activation in these GNAS R201C; ApcMin/+ mice mirror the increase we observed in 
Gpr182lacZ/lacZ; ApcMin/+ mice, further supporting the mechanistic involvement of cAMP and 
Erk1/2 signaling pathways downstream of Gpr182. 
To our knowledge, this is the first study to use a genetic mouse model to 
simultaneously map Gpr182 expression patterns and elucidate novel physiological functions 
and signaling that negatively regulate intestinal proliferation during regeneration and 
adenoma formation.  Future studies to identify the ligand for this exciting and 
physiologically-relevant orphan GPCR will shed light on its tractability as a potential 
therapeutic target. 
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Figures 
 
Figure 6-1:  Murine Gpr182 expression profile during development and adulthood.  (A) 
The targeting vector of the Gpr182tm2a(KOMP)Wtsi/+ (knockout first/promoter driven) lacZ reporter 
mouse model.399-401  (B) Whole mount X-gal staining of e8.0 Gpr182lacZ/lacZ embryo.  DA, 
dorsal aorta; VV, vitteline vein.  (C) Optical projection tomography (OPT) of whole mount X-
gal stained wild-type and Gpr182lacZ/lacZ e13.5 embryos.  X-gal staining in Gpr182lacZ/lacZ e13.5 
heart (D) and e17.5 (E) lung, kidney, liver, yolk sac, and stomach, pancreas, and 
duodenum.  Representative Gpr182 lacZ expression in adult heart (F), lung (G), kidney (H), 
liver (I), and glandular stomach (J) stained with X-gal and/or -gal (green).  Sections were 
costained with DAPI (purple) and either the endothelial marker CD31 (F) or the podocyte 
marker, Pdpn (H).  X-gal stained sections were counterstained with eosin (F-H) or Neutral 
Red (D, I-J).  Scale bars represent 200 m (B, D), 1 mm (C, E), and 100 m (F-J).  
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Figure 6-2:  Gpr182 is enriched in CBC intestinal stem cells.  (A) Optical projection 
tomography of X-gal stained optically cleared duodenum from Gpr182+/+ and Gpr182lacZ/lacZ 
adult mice.  (B) Representative whole mount X-gal stained small intestine and colon of adult 
Gpr182lacZ/lacZ mice. (C) Cross-sectional X-gal from adult Gpr182lacZ/lacZ small intestine and 
(D) -gal (green) IHC from adult Gpr182+/+ and Gpr182lacZ/lacZ intestine.  (E) Crypt of 
Gpr182lacZ/lacZ jejunum costained with -gal (green), the Paneth cell marker lysozyme 
(magenta), and DAPI (blue).  Yellow asterisks mark CBC ISCs as defined by morphologic 
position, elongated nuclei, and lysozyme negative.  Scale bars represent 500 m (A-B) and 
100 m in low magnification (C) and 10 m in crypt images (C-E).  Relative Gpr182 
expression in isolated cell populations from the (F) Sox9-EGFP BAC transgenic mouse or 
(G) Lgr5-EGFP mouse.  Enterocytes/goblet cells (Sox9-EGFPNegative); transit-amplifying cells 
(Sox9-EGFPSublow); CBC ISC (Lgr5-EGFPHigh and Sox9-EGFPLow); enteroendocrine/tuft/+4 
ISC (Sox9-EGFPHigh); Paneth cells (Sox9-EGFPNegative:CD24High:SSCHigh); early 
progenitors/+4 ISC (Lgr5-EGFPLow); and differentiated cells (Lgr5-EGFPNegative).  Expression 
was normalized to Sox9-EGFPNegative or Lgr5-EGFPNegative and -actin or Rn18S. Biological N 
= 2-5 (F).  Significance was determined by 1-way ANOVA with Tukey’s Multiple Comparison 
Test. 
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Figure 6-3:  Gpr182 knockdown does not alter basal proliferation.  (A) RT-PCR analysis 
of Gpr182 expression in adult jejunum from Gpr182+/+, Gpr182lacZ/+, and Gpr182lacZ/lacZ mice.  
Expression was normalized to Gpr182+/+ and Gapdh. (B-C) Small intestine and colon length 
from adult Gpr182+/+ and Gpr182lacZ/lacZ mice.  (D) Morphometric quantification of crypt 
density and (E) histological quantification of crypt depth between Gpr182 genotypes.  (F) 
Representative images and (G) EdU incorporation quantification of intestinal proliferation 
between Gpr182+/+ and Gpr182lacZ/lacZ animals.  (H) Analysis of the cellular position of EdU+ 
cells along the crypt-axis expressed as a percentage of the total number of cells in that 
position in all crypts.  The Gpr182 Zone (green gradient) is the relative cellular position of -
Gal+ cells along crypt-axis.  Biological N = 5 per genotype.  Scale bars represent 100 m. 
Significance was determined either by the 1-way ANOVA with Tukey’s Multiple Comparison 
Test (A) and Student’s (B-E, G) or Mann Whitney T-test of area under curve (AUC) (H). 
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Figure 6-4: Decreased Gpr182 leads to hyperproliferation during the regeneration 
phase after irradiation-induced injury.  Adult Gpr182+/+ (purple) and Gpr182lacZ/lacZ (green) 
mice irradiated (IRR) with a 14 Gy dose radiation to abdomen.  (A) Body weight changes (% 
of pre-IRR weight) of Gpr182+/+ and Gpr182lacZ/lacZ mice for five days following IRR compared 
to non-IRR controls.   (B-C) Small intestine and colon lengths from IRR Gpr182+/+ and 
Gpr182lacZ/lacZ animals.  (D) Whole mount X-gal stained small intestine of non-IRR 
Gpr182lacZ/lacZ and IRR Gpr182lacZ/lacZ animals five days post-IRR. Relative (E) Gpr182 and 
(F) Lgr5 expression in whole jejunum from Gpr182+/+ IRR, Gpr182lacZ/lacZ IRR animals and 
non-IRR controls.  Expression was normalized to non-IRR Gpr182+/+ and Gapdh.  (G) Crypt 
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depths in regenerating intestine from Gpr182+/+ IRR and Gpr182lacZ/lacZ IRR animals.  (H) 
Representative images and (I) EdU quantification of intestinal proliferation between IRR 
Gpr182+/+ and Gpr182lacZ/lacZ animals.  (J) Analysis of the cellular position of EdU+ cells along 
the crypt axis expressed as a percentage of the total number of cells in that position in all 
regenerating crypts.  Biological N = 4-5.  Scale bars represent 5 mm (D) or 100 m (H).  
Significance was determined by Student’s T-test (B-C, G, I), one-way ANOVA with Tukey’s 
Multiple Comparison Test (E-F), or Mann Whitney T-test of AUC (J). 
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Figure 6-5:  Reduced Gpr182 increased lethality and polyp number in ApcMin/+ mice. 
(A) Kaplan-Meier survival curve comparing Gpr182lacZ/lacZ Apc+/+ (black), Gpr182+/+; ApcMin/+ 
(yellow), Gpr182lacZ/+; ApcMin/+ (blue), and Gpr182lacZ/lacZ; ApcMin/+ (red) animals.  (B) Body 
weights of five month old female and male ApcMin mice from different Gpr182 genotypes. (C) 
Spleen weight normalized to body weight from Gpr182+/+; ApcMin/+, Gpr182lacZ/+; ApcMin/+, and 
Gpr182lacZ/lacZ; ApcMin/+ mice.  (D) Small intestine length from Gpr182lacZ/lacZ; ApcMin/+ animals 
compared to controls.  (E) Representative images of adenoma number and size from 
Gpr182+/+; ApcMin/+ and Gpr182lacZ/lacZ; ApcMin/+ intestines.  Scale bar represents 5 mm.  (F) 
Quantification of polyp number throughout the small intestine of Gpr182+/+; ApcMin/+, 
Gpr182lacZ/+; ApcMin/+, and Gpr182lacZ/lacZ; ApcMin/+ mice.  (G) The distribution of the number of 
polyps throughout the small intestine based on approximate polyp size.  All significant trends 
were observed in both males and females.  Biological N = 25-50 per genotype (A), N = 10-
20 per genotype per gender (B), N = 20-35 per genotype (C-D, F-G).  Significance was 
determined either by the Mantel-Cox Test (A) or 1-way ANOVA Kruskal-Wallis Test and 
Dunn’s Multiple Comparison Test (B-G). 
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Figure 6-6:  Mosaic Gpr182 staining within polyps corresponded to polyp proliferation 
heterogeneity. (A) Histology from five month old from Gpr182+/+; ApcMin/+ and Gpr182lacZ/lacZ; 
ApcMin/+ jejunum polyps labeled with H&E and -catenin (white).  (B-C) Polyp proliferation 
assessed by Ki67 (blue) staining normalized to DAPI (purple) in Gpr182+/+; ApcMin/+ and 
Gpr182lacZ/lacZ; ApcMin/+ mice.  (D) Gpr182 expression in polyps from jejunum of Gpr182+/+; 
ApcMin/+ and Gpr182lacZ/lacZ; ApcMin/+ mice compared to Apc+/+ jejunum.  Expression was 
normalized to Gpr182+/+ and Rn18S.  Macroscopic (E) and histologic (F-G) X-gal staining of 
Gpr182lacZ/+; ApcMin/+ polyps.  (H) Serial sections stained with -Gal (green), Ki67 (blue), and 
DAPI (magenta) in Gpr182lacZ/lacZ polyps. Biological N = 15-60 polyps from 5 mice per 
genotype (C) and N = 4-5 (D) Scale bars represent 100 m (A-B, F-H) and 1 mm (E).  
Significance was determined either by the Mann-Whitney T-test (C) or 1-way ANOVA with 
Tukey’s Multiple Comparison Test (D). 
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Figure 6-7: Gpr182 knockdown leads to elevated Erk1/2 signaling upstream of the 
hyperproliferative intestinal crypt microenvironment.  (A)  Representative immunoblots 
and quantification of relative phosphorylated Erk1/2 between Gpr182+/+ and Gpr182lacZ/lacZ    
from unchallenged, 5 day post-irradiation, and ApcMin/+ polyps from whole jejunum.  Samples 
were normalized to total Erk1/2 and Gpr182+/+.  N = 4-7 per genotype per condition. 
Significance was determined by unpaired T-test.  (B) Model summarizing Gpr182 -Gal 
expression pattern (blue) in the whole mouse (heart, lungs, liver, stomach, small intestine, 
colon, kidney, and testis) with more specific expressional detail within the small intestine, as 
well as Gpr182 function to inhibit intestinal Erk1/2 signaling and proliferation. 
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Figure 6-8:  Low GPR182 expression in human carcinomas.  (A) RT-PCR of GPR182 
expression in human cell lines, including colorectal carcinoma cell lines, intestinal epithelial 
cell (hIEC), and venous endothelial cells (HUVEC).  Expression was normalized to hIEC and 
GAPDH.  (B) Relative GPR182 expression from TCGA achived RNA-seq in patient-matched 
normal (N) and tumor (T) tissue. Breast invasive carcinoma (BRCA), N = 98; colon 
adenocarcinoma (COAD), N = 26; kidney chromophobe (KICH), N = 25;  kidney renal clear 
cell carcinoma (KIRC), N = 71; kidney renal papillary cell carcinoma (KIRP), N = 32; liver 
hepatocellular carcinoma (LIHC), N = 50; lung adenocarcinoma (LUAD), N = 57; lung 
squamous cell carcinoma (LUSC), N = 50; pancreatic adenocarcinoma (PAAD), N = 58; 
rectum adenocarcinoma (READ), N = 6, stomach adenocarcinoma (STAD), N = 32; thyroid 
carcinoma (THCA), N = 57.  Significance was determined by the Wilcoxon matched pairs T-
test. 
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Supplemental Table 
Allele 
Forward Primer 
(5’ – 3’) 
Reverse Primer 
(5’ – 3’) 
Taqman Probe 
Gpr182 Wild-type 
CTGCAGCCTCC
TGGCACTAACA
GC 
CATTGTCCGGT
TCCAAGGTGGA
GAC 
 
Gpr182tm2a(KOMP)Wtsi 
Targeted 
GAGATGGCGCA
ACGCAATTAAT 
GGGAGGATACC
ACAGGGAAATA
GAGC 
 
Gpr182 lacZ 
Targeted 
TTCACTGGCCG
TCGTTTTACAAC
GT 
ATGTGAGCGAG
TAACAACCCGT
CGGATTCT 
 
Apc Wild-type 
GCCATCCCTTC
ACGTTAG 
TTCCACTTTGG
CATAAGGC  
Apc Min Allele 
TTCTGAGAAAG
ACAGAAGTTA 
TTCCACTTTGG
CATAAGGC 
 
mouse Gpr182 
(Admr) 
  
Mm01946034_s1 
(Applied Biosystems) 
mouse Lgr5   
Mm00438890_m1 
(Thermo Scientific) 
mouse Olfm4   
Mm01320260_m1 
(Thermo Scientific) 
mouse Cyclin D1   
Mm00432359_m1 
(Thermo Scientfic) 
mouse Hes1   
Mm01342805_m1 
(Thermo Scientific) 
mouse CgA   
Mm01209400_m1 
(Thermo Scientific) 
mouse Lysozyme   
Mm00657323_m1 
(Thermo Scientific) 
human GPR182    
Hm01922099_s1 
(Applied Biosystems) 
mouse Rn18s   
Mm03928990_g1 
(Applied Biosystems) 
human GAPDH   
4310884E (Thermo 
Fisher Scientific) 
mouse -actin   
Mm02619580_g1 
(Thermo Scientific) 
mouse Gapdh   
Mm99999915_g1 
(Applied Biosystems) 
 
Supplemental Table 6-S1:  RT-PCR and Genotyping Primers and Probes 
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Supplemental Figures 
 
 
Supplemental Figure 6-S1:  Additional murine Gpr182 expression during development 
and adulthood.  Representative whole mount X-gal staining of Gpr182lacz/lacZ tissue during 
development (A-D) and adulthood (E-O).  X-gal staining (A) of an e8.0 embryo, (B) OPT, 
and (C) microdissected of an e13.5 embryo.  (D) Gpr182 lacZ in heart, lung, liver, kidney, 
stomach, and small intestine of an e17.5 embryo. Representative images of X-gal staining in 
adult heart (E), lung OPT (F), kidney (G), stomach (H), testis (I), spleen (J), mesenteric 
lymph node (K), hindlimb skeletal muscle (L), pancreas (M), brain (N), and spinal cord (O).  
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(E) LV, left ventricle; RA, right atria; V, cardiac valve; A, aorta; (H) E, esophagus; Fo, 
forestomach; F, fundus; An, antrum; (O) DRG, dorsal root ganglia.  X-gal sections were 
counterstained with Neutral Red (D, I-K, M).  Scale bars represent 200 µm (A,D,I-K,M) or 1 
mm (B,C,E-H,L,N,O). 
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Supplemental Figure 6-S2:  Gpr182 knockout does not alter X-gal expression pattern 
or cell markers.  (A) RT-PCR analysis of Gpr182 expression in whole jejunum from 
ubiquitously expressed CMV-Cre+ Gpr182+/+, Gpr182/+, Gpr182/, and CMV-Cre negative 
Gpr182lacZ/lacZ adult mice.  (B) Representative whole mount X-gal stained small intestine and 
colon of adult Gpr182/+; CMV-Cre+ mice.  (C) Representative cross-sections from whole 
mount X-gal stained stomach, small intestine, and colon from Gpr182+/+, Gpr182/+, 
Gpr182/ animals. (D) Expression of cyclin D1, Lgr5, Olfm4, Hes1, CgA, lysozyme in whole 
jejunum from Gpr182+/+; CMV-Cre+ and Gpr182/; CMV-Cre+ mice.  Expression was 
normalized to Gpr182+/+; CMV-Cre+ and Rn18S or Gapdh.  Biological N = 3-5.  Significance 
was determined by 1-way ANOVA with Tukey’s Multiple Comparison Test (A) or Student’s 
T-test (D). 
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Chapter VII:  Conclusions and Future Directions 
 
Summary  
Part II of this dissertation focused on the orphan GPCR, Gpr182, of which almost 
nothing has been published.  Chapter V summarized Gpr182 in a historical context and how 
Gpr182 was initially identified as an adrenomedullin receptor, then orphanized, and largely 
forgotten for over a decade.  Chapter VI describes a novel role of Gpr182 in regulating adult 
intestinal proliferation during regeneration and adenoma formation.  Gpr182 is enriched in 
intestinal stem cells, which are one of the most proliferative cell populations during 
adulthood and have been directly implicated in nearly every gastrointestinal disease.  
Considering relatively nothing is known regarding the pharmacology and functions of 
Gpr182, this initial study will help lay the groundwork to understand this GPCR during 
development, homeostasis, and disease.  Chapter VII will further highlight Gpr182 in the 
broader context of gastrointestinal physiology and disease and provide numerous future 
directions to better understand the potential of Gpr182 as a therapeutic target.   
 
Current State of the Field 
Intestinal Stem Cell Identity 
The intestinal stem cell (ISC) field has exploded over the past decade and now ISCs 
are one of the best characterized stem cell populations in the body.  Discoveries have been 
fueled by the identification of numerous ISC-specific markers, genetic techniques to 
manipulate genes specifically within these ISCs, and the development of ex vivo culture 
techniques to further study ISCs functions.385, 386  Understanding the genetic signature and 
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function of ISCs remains a very active area of research.  Since its initial characterization by 
Barker et al. the Lgr5-EGFP-ires-CreERT mouse has remained the predominant model used 
in the vast majority of ISC studies and is almost required to verify novel ISC markers and 
functions.390, 425 Single cell transcriptome analysis has revealed that ISCs are very 
heterogeneous.403, 426 The use of only one ISC marker, such as Lgr5, could skew the field 
towards select ISC subpopulations while excluding other ISC populations.  Single cell 
expressional analysis will hopefully identify additional ISC-specific markers that have been 
missed previously due to the use of heterogeneous cell populations. Additional ISC markers, 
specifically surface markers and targetable receptors, would be instrumental to the field.   
Crypt isolation and fluorescent reporters in mice have allowed for the ex vivo culture 
of whole crypts or single Lgr5-EGFP+425 or Sox9-EGFP+402, 403 ISCs, respectively.  These 
techniques are commonly used to verify in vivo results, but the use of fluorescent proteins to 
isolate ISCs is not amenable for studying human ISCs.  Furthermore, these techniques 
isolate the intestinal epithelium, but exclude the other cell types present in the complex ISC 
microenvironment.  New techniques have emerged that utilize reprogramed human 
pluripotent stem cells into multicellular intestinal organoids, which better model human 
gastrointestinal development and diseases.427-431  Using these organoids to model various 
human gastrointestinal diseases is a new and exciting area of research.  Stomach organoids 
have been used to study the mechanisms of H. pylori infection on the gastric epithelium to 
further understand the pathogenesis of human gastric cancer.427  Furthermore, gene editing 
techniques, like CRISPR/Cas9, are being utilized in mouse intestinal organoids and 
potentially human organoids to study the consequences of common genetic mutations.432 
Identifying and understanding the factors that regulate ISC growth and survival, ex vivo and 
in vivo, is crucial for the translational success of ISCs in humans therapeutics.  
While the ISC niche of the small intestine is well-defined, the stem cell niches of 
other gastrointestinal tissues, such as the esophagus, stomach, and colon, are far less 
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understood.  Few gastric or colonic stem cells-specific markers have been identified.  Lgr5 is 
expressed in select cells at the base of colonic and gastric antral glands.  Lineage trace 
experiments confirmed that these Lgr5+ cells can give rise to the differentiated epithelial 
cells types within these tissues, although it is very heterogeneous.390, 433  Lgr5 is not 
expressed in the fundus region of the stomach.  The fundus is thought to have two distinct 
stem cell populations, one at the base of gland that is fairly quiescent and the other residing 
near the top of the gland that can rapidly proliferate and undergo bidirectional migration in 
order to maintain epithelial barrier function under constant acidic insult.434, 435  Very few stem 
cell markers for this region of the stomach have been identified.  Sox2 is expressed in the 
stem cells zones of both the fundus and antrum and Sox2+ cells are multipotent.436  Mist1 is 
also expressed in gastric stem cells and maintains homeostatic and neoplastic proliferation, 
partly through Cxcr4/SDF1 signaling in the endothelium and innate immune cell-derived 
Wnt5a.437  Additional studies have identified that differentiated pepsinogen-producing chief 
cells in the antrum (Lgr5) or fundus (Troy1, Mist1) can act as reserve stem cells that are 
activated upon damage.433, 438  Notch1 and Notch2 signaling is essential to regulate Lgr5+ 
antral stem cells proliferation, apoptosis, and differentiated.439, 440 The localization of Gpr182-
lacZ within the stomach epithelium is consistent with the predicted stem cell niches of both 
the fundus and antrum, which merits further investigation into the functional roles of Gpr182 
in the stomach. 
 
Intestinal Damage and Regeneration  
Understanding different ISCs populations and their roles following intestinal damage 
remains an intense area of research.  While the CBC ISCs are the primary stem cells 
responsible for the homeostatic turnover of the intestine, there are reserve/activatable ISCs 
that are required when CBC stem cells are loss due to intestinal damage caused by 
irradiation, infection, or toxins.  Numerous cell types at different stages of differentiation can 
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dedifferentiate into regenerative proliferative ISCs following intestinal damage.  More 
specifically, it has been demonstrated both by lineage trace experiments and organoid 
formation that label retaining cells, Dll1+ secretory progenitors, Sox9-EGFPHigh cells, Dclk1+ 
tuft cells, or Alpi+ enterocytes can all dedifferentiate to repopulate the intestine upon 
epithelial damage.389, 404, 407, 441-445  It is interesting that Gpr182 is primarily enriched in CBC 
ISCs, yet the proliferation phenotype is primarily observed during intestinal regeneration 
(Figure 6-4), which suggests that it may be expressed in both CBC and activatable ISC 
populations, similar to Lrig1.391, 418  There is significant interconversion between these two 
ISC populations, which is regulated partly by Notch signaling.403, 404, 418, 446  The number of 
surviving Lgr5+ ISCs following damage is also important for regeneration and survival, with 
either 15 Gy IRR or diphtheria toxin Lgr5 ablation leading to the complete loss of Lgr5+ ISCs 
and the failure of the epithelium to regenerate.408, 447  The 14 Gy dose of IRR used on 
Gpr182lacZ/lacZ mice depleted the vast majority of CBC ISCs (Figure 6-4D).  This also 
supports the hypothesis that Gpr182 downregulation or loss leads to a more proliferative 
microenvironment, which is essential during regeneration.  Gpr182 may be involved in 
returning the intestinal proliferation back to homeostasis following damage, a process of 
which not much is known.   
While it is clear that the Wnt signaling pathway is the main driving force of intestinal 
proliferation during homeostasis, there is significant interest to understand other pathways 
that regulate ISC proliferation during regeneration.  Mice with ablated Sox9 expression have 
a blunted regenerative response and succumb to epithelial damage-induced lethality.404  
High fat diet regulates ISC numbers and function basally and following IRR damage, which 
is regulated by IGF signaling.448-451  The Notch pathway is also important in maintaining ISC 
numbers and proliferation.  Pharmacologic inhibition or genetic removal of the Notch 
receptors decreases CBC ISC numbers and proliferation during homeostasis and these 
mice fail to successfully regenerate their epithelium following IRR damage.452, 453  Notch 
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signaling regulates the interconversion between the active Lgr5+ CBC ISCs and the 
activatable Bmi-1+ reserve ISCs.446  The YAP/Hippo pathway is also critical for intestinal 
regeneration.  YAP signaling is able to reprogram CBC ISCs to suppress Wnt signaling in 
order to activate the EGF/EGFR pathway, which is essential for regeneration.454, 455  Gpr182 
plays a role to regulate MAPK signaling that is essential for regenerative proliferation, 
supporting why the primary phenotype observed in the Gpr182lacZ/lacZ animals is during 
regeneration. 
Mucosal-stem cell crosstalk activated by microbiota and/or inflammation has been a 
major area of research for years.  The functional characterization of tuft cells in vivo has 
recently moved to the forefront of the field.   It was recently demonstrated that upon parasitic 
infection of the intestine, the ISCs increase the production of tuft cells, which are required for 
secreting IL-25 in order to mount an effective innate immune response to resolve the 
infection.456, 457  Furthermore, deletion of tuft cell marker Dclk1 impairs epithelial 
regeneration following radiation injury due to a large number of changes to ISCs expression 
signature.442  Innate lymphoid cells produce IL-22 following intestinal injury, which increases 
organoid growth and the regenerative response through the JAK/STAT3 pathway in ISCs.458  
The innate immune system also provides SDF1 leading to enhanced tumor growth.437  While 
the direct effects of Gpr182 on the innate immune system are unknown, it is clear that 
epithelial damage by irradiation or infection activates innate lymphoid cells, which support 
the regenerative response of the epithelium. 
 
Pathogenesis of Intestinal Adenomas and Colorectal Carcinomas  
The majority of research regarding the regulation of ISCs during homeostasis and 
regeneration has direct implications in the pathogenesis of gastrointestinal neoplastic 
diseases.  The majority of studies utilize the spontaneous adenoma ApcMin or Apcflox/flox 
mouse models due to Apc ability to initiate adenoma formation and the high incidence of 
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APC mutations present in human carcinomas.  Adenomas are benign growths usually 
initiated by aberrant Wnt signaling activation.  Adenomas progress to malignant carcinomas 
with additional oncogenic mutations to the MAPK (Kras,Braf), BMP (SMAD4), and/or Akt 
(PTEN, p53) signaling pathways.  Interestingly, these are same signaling pathways used to 
grow and maintain organoids in culture.  There is strong evidence that gastrointestinal 
adenomas are initiated and driven by oncogenic mutations specifically within ISCs, but it 
remains an active area of research to determine if these acquired mutations are in the rapid 
or quiescent ISC populations.391, 395, 398, 459, 460  There is evidence of competition between 
ISCs within individual crypts and ISCs with oncogenic mutations typically have a selective 
growth advantage and are more likely to out compete the normal ISCs.  Adenomas can 
arise from a small number of mutated ISCs, but larger adenomas are typically 
heterogeneous because they consist of mutations in ISCs from adjacent crypts.461462, 463   
Unlike Apc mutations, activating mutations in Kras or loss of PTEN does not initiate 
adenoma formation, but rather cause adenoma growth and progression when combined 
with Apc mutations.419, 464, 465  As discussed in Chapter VI, the MAPK pathway is critical for 
adenoma formation and the Gpr182lacZ/lacZ; ApcMin mice have high Erk1/2 activation and 
increased adenoma formation (Figure 6-5 and 6-7).  Zebrafish KrasG12D mutations 
increased Erk1/2 activation, but did not alter cell proliferation without homozygous loss of 
Apc.421  YAP-/- mice are almost completely protected from Apc-induced adenoma formation, 
primarily through transcriptional downregulation of the EGF/EGFR/ERK signaling 
pathway.416, 454  The PPAR pathway, which is downstream of high fat diet and was shown to 
alter the proliferation of Lgr5+ ISCs, is also involved in the progression of adenomas to 
carcinomas in ApcMin mice.466 
The identification of potential targets to block adenoma formation and colorectal 
carcinoma growth remains an intense area of research.  Gpr182 may be a targetable GPCR 
to inhibit adenoma formation similar to that observed with EGFR and MEK inhibitors.416  
163 
 
Targeting pathways upstream of MAPK signaling, such as GPCRs or YAP signaling, could 
block adenoma formation.467  ApcMin adenomas are responsive to rapamycin-induced 
mTORC inhibition, but only if Kras and Erk1/2 signaling are unchanged.423  Apc loss in 
Dclk1+ cells can initiate adenomas, but only if the intestine is undergoing regeneration 
following damaged.441  Dclk1 is typically not expressed in ISCs, but is specifically 
upregulated in cancer stem cells, so targeting this glycoprotein could be selective towards 
mutated ISCs within adenomas and not normal ISCs.468  Using a doxycycline-inducible Apc 
mouse model, Dow et al. demonstrated that reintroducing Apc expression into mice with 
adenomas could not only prevent the formation of additional adenomas, but could also 
return adenomas back to normal mucosa.420  With the use of elaborate genetic model 
systems, the ISC field continues to expand with added layers of complexity and alternative 
signaling pathways that play a role in regulating the function of ISCs during homeostasis, 
regeneration, and cancer.  
 
Future Directions 
Gpr182 Expressional Regulation and Roles in Cardiovascular Development and Disease 
Gpr182 may be important in the development and maintenance of other stem cell 
niches, such as the hematopoietic stem cells.  Hematopoietic stem cells originate in yolk sac 
as hemangioblasts and move to fetal liver as definitive progenitors. These populations give 
rise to both the primitive and definitive RBCs and the hematopoietic stem cells in fetal liver 
ultimately populate the thymus and bone marrow.469-471  In addition to the hemangioblasts 
from the yolk sac, it was recently demonstrated that hematopoietic stem cells emerge from 
specialized dorsal aortic endothelium, known as hemogenic endothelium, which undergoes 
endothelial to hematopoietic transition.472-474  Our lab and others have observed Gpr182 
localization in the dorsal aorta, vitelline vein, and hemangioblast-like cells in the yolk sac 
during early murine development (Figure 6-1A and Figure 6-S1A).  Additionally, Gpr182 is 
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present in the fetal liver and yolk sac at later stages of embryonic development (Figure 6-
1C, E and Figure 6-S1D),381 as well as in the bone marrow, spleen, and lymph nodes during 
adulthood (Figure 6-S1J-L).  These anatomical locations are consistent with the reported 
locations of the hemogenic endothelium, primitive, and definitive hematopoietic progenitor 
populations during development and adulthood.  Interestingly, Gpr182-lacZ does not appear 
to be expressed in mature hematopoietic, myeloid, or lymphoid lineages (Figure 6-S1J-K).  
Gpr182 expression in the dorsal aorta and hemogenic endothelium was further validated in 
a recent study that identified Gpr182 as one of the highest enriched genes (5/516 altered 
genes) in GFP+ (under the Runx1 +23 enhancer) hemogenic endothelium compared to non-
hemogenic endothelium from e8.5 dorsal aorta endothelium.475  Another group 
overexpressed HRas and/or Notch intracellular domain (NICD) in zebrafish hemogenic 
endothelium in order to create a model of myeloid leukemia.  They also identified Gpr182 as 
1/23 genes to fit the signature of being two-fold enriched by overexpression of Ras and two-
fold decreased by Notch overexpression.384  These studies not only support that Gpr182 is 
enriched in hemogenic endothelium, but also suggest Gpr182 may be involved in 
hematopoietic stem cell development and the pathogenesis of myeloid leukemia.  Further 
hematological workup is needed to confirm this hypothesis and to understand how Gpr182 
affects hematopoietic development and disease. 
The data from Alghisi et al. also suggest that Ras and/or Notch signaling may be 
transcriptional upstream of Gpr182.  There is evidence that Ras can suppress Notch 
signaling,384 so the increased Gpr182 expression with HRas overexpression may be due to 
inhibited Notch signaling and not directly caused by increased HRas.  This regulation 
potentially extends beyond the hemogenic endothelium and Notch signaling appears to be 
inversely correlated with Gpr182 levels in multiple tissues.  For example, Gpr182 expression 
is highly enriched in mammary tumor endothelium compared to normal mammary 
endothelium,201 which could reflect the transcriptional profile of developmental endothelium.  
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It was recently observed that mammary tumor endothelium is heterogeneous and particular 
tumor endothelial cells had decreased Notch1 expression, which potentially supports the 
increased Gpr182 expression.296  It remains unclear if the elevated Gpr182 expression in 
tumor endothelium has distinct roles in tumor angiogenesis, tumor vasculature integrity, 
and/or altered metastatic properties.  Beyond tumors, Notch signaling between the 
endocardium and the myocardium is essential for trabeculae formation and ventricular 
maturation of the heart.280-283  Gpr182 expression was observed in the endocardium at 
similar developmental stages (Figure 6-1D, F and Figure 6-S1D), suggesting that it may be 
involved in or downstream of cardiac trabeculae development.  To further support the 
hypothesis that Notch signaling suppresses Gpr182 expression beyond the endothelium, I 
utilized epithelial RNA (kindly provided by Dr. Linda Samuelson, University of Michigan) from 
mice overexpressing NICD under the Villin, intestinal epithelium-specific, promotor (Figure 
7-1A).  Intestinal epithelial-specific activation of NICD significantly reduced Gpr182 
expression compared to controls (Figure 7-1B), which is similar to that observed with NICD 
overexpression in zebrafish endothelium.384  These data support the notion that Gpr182 
expression is likely downstream of the Notch pathway.  Notch signaling governs the early 
fate decisions of hemogenic endothelium, cardiac development, intestinal epithelium 
differentiation, and is dysregulated in oncogenic diseases; all of which Gpr182 could be 
playing a supporting role and requires further studies. 
In addition to developmental endothelial expression, Gpr182 is highly expressed in 
adult atria and ventricle endocardium, cardiac valves, and the endothelium of major arteries 
(Figure 6-1F, Figure 6-S1B-E).  Additionally, Gpr182 was expressed in podocytes and 
glomerulus of the kidney (Figure 6-1H).  It would be interesting to investigate the effects of 
Gpr182 loss (using CMV-Cre, conditional Cdh5-Cre, or podoplanin-Cre) on basal cardiac 
function, blood pressure, vessel compliance, angiogenesis, and/or renal function.  
Considering the overall survival and wellness of Gpr182 KOs appears unchanged, these 
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mice could be challenged with different cardiovascular disease models, including ischemia 
reperfusion, AngII-induced hypertension, high salt or high fat diets, tumor implantation, or 
inflammation.  While it is evident that Gpr182 is expressed in numerous vascularized organs 
during development and adulthood, relatively nothing is known about the actual function of 
Gpr182 in these tissues.  
 
Verification of Gpr182 Expression Pattern and its Cell Autonomous Roles as a 
Gastrointestinal Stem Cell 
The use of the Gpr182lacZ/+ knock-in mouse could potentially alter Gpr182 
localization, especially considering Gpr182 negatively regulates MAPK signaling (Chapter 
VI).  Therefore, it is possible that the observed X-gal staining profile does not correlate with 
the endogenous Gpr182 expression pattern.  Unfortunately, the vast majority of GPCR 
antibodies are not reliable, including Gpr182, making it difficult to verify endogenous Gpr182 
protein localization.  Without a reliable antibody, endogenous Gpr182 expression could be 
verified using ISH and RT-PCR in Gpr182+/+ mice.  These assays are also needed to 
confirm expression pattern consistent in mice and humans.  It is clear that endogenous 
Gpr182 expression is highest in vascularized tissues, mainly in endothelial cells (Figure 6-1). 
Epithelial expression in gastrointestinal tract is relatively low, which potentially explains why 
Gpr182 is routinely overlooked on whole genome analyses of these tissues.  The use of 
Gpr182-independent mouse lines, such as the Sox9-EGFP and Lgr5-EGFP mice, helped 
confirmed that the ISC expression of Gpr182 was not secondary to Gpr182 reduction 
(Figure 6-2).  Similarly, while only trending Gpr182 expression was enriched in Lgr5-EGFP 
ISCs when compared to Lrig1-EGFP ISCs.391  ISH was previously used to demonstrate 
Gpr182 expression in e8.5 dorsal aorta and yolk sac, which further verified that 
Gpr182lacZ/lacZ expression pattern was not artifact (Figure 6-1A).381  MACS isolation of CD31+ 
lung endothelial cells from wild-type mice supported that Gpr182 was mainly expressed in 
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the lung endothelium (Figure 6-1F and data not shown).  Together these data support that 
the lacZ knock-in does not totally alter endogenous Gpr182 expression pattern, but it does 
not exclude potential differences.  For example, the density of X-gal labelled crypts and 
secretory cells in the distal intestine appeared higher in Gpr182; CMV-Cre+ compared to 
Gpr182/+; CMV-Cre or the Gpr182lacZ/lacZ animals (Figure 6-S2).  Some tissues, such as 
breast, pancreas, brain, and mesentery had detectable Gpr182 expression by RT-PCR, but 
had negligible X-gal staining.  Further characterization of the endogenous expression 
pattern of Gpr182 is needed to fully understand the in vivo functions of Gpr182 and whether 
genetic disruptions cause changes in Gpr182 localization.   
Using both the lacZ reporter and expressional analysis from CBC-enriched 
populations from the Sox9-EGFP and Lgr5-EGFP mice; Gpr182 is enriched in CBC ISCs 
(Figure 6-2).  However, the “gold standard” in the ISC field to verify new stem cells markers 
is to demonstrate that Gpr182+ cells can self-renew and are multipotent,385, 386 which is not 
possible using the Gpr182lacZ/+ animal.  This can be accomplished by generating the 
Gpr182-EGFP-ires-CreERT mouse, which when crossed to the Rosa26-lacZ reporter and 
injected with TAM can be used to lineage trace Gpr182+ daughter cells.  This experiment 
would verify Gpr182 as a ISC marker if all absorptive and secretory cells of the intestinal 
epithelium can be labeled (multipotent) and if the label at the base of the crypt is maintained 
overtime (self-renewal).  While the ISC niche in the small intestine is relatively well 
anatomically defined, the stem cell zones of the gastric and colonic epithelium are far less 
defined.  Therefore, lineage tracing would be required to determine if Gpr182 is enriched in 
stomach and colonic stem cells, as well as other stem cell populations throughout the body.  
Gpr182 lineage tracing following IRR or during adenoma formation and progression would 
help determine the roles of this Gpr182 expression during these conditions and could shed 
new light on the mechanisms behind Gpr182 heterogeneity in adenomas (Figure 6-4, 6-6).  
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The inducible Gpr182-EGFP-ires-CreERT mouse would allow conditional deletion of genes 
of interests, such as Apc, to identify if alterations of in these genes specifically within Gpr182 
expressing cells have phenotypic consequences, which has been done using the Lgr5 and 
Lrig1 promoters.391, 398, 463  The incorporation of EGFP or a fluorescent reporter would allow 
the isolation of Gpr182-EGFP+ cells by FACS for RNA analysis and ex vivo organoid 
experiments.  Isolated single cells would help confirm whether the phenotypes-associated 
with Gpr182 are cell autonomous.  Alternatively, cell autonomy could be demonstrated using 
cell-type specific Cre animals, such as the Villin-CreERT or the Lgr5-EGFP-ires-CreERT2 
mouse to conditionally delete Gpr182 in the intestinal epithelium or CBC ISCs, respectively.  
The Gpr182lacZ/+ mouse is a conditional allele only after it is crossed to the C56BL/6-Rosa26-
FLPe (Jackson 003800) mouse to remove the En2 splice acceptor-mediated lacZ knock-in.  
This strategy could also identify determine the functions of Gpr182 in the specific-
differentiated cell types that express Gpr182.  These studies will both confirm the expression 
pattern of Gpr182 in vivo, as well as help investigate the cell autonomous functions of 
Gpr182. 
 
Further Exploration of the Functions of Gpr182 during Gastrointestinal Homeostasis, Injury, 
Regeneration, and Neoplasia 
Chapter VI focused on the proliferative functions of Gpr182 in the small intestine.  
The phenotypes were attributed to the loss of Gpr182, but it is possible that the proliferative 
phenotypes are caused by the upregulation of other receptors, signaling pathways, and/or 
transcription factors caused by altered Gpr182.  It is important to characterize the number 
and distribution of CBC ISCs, activatable +4 ISCs, and differentiated cell types in the 
Gpr182 null intestines.  Additionally, the expression pattern of Wnt/Frizzled, DLL/Notch, 
BMP/BMPR, and EGF/EGFR need to be characterized.  The expression of signaling 
components could be mapped by RT-PCR, western, IHC, and/or genome-wide arrays.  To 
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assess relative changes in the number of particular cell types, differentiated cells could be 
stained with Alcian Blue (goblet cells), chromogranin A (enteroendocrine cells), Lysozyme 
(Paneth cells), Dclk1 (tuft cells), or Sucrase Isomaltase (enterocytes) and counted manually 
or by flow cytometry.  These differentiated cells are all present in Gpr182lacZ/lacZ intestines 
and the relative expression of specific markers of these cells was unchanged (Figure 6-
S2D).  To determine the number of CBC ISCs, Gpr182lacZ/+ could be crossed to the Lgr5-
EGFP mouse and the relative distribution of Lgr5-EGFPHigh cells between Gpr182 null and 
wild-type animals could be quantified by flow cytometry.  Activatable reserve ISCs can be 
labelled by EdU followed by an extended washout period and label retaining cells can be 
quantified.  In addition to proliferation and differentiation, it would be informative to 
investigate changes in apoptosis in Gpr182 null intestines.    
Decreased Gpr182 increased proliferation five days post-IRR (Figure 6-4).  It is worth 
investigating the expression and functions of Gpr182 throughout the damage and repair 
process following IRR, including the return to homeostasis following damage, of which the 
mechanism remains relatively unknown.   Radiation-induced DNA damage and causes 
apoptotic death of actively cycling CBC ISCs.  Gpr182 expressing cells are lost following 
IRR and the Gpr182 promoter remains OFF during the regeneration phase (Figure 6-4D), 
which could be necessary in order to allow the physiologic hyperproliferation in order to 
maintain barrier function.  It would be interesting to look 6 and 24 hours following IRR to see 
how Gpr182 loss affects initial cell death and DNA-damaged apoptosis, respectively.389, 408  
Overall damage severity and initial regeneration could be assessed 2 or 3.5 days following 
IRR, respectively.389, 404, 408, 447, 454  Beyond damage severity, it would also be informative to 
look at later time points, such as day 7 or day 9 to determine whether the IRR-induced 
hyperproliferation in the Gpr182 null animals returns to homeostasis or whether Gpr182 
function is required for the downregulation of this proliferation.  The temporal requirements 
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of Gpr182 during initial IRR injury and recovery to homeostasis, as well as whether Gpr182 
is beneficial or detrimental to overall survival remains to be determined.   
It has been well established that intestinal adenomas are highly mosaic.462, 463 
Gpr182 promotor activity was also mosaic in polyps and appeared to be inversely correlated 
with proliferation, which requires further examination.  If Gpr182 is a negative regulator of 
proliferation, than Gpr182-lacZ+ areas of polyps would be expected to have a competitive 
growth advantage over Gpr182-lacZ negative areas,461 but this does not appear to be the 
case.  The Gpr182-lacZ negative areas represent a lack of promoter activity and are most 
likely not indicative of a failure of the En2 splice acceptor to remove the protein coding 
region.  Therefore, the transcriptional regulation of Gpr182 is different in lacZ+ modest 
proliferation areas compared to high proliferation Gpr182-lacZ negative areas.  While these 
Gpr182-lacZ+ areas are part of adenoma as evident by nuclear -catenin staining, there are 
other differences in these areas.  For example, Dclk1 has been shown to label tuft cells 
normally, but can act as a cancer initiating cell and a specific marker of cancer stem cells.441, 
468  The authors reported that whole polyps labelled with Dclk1, similar to the Gpr182-lacZ 
negative areas, while the Gpr182-lacZ positive areas have single Dclk1+ cells that look like 
differentiated tuft cells (data not shown).  This potentially indicates there are low levels of 
differentiation occurring in these Gpr182-lacZ+ areas.  I hypothesize that Apc adenomas 
form in areas where the Gpr182 promoter and expression are downregulated.  The Gpr182-
lacZ+ areas in the Gpr182lacZ/lacZ animals likely represent areas where if Gpr182 was present 
in a Gpr182+/+ mouse, then these areas would not have developed into an adenoma. This 
could explain why more polyps form in the Gpr182lacZ/lacZ animals.  Looking at Gpr182 levels 
at different time points during Apc polyp formation and progression would be informative, but 
would likely require ISH or an antibody to detect endogenous Gpr182 levels.      
In addition to IRR and ApcMin adenoma challenge models, nothing is known 
regarding the roles of Gpr182 during intestinal inflammation.  It would be informative to 
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challenge Gpr182 null mice with inflammatory models; including, high fat diet, acute and 
chronic colitis and ileitis induced by indomethacin or DSS, as well as different cancer 
models, such as DSS AOM or genetic crosses with activated Kras or PTEN mutant mice.  
Furthermore, the generation of a Gpr182 overexpression transgenic mouse could help 
determine whether high Gpr182 is protective or if overexpression can rescue any of the 
phenotypes observed in the Gpr182lacZ/lacZ mice.  It would be best if this mouse has a 
fluorescent reporter for in vivo detection and either a doxycycline-inducible Tet-ON/OFF 
switch or a floxed Stop codon in the promotor of the transgene to allow spatial and temporal 
control of Gpr182 activation.  An inducible switch would allow the removal of Gpr182 to 
activate adenoma formation, followed by the reconstitution of Gpr182 in order to try to 
reverse polyp formation, similar to Apc.420 This would help determine whether Gpr182 is 
dispensable once an adenoma forms or if it is required for adenoma maintenance and 
progression. 
 
Insights into Gpr182 Biochemistry and Mechanistic Signaling 
Without an endogenous ligand, agonist, or antagonists, as well as not knowing 
anything regarding its G protein-coupling or -arrestin induced downstream signaling, it is 
impossible to fully tease apart the mechanism by which decreased Gpr182 caused a 
hyperproliferative microenvironment during regeneration and adenoma formation.  While 
enhanced signaling through Erk1/2 in the Gpr182lacZ/lacZ mice (Figure 6-7A) is likely 
responsible for some of the phenotypes,416 the overall signaling and numerous 
compensatory feedback mechanisms in the intestinal epithelium are likely very complex.  
Basally, the adaptable intestine is able to compensate for elevated MAPK signaling resulting 
in no overall change in proliferation, indicating that Gpr182 is fairly dispensable during 
homeostasis (Figure 6-3).  This is consistent with other models with enhanced Erk1/2 
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phosphorylation that do not have basal proliferation phenotypes.414  It is important to show 
by IHC which intestinal cell types are responsible for the increased pErk1/2 observed by 
western blot.  One could investigate other common signaling pathways important for 
maintaining intestinal proliferation, including Wnt, Notch, BMP, EGFR, EphB, p38, JNK, 
PTEN, Akt, JAK/STAT3, and the Hippo/YAP pathways for a better understanding of the 
complexity of signaling.  Currently, it is unclear why hyperproliferation was only observed 
during regeneration and increased adenoma initiation and not basally or within formed 
adenomas, especially considering the elevated MAPK signaling during all conditions 
(Chapter VI).  Looking at other signaling pathways, via western, phosphorylation arrays, or 
kinome profiling could help reveal the underlying compensatory signaling mechanisms.   
Without a basal hyperproliferation phenotype, I hypothesize that the Wnt/-catenin 
signaling pathway is not directly affected by Gpr182 loss.  Total levels of -catenin are 
relatively unchanged in Gpr182lacZ/lacZ jejunums (Figure 7-2A-B).  Likewise the downstream 
Wnt target, Lgr5 expression was unchanged in Gpr182; CMV-Cre+ jejunums (Figure 6-
S2D).  Wnt and MAPK pathways do have common downstream signaling targets, including 
Gsk-3 and c-myc.  Erk1/2 activation has been shown to increase oncogenic c-myc 
stabilization leading to increased proliferation and adenoma formation and thus should be 
investigated in Gpr182lacZ/lacZ animals.416, 476  Preliminary results suggest that p-Gsk-3 is 
trending higher in Gpr182lacZ/lacZ adenomas (Figure 7-2C).  Gsk-3 is downstream of MAPK, 
Akt, and Wnt and when phosphorylated allows -catenin to move to the nucleus.   Activated 
STAT3 was unchanged with Gpr182 knockdown (Figure 7-2D), supporting that the 
JAK/STAT pathway is likely not affected.  Interestingly, activated Akt was trending down in 
Gpr182lacZ/lacZ intestines basally and in adenomas, but not post-IRR (Figure 7-2E-F).  The 
altered Akt pathway could potentially be responsible for the lack of proliferative phenotypes 
basally and within adenomas, but this needs to be further verified.   
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While I hypothesize that the Notch pathway is transcriptionally upstream of Gpr182, I 
have no reason to believe that Gpr182 loss disrupted Notch signaling.  Secretory cell 
differentiation appears normal and the expression of the Notch pathway transcription 
factors, Olfm4 or Hes1, was also unchanged.  As mentioned previously, NICD 
overexpression in the intestinal epithelium decreased Gpr182 expression (Figure 7-1B), but 
this regulation is likely more complex than direct transcriptional control.  Mice treated with an 
inhibitor (DBZ) of -secretase, which is responsible the cleavage of Notch receptor during 
Notch signaling and therefore prevents NICD translocation to the nucleus and NICD-
regulated transcription (Figure 7-1C), caused a trending decrease in Gpr182 expression in 
isolated intestinal epithelium (Figure 7-1D).  It has previously been shown that DBZ 
decreases CBC ISC numbers,452 which could be responsible for decreased Gpr182 
expression.  Likewise Notch overexpression decreases secretory cell numbers, which if 
Gpr182 is expressed in differentiated tuft or enteroendocrine cell, this could be why there is 
reduced Gpr182 expression.  Much more work is needed to determine how Gpr182 is 
transcriptionally regulated.  If Notch is upstream of Gpr182 expression, then it would be 
interesting to challenge Gpr182 null animals with Notch inhibitors to determine whether 
Gpr182 is involved in the reported secretory cell hyperplasia.452, 477, 478 
Interestingly, a recent study by Gregorieff et al. demonstrated the functions of 
YAP/Hippo signaling pathway during intestinal regeneration and adenoma, which had some 
striking similarities to the observed Gpr182 phenotypes.454  YAP signaling appears 
dispensable for homeostatic proliferation, but is critical for regeneration following IRR and 
during adenoma formation.455  More specifically, conditional YAP-/- mice had delayed 
regeneration following IRR and failed to form polyps when crossed to the Apc model.454  The 
YAP dependent mechanism responsible for the regenerative and adenoma phenotypes was 
through the induction of EGFR signaling and activated Erk1/2 signaling.  While I hypothesize 
Gpr182 is Gi-coupled and inhibits cAMP generation leading to decreased Erk1/2 signaling, 
174 
 
an alternative hypothesis is that Gpr182 signals through Lats1/2 to block YAP activation, 
which has been shown with other GPCRs.467  With Gpr182 loss, YAP loses its brake, 
translocates to the nucleus, increases EGFR levels and signaling, and ultimately causes 
increased Erk1/2 activation and proliferation.  Like YAP/Hippo signaling, Gpr182 is 
dispensable during homeostasis, but important in regenerative phase following damage and 
during adenoma formation.  To further demonstrate this pathway’s involvement, YAP 
activation and subcellular localization could be assessed in Gpr182 null intestines under 
basal and challenged conditions.  Alternatively YAP overexpression mice could be crossed 
to Gpr182 null animals to demonstrate an exacerbated YAP overexpression phenotype.   
It is clear the signaling mechanism is likely very complex, but it would be informative 
to further tease apart the functional consequences of the Gpr182lacZ/lacZ enhanced Erk1/2 
signaling.  EGF is an important trophic factor required for organoid growth ex vivo.425  
Therefore, it would be interesting to determine if Gpr182 null organoids can grow without 
EGF supplementation.  Gpr182 null mice and/or organoids could be challenged with EGFR 
or MEK inhibitors or Forskolin to test how they respond.  It has been demonstrated that MEK 
inhibitors completely block adenoma formation in Apc mice or organoid growth,416, 454 and 
therefore it will be hard to tease apart the Gpr182 dependent roles in this signaling.   
For gain-of-function studies, organoids could be generated from a Gpr182 
overexpression mouse.  Alternatively human colorectal carcinoma cell lines, which express 
low levels of GPR182 (Figure 6-8) could be transfected to overexpress GPR182.  These 
gain-of-function cells would help determine whether increased GPR182 expression in tumor 
cells can inhibit growth, survival, and/or MAPK signaling.  The high proliferation and low 
expression of GPR182 in these cell lines likely does not merit the shRNA knockdown of 
GPR182.  Cell line choice may be critical, since different mutations in different cancer cell 
lines could affect results.  For example, DLD-1 colorectal cancer cells with an activating 
G13D KRAS mutation were challenged with a genome-wide RNAi screen and the 
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combination of G13D RAS and GPR182 RNAi was trending towards synthetic lethality, 
although this was not further verified.479  Additionally, all the human pancreatic cancer cells 
lines assessed in Ramachandran et al. had RAS-activating mutations, so if Gpr182 
knockdown is synthetic lethal with these activating mutations, it could explain why they 
observed decreased proliferation and tumor size due to decreased viability.102, 380  In addition 
to tumor cells, GPR182 could be knockdown in normal cells to determine if this leads to a 
proliferative or survival advantage.  The main limitation to all of these ex vivo and in vitro 
experiments is that they will likely depend on Gpr182 ligand availability, and without a known 
ligand it will be difficult to attribute any effects directly to Gpr182 signaling.   
As discussed in Chapter V, Gpr182 was once thought to be an AM receptor, but was 
shown not to bind nor signal with AM and was classified as an orphan GPCR.356, 363  
Recently Klein et al. published that Cxcr7, another former AM receptor, could potentially 
bind AM as a “ligand sink” or decoy receptor.332, 359  While direct binding remains 
controversial, it is clear that AM can alter Cxcr7 transcriptional levels and vice versa, so they 
are somehow connected transcriptionally.  Gpr182 could be investigated as an AM decoy 
receptor, like its paralog Cxcr7.  While it seems clear that Gpr182 and Cxcr7 likely do not 
signal through Gs-coupled cAMP generation, downstream coupling to and signaling 
through Gq, Gi, or -arrestins needs to be further investigated.  However, it is impossible 
to prove signaling and coupling without an endogenous ligand or synthetic compound to 
activate the receptor.  Currently strategies to identify ligands, such as screening compound 
libraries and assessing changes in GPCR subcellular localization have been unsuccessful to 
identify ligands of Gpr182, at least publically.  Mapping the subcellular localization of tagged 
GPR182 in transfected cells would be informative to answer whether it is present at the cell 
surface or restricted in intracellular organelles.  Gpr182 is grouped with chemokine receptors 
by phylogeny, which could provide insight into potential chemokine ligands as candidates, 
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but these Class A GPCRs are typically promiscuous.480  Gpr182 could require an 
interactions partner, such as RAMPs or LRPs, to translocate it to the membrane or facilitate 
signal, but current investigation in our lab indicate that Gpr182 does not interact with the 
known RAMPs.  Gpr182 appears to be an inhibitor of MAPK signaling and proliferation and 
therefore these could be the readouts to screen compound libraries.  Ex vivo model 
systems, such as the organoids, could be useful models to test ligands and chemical 
compounds to look for altered MAPK signaling and growth efficiency.  Discovering the 
pharmacology behind Gpr182 signaling would be a significant advancement to our current 
understanding of Gpr182. 
 
Concluding Remarks 
Part II of this dissertation focused on the in vivo expression and function of murine 
Gpr182, an orphan GPCR of which almost nothing published.  Considering the therapeutic 
success of targeting GPCRs to treat a large variety of human diseases, it is crucial to 
interrogate the function all GPCRs.  While this study is an initial step in understanding the 
expression and function of Gpr182 in vivo, the findings regarding its spatial and temporal 
expression pattern, the identification that Gpr182 is enriched in ISCs, and that Gpr182 is 
involved in regulating proliferation will spark the interest of biologists and pharmacologists to 
build on this study and identify the ligand and therapeutic potential of this “forgotten” GPCR.  
Together, the work presented in this dissertation identified novel functions of two 
underappreciated GPCR signaling pathways in both cardiovascular and neoplastic 
diseases.  
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Figure 7-1:  Notch signaling is potentially an upstream regulator of Gpr182 
expression.  (A) Method of inducible intestinal epithelial-specific genetic overexpression of 
Notch intracellular domain (NICD).  (B) Intestinal epithelial-specific Gpr182 expression in 
control and NICD overexpression mice. (C) Method to pharmacological inhibition of Notch 
signaling using -secretase inhibitor DBZ. (D) Intestinal epithelial-specific Gpr182 expression 
in vehicle and DBZ treated mice. Samples normalized to controls and Gapdh.  N = 4. 
**p<0.01.  RNA was kindly provided by Dr. Linda C. Samuelson at University of Michigan. 
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Figure 7-2:  Reduced Gpr182 decreased Akt signaling in normal intestines.  (A) 
Representative immunoblots and (B) quantitation of total -catenin in jejunums from 
Gpr182+/+ and Gpr182lacZ/lacZ mice basally, 5 days post-IRR, and in polyps from ApcMin mice.  
(C) Representative pGsk-3 from ApcMin polyps and (D) pStat3 and total Stat3 levels from 
unchallenged Gpr182+/+ and Gpr182lacZ/lacZ mice.  (E) Representative immunoblots and (F) 
quantitation of pAkt normalized to total Akt protein in jejunums from Gpr182+/+ and 
Gpr182lacZ/lacZ mice basally, 5 days post-IRR, and in polyps from ApcMin mice.  Levels were 
normalized to Gpr182+/+ and Gapdh (B) or Akt (F).  N = 3-5 (A, E) and N =1-2 (C, D).  
Significance determined by Student T-test with **p<0.01. 
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